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Summary
Diabetic patients are prone to develop cataract, compared to non-diabetic patients 
(Kyselova et al., 2004). The global prevalence of diabetes is around 150 millions in 2004 
(5% of the world population), with 1.8  million people in the United Kingdom affected 
(Diabetes UK, 2004). In western countries, diabetes accounts for around 12% of the total 
cataract population (Harding, 1999). It has been proposed that hyperglycemia is the major 
risk factor in diabetic cataract, and could be the starting point for all of the consequent 
pathological changes including, glucoxidation, glycation and activation of the polyol 
pathway, which finally result in diabetic complications (Sensi et a l , 1995; Hotta, 1997; 
Brownlee, 2001).
The present study aimed to characterise the mechanism of glucose transport into the 
aqueous humour. Using the Ussing-type chamber technique, glucose transport kinetics 
were characterised for the bovine CBE. The glucose fluxes were sensitive to a number of 
glucose transporter inhibitors including cytochalasin B (~ 80% inhibition), phloretin (~ 
59% inhibition) and phlorizin (-21%  inhibition), and it also varied with stromal glucose 
concentration.
In an investigation of mRNA expression using RT-PCR, GLUT1, GLUT3, GLUT4, 
GLUT5 and SGLT2 were found to be expressed in the bovine CBE. Due to difficulties 
encountered in the protein expression study, it was not possible to confirm that all of 
these mRNAs are translated.
Nevertheless, the major glucose transport mechanism across the bovine CBE was 
determined to be a facilitative and carrier-mediated mode, since the glucose transport was 
effectively inhibited by the addition of cytochalasin B and phloretin. The transport system 
is likely to saturate when the plasma glucose concentration reaches 10.6 mM. These 
results, together with the gene expression data, may provide a new insight into devising a 
therapeutic strategy in the control of aqueous glucose levels which may eventually 
prevent the diabetic cataract formation.
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1
Introduction
1.1 Anatomy and physiology of the ciliary body/ epithelium (CBE)
The ciliary body (CB), together with the iris and choroid, forms the uveal tract. It is 
triangular infection, with an outer region that attaches to the sclera. It lies in between the 
retina posteriorly and the scleral spur anteriorly. The ciliary muscle that is located below 
the sclera within the CB controls the crystalline lens accommodation, thus, governing the 
accommodative power of the eye (Glasser and Kaufman, 2003).
The CBE is a polarized epithelium that lies along the innermost layer of the CB (Caprioli,
1992). It is the forward continuation of the retina, with a double layer of cells, the outer 
pigmented epithelium (PE) and the inner non-pigmented epithelium (NPE). These two 
layers face each other, with their apical membranes adjoining. Together with gap 
junctions, they form a functional syncytium (Green et al., 1985; Edelman et al., 1994; Oh 
et al., 1994). These bilayer cells are connected electrically by gap junctions (Raviola, 
1977; Raviola and Raviola, 1978; Abdel-Latif, 1997). Functionally, the CBE is widely 
recognized as the site of aqueous humor production (To and Do, 1998d; Wetzel and 
Sweadner, 2001).
Electrophysiological studies showed a potential difference (PD) of ~lmV across the CE, 
with the aqueous side consistently negative (Coca-Prados et al., 1995; Jacob and Civan, 
1996). Bicarbonate and chloride ions were believed to be responsible for generating this 
negative potential in rabbit and in bovine respectively (Coca-Prados et al., 1995; Krupin 
and Civan, 1995; Do and To, 2000).These ions are, therefore, considered to play a crucial 
role in driving aqueous humor formation in different species.
The CBE can be divided into two regions, the pars plicata (anterior) and the pars plana 
(posterior) (Morrison and Freddo, 1996; Abdel-Latif, 1997). The two regions demonstrate 
different structural and functional features (see section 1 .1 .4 ).
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1.1.1 Pigmented epithelium (PE)
The PE is the anterior continuation of the retinal pigment epithelium (RPE) and is the 
outer layer of the CBE (Davson, 1990). It is a 5-6 pm high cell layer with a dark brown 
appearance due to the presence of melanin granules. The dark colour is further 
contributed by the unusually compact arrangement of the cytoplasmic organelles and the 
conspicuous presence of cytoplasmic fibrils (Kozart, 1968). Such an appearance makes it 
easily distinguishable from the NPE. Compared to the NPE, the PE has a higher 
anaerobic metabolic rate (Shimizu et al., 1967) and a lesser number of mitochondria 
(Cole, 1984). It has a large surface area, built by the infoldings of its basal surface, which 
facilitates solute uptake from the blood stream (Edelman et al., 1994).
1.1.2 Non-pigmented epithelium (NPE)
The NPE is the inner layer of the CBE. It consists of a monolayer cell of 6 - 8  pm wide 
and 10-15 pm high (Kozart, 1968). It is the anterior continuation of the neurosensory 
retina (Morrison and Freddo, 1996; Glasser and Kaufman, 2003), and lies between the PE 
and the aqueous humor. It possesses numerous basal infoldings and interdigitations, and 
was originally believed to be the only site responsible for aqueous humor formation 
(Okisaka and Kuwabara, 1974). In addition, it is the sole layer in the CBE that has 
intercellular tight junctions that serve the purpose of selective solute transport at the 
blood aqueous barrier (BAB) (Raviola, 1971). Compared to the PE, the NPE has more 
mitochondria and rough endoplasmic reticulum, as well as a higher activity of Sodium- 
Potassium adenosine triphosphatase (Na+, K+-ATPase) and adenylate cyclase, enzymes 
that participate in active fluid secretion (Elena et a l, 1984; Riley and Kishida, 1986;
3
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Flugel et al., 1989; Eichhom et al., 1993a). The NPE expresses enzymes for aerobic 
metabolism at a very high level (Cole, 1966; Shimizu et a l , 1967). All these 
characteristics indicate its activeness in both secretion and metabolism.
1.1.3 Intercellular junctions
1.1.3.1 Tight junctions
Tight junctions, also known as zonula occludens, are located only at the apical-lateral 
side of the NPE cells (Raviola and Raviola, 1978). They form a continuous network in 
which each junction consists of two or more superimposed strands, indicating the co­
existence of relatively tight and leaky sites (Noske et al., 1994). They restrict the inter­
cellular movement of small water soluble molecules and also membrane protein 
movement (Bill, 1986). However, these junctions are still regarded as a “leaky” type of 
tight junction, due to their low fluid permeability (Cunha-Vaz, 1979) and pressure- 
dependent transport features (Pederson, 1982). Nevertheless, research has suggested that 
the bilayers’ electrical resistance could be high if one considers the total unfolded surface 
area of the CBE (Krupin et al., 1984). The “tight” epithelial nature has been corroborated 
in the rabbit iris-ciliary body, which bore the same mannitol permeability as other tight 
epithelia (Chu and Candia, 1987a). Concerning the transepithelial resistance, anterior 
ciliary processes were “less leaky” (i.e. possessed a higher resistance) than posterior 
ciliary processes or pars plana. In the rat, the number of tight junctions appeared to be 
inconsistent, since the junctional depth and number of superimposed junctional fibrils 
decreased with age (Arguillere et a l , 1986). Despite this, tight junctions of NPE are 
believed to act as the major “sieve” used for aqueous humor formation. In conjunction
4
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with gap junctions (Bill, 1986), the NPE tight junctions constitute the BAB, with another 
endothelial component at the level of the iris blood vessels (Cunha-Vaz, 1979) and ciliary 
muscle capillaries (Schlingemann et al., 1998). This barrier behaves as an isoporous 
membrane (Demouchamps and Heremans, 1975) to limit substrate passage (DiMattio and 
Zadunaisky, 1981; Chu and Candia, 1988) and assure transparency of ocular media by 
restricting the diffusion of macromolecules into the aqueous chamber (Vegge, 1971; 
Hirsch et al., 1980). Its barrier function is further validated by the extremely low level of 
protein in the aqueous humor (Hirsch et al., 1985; Bill, 1986).
1.1.3.2 Gap junctions
Gap junctions (2 nm gap) are highly organized structures composed of “connexon” 
plasma membrane proteins. They connect the cytoplasm of adjacent cells, as hydrophilic 
channels (Shin et a l , 1996) and act as ion-gated channels for signalling communication 
between cells (Bazzoni and Dejana, 2004). They allow the passage of small molecules up 
to molecular size of 1 kDa (Bennett et al., 1991) and 12 A in diameter (Oh et al., 1994).
In the CBE, gap junctions are found in between all cells (i.e. within each epithelial layer 
and between the bilayers) and are most abundant in between the NPE and PE cells 
(Raviola and Raviola, 1978; Coca-Prados et a l, 1992). No significant difference was 
found in both the intracellular ion contents (Bowler et al., 1996) and membrane potential 
(Carre et al., 1992) between these cell bilayers, indicating the presence of free solute or 
ion exchange. Further evidence of cell-to-cell communication was demonstrated using a 
micro-iontophoretic dye, which revealed the presence of cell-to-cell substrate coupling. 
However, such coupling was found to be pH sensitive, and sensitive to high calcium
5
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concentration, as dye coupling ceased under extracellular acidosis or high calcium 
concentration (Oh et al., 1994). Despite this, gap junctions are an important route of 
intercellular communication, which ultimately help to build a functional syncytium from 
the CBE bilayer (Edelman et al., 1994; Oh et al., 1994).
1.1.4 Regional differences in the CBE
The pars plicata is the anterior part of the CBE, which can be further divided into the 
iridial processes, the ciliary muscle and the ciliary processes (Hara et al., 1977). Its 
innermost layer folds into finger-like projections, which are believed to be the major site 
for aqueous humor formation. The pars plana is a smooth, membranous layer of posterior 
CBE, which has significantly less rough endoplasmic reticulum and mitochondria than 
pars plicata. It is the region which provides mechanical zonular support to the crystalline 
lens (Noske et al., 1994), but not a site regarded for active secretion, since Na+, K+- 
ATPase was scarcely observed in it (Flugel et al., 1989). In contrast, different isoforms 
(alpha 1, alpha 2, alpha 3, beta 1 and beta 2) of Na+, K+-ATPase were intensely stained at 
the pars plicata (Ghosh et al., 1991). In addition, endothelin-1 (ET-1), a chemical 
messenger which constricts blood vessels to instantly lower intraocular pressure, was 
mostly observed at the crests of the pars plicata, but not the pars plana (Eichhom and 
Lutjen-Drecoll, 1993b). The same was found for carbonic anhydrous staining (Muther 
and Friedland, 1980). These findings indicate again the active involvement of the pars 
plicata in aqueous formation.
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1.2 Glucose
1.2.1 Structure and function
Glucose is a common form of hexose, which is one of the most important nutrients for 
mammalian cells (Takata et al., 1993). Living cells require glucose as a starting material 
for energy production (Mueckler, 1994a). The ability of a plasma membrane to transport 
glucose is, therefore, a common cellular feature, to maintain this major source of 
metabolic energy supply (Bell et a l , 1990). In general, D-glucose, is the principle 
isoform of glucose utilized by higher organisms, that exists in three different forms: two 
hemiacetal structures and one linear structure (Lodish et al., 2003). Under different 
environment conditions, D-glucose can change its structure to achieve various biological 
purposes. Figure 1.1 shows the three different structures of D-glucose.
CH2OH c h 2o h
HCOH O
H C OH
HO C H
H C OH
H OH H C OH H OH
D-Glucofuranose
CH2OH
D-glucose D-Glucopyranose
Fig. 1.1 Chemical structures of glucose.
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1.2.1.1 Glycolysis
Glucose is a crucial substrate for cell nourishment. It is used to generate adenosine 
triphosphate (ATP) through glycolysis. Glycolysis is a series of reactions that takes place 
in the cell cytoplasm, to break down glucose to produce ATP. In each glycolytic cycle, 
two net ATPs are generated from every glucose molecule. Glycolytic intermediates can 
further be utilized as substrates to generate more ATP, e.g. pyruvate is consumed in the 
citric acid cycle of mitochondria, or used for biosynthetic pathways. In the presence of 
oxygen (i.e. aerobic conditions), nicotinamide adenine dinucleotide (NADH) and 
pyruvate, two of the glycolytic intermediates, can undergo oxidative phosphorylation for 
efficient ATP production (~ 30 ATPs per glucose molecule). In anaerobic condition, 
pyruvate is converted to lactic acid, while NADH is oxidized to NAD+ that can be reused 
in glycolysis. The anaerobic metabolism can still generate ATP yet the efficiency is much 
reduced (i.e. two ATPs per cycle). In the eye, glycolysis is important as it provides the 
necessary energy to support phototransduction and nicotinamide adenine dinucleotide 
phosphate (NADPH) for other NADPH-requiring processes such as rhodopsin 
regeneration in the retina (Hsu and Molday, 1994). In other words, the presence of 
glucose is vital for the normal functioning of the eyes.
1.2.2 Transepithelial pathways
The plasma membrane consists of a phospholipid bilayer and acts as a selectively 
permeable barrier. Some molecules such as water and urea can pass through it unaided, 
while others like amino acids, ions and sugars require integral membrane transporter 
proteins for their passage. Since glucose is a polar and hydrophilic molecule, an integral
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transporter protein is required if it needs to pass across the plasma membrane (Bell et al., 
1990). However, glucose can also traverse cells, across tight junctions and along the 
lateral intercellular spaces without passing through the cells. The former pathway is 
called the transcellular pathway, whilst the latter is called the paracellular pathway.
Figure 1.2 illustrates these two pathways, based on the structure of the CBE. In the 
transcellular pathway, glucose is taken up by glucose transporters along the basolateral 
side from the extracellular spaces, into intracellular compartments. From here, they pass 
through gap junctions and reach the second epithelial layer and are transported out of the 
cell layer by other transporter proteins along the basolateral membrane.
PE NPE 0  Glucose transporter 
=  Gap junction 
Tight junction
mo.m oPlasma Aqueous humor
Fig. 1.2 Schematic diagram showing the transepithelial pathways for glucose in 
the CBE. The solid and dotted arrows indicate the paracellular and 
transcellular pathways respectively.
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1.2.3 Glucose transporter families
The plasma membrane, which isolates the cell body from the extracellular environment, 
is composed of a phospholipid bilayer that is impermeable to hydrophilic substances such 
as glucose. Therefore, glucose needs a special transport mechanism in order to diffuse 
into cells in a rapid and efficient manner. As integral membrane proteins, glucose 
transporters help to mediate the transport of glucose (or similar substances like fructose) 
across the cellular membrane (Baly and Horuk, 1988; Carruthers, 1990; Baldwin, 1993) 
via one of the two different mechanisms. The first mechanism involves passive 
facilitative transport, and is mediated by members of the facilitative glucose transporter 
(GLUT) family (gene symbol SLC2). The second mechanism involves active transport by 
sodium-dependent glucose cotransporters (SGLTs) (Silverman, 1991; Baldwin, 1993; 
Wright and Turk, 2004).
1.2.3.1 The GLUT family
Classification, Currently, 14 isoforms of the SLC2 family have been identified. This 
glucose and polyol transporter family comprises members including GLUT1-12,
GLUT14 (Wu and Freeze, 2002) and the proton-dependent- /wyo-inositol cotransporter 
(HMIT) (Uldry and Thorens, 2004) (Table 1.1). GLUTs have been named and 
distinguished according to their amino sequence, major tissue expression sites, specificity 
and, affinity and expression response to insulin (Kayano et al., 1990; Gould and Holman, 
1993; Mahraoui et al., 1994; Wu and Freeze, 2002; Wood and Trayhum, 2003). They are 
responsible for passive hexose transport driven by a glucose concentration gradient, 
without the consumption of energy (i.e. ATP) (Mueckler, 1994a). They exist in almost all
10
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mammalian cells and are believed to be crucial for basal glucose uptake (Bell et al.,
1993). The most common GLUTs in mammals are GLUT1-5, with GLUT1, GLUT2, 
GLUT3, GLUT4 classified as Class I GLUTs and GLUT5, GLUT7, GLUT9 and 
GLUT11 as Class II. The remainder are categorized as Class III. This classification 
system is based on their multiple sequence alignments (Wood and Trayhum, 2003). At 
present, no classification has been done for GLUT 14, yet there is a high possibility for it 
to be classified into Class I, as it was found as a duplicon (i.e. an alternate splice form) of 
GLUT3 specifically present in the testis (Wu and Freeze, 2002).
Structure. In 1985, the 12-helix model for the structure of GLUTs was suggested on the 
basis of a hydropathy plot (Mueckler et al., 1985), which was later supported by a 
glycosylation scanning study (Hresko et al., 1994) and by sequence analysis (Sato and 
Mueckler, 1999). Today, the presence of 12-transmembrane helical domains in GLUT 
proteins is considered their structural hallmark (Joost and Thorens, 2001). All GLUT 
proteins have both their amino and carboxy-termini located on the cytoplasmic side of the 
plasma membrane, together with a N-linked oligosaccharide side-chain located either on 
the first or fifth extracellular loop (Uldry and Thorens, 2004). The 12-helices, together 
with intracellularly located carboxyl- and amino-termini, provide the necessary 
orientation in the plasma membrane and participate in the conformational changes during 
transport process (Schurmann et al., 1997; Joost and Thorens, 2001). Several charged 
residues in the cytoplasmic surface were also suggested to mediate the conformational 
alteration of the protein during translocation process as revealed in mutational analysis 
(Tamori et al., 1994; Doege et al., 1998). For example, the tryptophan in helix 11, and the
11
Introduction
glutamine 161 residue at the amino-terminus of GLUT1, are crucial in mediating the 
transport activity and substrate binding capacity (Inukai et al., 1994; Mueckler et al., 
1994b; Wandel et a l , 1996), while serine-294 and threonine-295 are important for 
normal GLUT4 transport activity (Doege et al., 1998).
GLUT1 or erythrocyte/brain/HepG2-glucose transporter: GLUT1 is a hydrophobic 
glycoprotein expressed at highest level in the plasma membrane of erythrocytes and in 
brain tissues (Bell et al., 1993; Wagstaff et al., 1995; Zhang and Ismail-Beigi, 1998). 
Moderate levels were observed in adipose tissue, muscle and liver (Zeller et al., 1994; 
Rudich et al., 2003). The differential N-linked glycosylation (Asano et al., 1993) resulted 
in different GLUT1 glycoforms (with the 45 kDa form the most common) with a core 
protein of approximately 40 kDa (Morgello et al., 1995; Takahashi et al., 1996; Yu and 
Ding, 1998). The real function of the glycosylation is unknown, yet it has been suggested 
to play a role in governing the glucose transport activity that could affect the overall 
transport capacity (Feugeas et al., 1990) or affinity (Asano et al., 1993).
GLUT1 is considered as the house-keeping transporter responsible for glucose entry into 
most animal cells (Takata et al., 1990; Takata, 1996) with a relatively high transport 
capacity (Brown, 2000). Glucose transport by GLUT1 occurs in a bi-directional manner, 
depending on the concentration gradient across the membrane (Carruthers, 1990).
GLUT 1-mediated transport can be specifically inhibited by phloretin and cytochalasin B 
(Bloch, 1973; Drewes et al., 1977; Seyfang and Duszenko, 1991; Fuhrmann et al., 1992). 
GLUT1 was the first glucose transport protein to be purified, having been confirmed 
from human erythrocyte ghosts as a zone 4.5 protein (Kasahara and Hinkle, 1977). It is
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recognized as the most widely distributed protein among the GLUT family in mammalian 
cells, being especially concentrated in areas with occluding or barrier functions that 
constitute the blood-tissue barriers (Harik et al., 1990; Takata et al., 1990; Takata et al.,
1992). GLUT1, on the other hand, is also believed to function as a water-channel that 
facilitates the passage of water across the plasma membrane (Fischbarg et al., 1990). 
Deficiency of GLUT1 has been widely reported (De Vivo et a/., 1991; Klepper et al.,
1999). Seizures, acquired microcephaly and developmental delay are found at infancy 
(Klepper et al., 1998) with GLUT1 deficiency. Other manifestation such as 
neurobehavioural disturbance has also been noted (Klepper et al., 1999). In patients with 
Alzheimer disease, a glycoform of GLUT1 was significantly reduced compared to 
controls, although the underlying mechanisms are not known (Simpson et a l, 1994).
GLUT2 or liver glucose transporter. GLUT2 is a low affinity, high capacity glucose 
transporter (Thorens, 1992), most abundantly expressed in liver, intestine, kidney and 
pancreatic beta-cells (Ohneda et al., 1993; Zhao et a l, 1993; Mahraoui et al., 1994). It is 
a crucial transporter in cells which play an important role in systemic glucose regulation 
(Thorens et al., 1988) and is known to have a significant regulatory function in systemic 
glucose homeostasis (Thorens, 1992). It is recognized as part of the sensing system for 
blood glucose coupling with secretion of insulin in the pancreatic beta-cells under 
hormonal control (Unger, 1991). Further evidences of GLUT2 being involved actively in 
glucose homeostasis has been found in intestinal glucose uptake (Shepherd et al., 2004), 
glucose reabsorption in the kidney (Cramer et al., 1992), and glucose uptake and release 
by the liver (Postic et al., 1993). Apart from glucose, GLUT2 is known as a galactose
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(Tsang et a l , 1994) and fructose transporter (Wright et al., 2003). GLUT2 has been 
suggested to be an important isoform as regards impaired insulin secretory responses and 
it showed a reduced expression level in both ageing and diabetic tissues (Novelli et al.,
2000). In a study of transgenic mice, the expression of a GLUT2 antisense gene in 
pancreatic cells led to an 80% reduction in GLUT2 expression and consequently, diabetes 
(Valera et al., 1994).
The first report of the presence of GLUT2 in the central nervous system (CNS) was the 
observation of GLUT2 mRNA and protein in retinal Muller cells at the apical membrane 
(Watanabe et al., 1994). This finding is in line with findings in other tissues such as 
pancreatic cells, where GLUT2 has been found to be located preferentially on microvilli 
facing adjacent beta-cells (Orci et al., 1989). As with the apical surface of the Muller 
cells, this site is very active with respect to nutrient transport (Reichenbach, 1989). The 
presence of GLUT2 in Muller cells suggests a role in ocular nutrient transport, 
distributing glucose within the retina (Watanabe et al., 1994). During hyperglycemia, 
GLUT2 expression is increased, whilst in hyperinsulinaemia the reverse effect is found 
(Postic et al., 1993). Furthermore, genetic defects of GLUT2 can cause Fanconi-Nickle 
syndrome, a rare autosomal recessive disorder, which happens at infancy, causing rickets, 
retarded growth and enlargement of liver and kidney resulting from glycogen 
accumulation (Santer et al., 1997; Matsuura et al., 2002).
GLUT3 or brain glucose transporter, GLUT3 is a high affinity glucose transporter, 
which works efficiently at a lower substrate concentration than the other isoforms 
(Mueckler, 1994a). It exists mainly in high glucose demanding tissues, such as brain
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(Kayano et al., 1990; Nagamatsu et al., 1992; Brown, 2000). However, GLUT3 mRNA 
and protein have been observed in other human tissues such as placenta, liver, fat and 
muscles (Bell et al., 1990; Gould et al., 1992). GLUT3 and GLUT1 work together to 
deliver glucose to the brain, with GLUT1 mediating the transport through endothelial 
cells, whilst GLUT3 completes the glucose transport to the neurons to support sufficient 
energy metabolism (Brown, 2000). After hypoxic injury, GLUT3 content decreases in 
the brain, due to death of neural cells (Vannucci et al., 1998a). Similar to GLUT1, the 
concentration of GLUT3 is reduced in Alzheimer disease, presumably due to neuronal 
damage (Simpson et al., 1994).
A recent study has revealed the conformational transitions of GLUTs by examining 
GLUT3 (Dwyer, 2001). It was suggested that GLUT3 mediates glucose transport through 
an accordion-like movement of the helices with respect to the membrane. This movement 
modulates the opening of the protein pore and makes the transmembrane segment more 
flexible for glucose carriage.
GLUT4 or muscle-fat glucose transporter. GLUT4 is an insulin-responsive GLUT 
isoform, which is found mainly in insulin-sensitive tissues like muscles, fat/adipose tissue 
and cardiac tissue (James et al., 1989; Bimbaum, 1992). Insulin stimulates glucose 
uptake in these tissues by upregulating the rate of GLUT4 exocytosis, coupled with a 
slower rate in endocytosis (Liu et al., 2004). When GLUT4 was released from 
intracellular GLUT4-containing vesicles onto the plasma membrane surface, it resulted in 
10 to 20 fold higher glucose transport rate (Shepherd and Kahn, 1999; Bryant et al.,
2002). This insulin-stimulated process is rapid, yet reversible (Mueckler, 1994a). It has
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also been suggested that the transport activity of GLUT4 is increased in response to 
insulin stimulation, independently of its increased translocation to the plasma membrane 
(Michelle Furtado et a l , 2003). This change in transport activity might be related to the 
degree of phosphorylation (Reusch et al., 1993), yet a solid conclusion has yet to be 
made.
In fasting conditions, rats show a decrease in GLUT4 expression in adipose tissues, but 
an increase in muscle cells (Charron and Kahn, 1990). Likewise, during sustained 
exercise, an increase of GLUT4 expression was observed in muscles (Ebeling et al.,
1993). A high-fat diet, however, resulted in a reduction of GLUT4 transcriptional level in 
both skeletal muscles and adipose tissues, which was associated with decreased glucose 
utilization (Pedersen et a l , 1991; Kim et a l , 1994). When comparing the response rate, 
changes in GLUT4 translocation happened in a much faster manner in response to insulin 
stimulation, than in response to altered metabolic conditions (Brown, 2000).
Studies have been carried out in a wide range diabetic and non-diabetic model systems, 
with the aim of drawing a link between GLUT4 expression and insulin resistance. 
However, the results have not been conclusive. In different GLUT4 knock-out mouse 
models, various degrees of diabetic complications were exhibited (Zisman et a l , 2000; 
Abel et a l , 2001). Therefore, downregulation of GLUT4 protein in diabetic model has 
been proposed as one of the causes of elevated extracellular glycemic level (Berger et al., 
1989; Garvey et a l , 1989; Sivitz et a l , 1989). However, these diabetic animal models 
demonstrated a reduction of GLUT4 expression only in adipose tissues, not in muscles 
(Shepherd and Kahn, 1999; Astrup and Finer, 2000), which argues against the idea that 
GLUT4 is the main causative factor in insulin resistance (Shepherd and Kahn, 1999).
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Researchers currently think that the reduction of GLUT4 expression might more likely be 
one of the outcomes of diabetes (Brown, 2000).
GLUTS or intestine glucose transporter. GLUT5 is the GLUT isoform heading the Class 
II category of the family: it possesses weak homology when compared to the Class I 
isoforms (Kayano et a l , 1990). It is more of a fructose transporter than a glucose 
transporter, and transports fructose preferentially in the furanose ring form (Kane et al., 
1997). It expressed at highest level in the small intestine, where it is generally believed to 
be crucial for nutritional daily fructose uptake (Davidson et al., 1992; Kane et al., 1997). 
In the intestine, it is expressed predominantly at the luminal surface of the absorptive 
epithelial cells, where together with GLUT2 it mediates glucose transport across the 
intestinal linings (Davidson et al., 1992). It was also reported to exist at a high level in 
human spermatozoa, and mediates the consumption of fructose by sperm cells from 
seminal fluid (Burant et al., 1992). Furthermore, it can be found in brain endothelium, 
kidney, muscle and fat cells, yet at a comparatively lower level (Hundal et al., 1992; 
Shepherd et al., 1992; Wood and Trayhum, 2003). It is a high affinity hexose transporter 
(Miyamoto et al., 1994) and possesses consistent fructose transport across a wide range 
of pH (i.e. pH 4.5-7.5) (Kane et al., 1997). However, the role of GLUT5 in the brain 
endothelial cells is unclear, since fructose is not the prime metabolic substrate in the brain 
(Mantych et al., 1993a).
Examination of GLUT5 transport activity in intestine and spermatozoa has shown that 
GLUT5 is insensitive to insulin and cytochalasin B, a competitive GLUT inhibitor 
(Burant et al., 1992; Shepherd et al., 1992). This contradicts a previous study, in which
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GLUT5 was observed as a cytochalasin B sensitive transporter in Xenopus laevis oocytes 
(Kayano et al., 1990). In addition, a recent study showed that chronic insulin incubation 
with a muscle cell line, caused a dose-dependent increase in GLUT5 expression and 
transport activity. This increase in abundance and functional activity of GLUT5 in 
skeletal muscle cells was suggested to be mediated via activation of the GLUT5 promoter 
(Hajduch et al., 2003). The discrepancy in results might be due to different tissues used in 
the experiment, yet little has been done to clarify the inconsistency.
GLUT6. The name GLUT6 was originally assigned to a pseudogene derived from the 
GLUT3 gene (Kayano et al., 1990). However, the GLUT6 designation has now been 
transferred to a gene originally designated GLUT9 (Joost et al., 2002). Human GLUT6 
mRNA is expressed predominantly in spleen, peripheral leucocytes and brain, but protein 
expression has never been observed (Doege et al., 2000b). When constituted in primary 
adipocytes, GLUT6 was retained in the intracellular compartment, and no stimulus has 
been shown to cause its translocation (Lisinski et al., 2001).
GLUT7. GLUT7 was recently characterised as a transporter possessing 68% similarity 
and 53% identity to GLUT5 (Li et al., 2004). It was identified in a genome homology 
search (Joost and Thorens, 2001) and is known to be expressed in small intestine, colon, 
testis and prostate as a high affinity glucose and fructose transporter (Li et al., 2004). It 
contains a six-amino acid chain at its carboxyl terminus, which is similar to a consensus 
motif in GLUT2 for retention of the protein in the endoplasmic reticulum (Mueckler, 
1994a; Joost and Thorens, 2001).
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GLUT8. Similar to GLUT6, GLUT8 (formerly GLUT11) was found to be entirely 
retained intracellularly. It is believed to be involved in mediating glucose homeostasis 
(Piroli et al., 2002). In addition, GLUT8 revealed a relatively high affinity for glucose 
transport (Ibberson et al., 2000), with the transport process being both fructose and 
galactose competitive (Wright and Turk, 2004). Insulin successfully induced 
translocation of GLUT8 to the plasma membrane in blastocytes (Carayannopoulos et al.,
2000), but failed in fat cells (Lisinski et al., 2001). Its mRNA was abundantly found in 
testis and brain, and at lower level in adipose tissues, heart and skeletal muscles (Ibberson 
et al., 2000; Sankar et al., 2002). Recently, it has been observed in liver, and suggested to 
be related to diabetic pathogenesis, as a reduction of GLUT8 mRNA level was found in 
mouse diabetic models (Doege et al., 2000a). It was suggested that, like GLUT2 and 
GLUT4, GLUT8 is another GLUT isoform closely involved in glucose homeostasis 
(Gorovits et al., 2003)
GLUT9. The GLUT9 isoform has the highest degree of similarity with GLUT5 (Joost 
and Thorens, 2001), which suggested a fructose transport property might exist. A recent 
study in which GLUT9 was expressed in Xenopus laevis oocytes, found that GLUT9 
transport activity was cytochalasin B-insensitive and had low transport affinity (Augustin 
et al, 2004). GLUT9 is mostly found in kidney and liver (Phay et al., 2000; Joost and 
Thorens, 2001). Low mRNA levels were detected in lung, small intestine, leukocytes, 
placenta (Phay et al., 2000) and human chondrocytes (Mobasheri et al., 2002).
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GLUT10. GLUT10 is a Class III GLUT with highest similarity to GLUT8 (Wood and 
Trayhum, 2003). It is expressed in liver and pancreas, with lower mRNA levels found in 
heart, kidney, placenta and skeletal muscles (McVie-Wylie et al., 2001). The 
chromosome localization of GLUT 10 lies in the same region as a type-2 diabetes 
susceptibility locus. Therefore, GLUT 10 has been suggested as a candidate gene involved 
in this metabolic disorder (Dawson et al., 2001).
GLUT11. Currently, three different alternative splice isoforms have been derived for 
GLUT11, due to the presence of three different first exons, that code for three 
corresponding N-termini (Sasaki et al., 2001). It presents as a functional isoform with 
low transport affinity, and cytochalasin B-sensitivity (Doege et al., 2001). It is expressed 
in different tissues, including heart and skeletal muscles (Wu et al., 2002), and at 
intermediates level in tissues such as brain and small intestine (Wu et al., 2002). A 
crucial role of GLUT11 has been suggested in muscle glucose homeostasis, due to its 
specific expression pattern in this tissue (Uldry and Thorens, 2004).
GLUT12. GLUT12 cDNA was cloned from a human embryonic cDNA library and found 
to be mainly expressed in heart, prostate and moderate levels at skeletal muscles, brown 
adipose tissues, muscle, small intestine and mammary gland (Rogers et al., 2002; 
Macheda et al., 2003). Strong expression has been found in breast tumours, which 
indicates a possible role of GLUT 12 in hexose supply under oncogenic conditions 
(Rogers et al., 2003b). In addition, GLUT 12 has shown selective affinity to D-glucose, 
followed by D-deoxyglucose, D-galactose and D-fructose (Rogers et al., 2003a).
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HMIT. No hexose transport activity has been found for HMIT, but it was determined as a 
specific transporter for /wyo-inositol (Joost and Thorens, 2001). Its transport activity is 
high and could be activated by lowering the pH, with a maximal transport capacity at pH 
5.0 (Uldry et al., 2001; Eladari et al., 2002). The transport affinity of HMIT is sensitive 
to several inhibitors such as phloretin, phlorizin and cytochalasin B (Hager et al, 1995). 
In the rat brain, it exists as a 75-90 kDa glycoprotein, but can be converted to a 67 kDa 
form upon enzymatic deglycosylation . HMIT is expressed in neurons and glial cells, 
located both intracellularly and on the membrane surface. It is the transporter isoform 
which is believed to be responsible for /wyo-inositol metabolism and signal transmission 
process in the brain (Uldry et al., 2001).
GLUT14, The most recently cloned GLUT isoform that was reported two years ago. 
GLUT 14 has remarkable identity to GLUT3, and is assumed to be a pseudogene that 
arose through duplication of GLUT3. It exists exclusively in the testis, and is present in 
two different splice forms. The long form (GLUT14-L) differs from the short form 
(GLUT14-S) by an additional exon coding for a novel N-terminus. In the testis, its 
mRNA level is three times higher than that of GLUT3 (Wu and Freeze, 2002). However, 
further details on its functional role have not been investigated.
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1.2.3.2 Sodium glucose cotransporters (SGLTs)/symporters
The sodium cotransporters belong to the SLC5 superfamily, which consists of 220 or 
more members in animal and bacterial cells (Wright and Turk, 2004). Among all, seven 
SGLT isoforms have been suggested to mediate glucose transport, but only four of them 
are functionally characterised (Wright, 2001; Wright and Turk, 2004). In the SGLT 
system, glucose is transported against its own concentration gradient, but down the 
sodium gradient across the plasma membrane (Wood and Trayhum, 2003) (Table 1.2). 
Since sodium in cells is constantly being pumped out by the Na+, K+-ATPase, glucose 
transport via the SGLTs is recognised as an active transport process (Wright, 2001; Wood 
and Trayhum, 2003). Thus, SGLTs are secondary active transporters, driven by a pre- 
established sodium gradient. Glucose transport is coupled such that a single glucose 
molecule is translocated across the plasma membrane with one or more sodium at one 
time (Horibe et al., 1997). The SGLTs are believed to play a major role in dietary glucose 
uptake, particularly at the small intestine (Ferraris, 2001; Stumpel et al., 2001).
Structure. Similar to GLUTs, all cotransporter family members have a 12 transmembrane 
alpha helical structure, accompanied by clear helical packing in the carboxy-terminus. 
Their secondary structure suggests the presence of 14 helices, with both the amino- and 
carboxy-termini on the extracellular side of the membrane (Turk and Wright, 1997; Jung,
2002). Only four amino acids are known to be essential for functional activity, since 
researchers are encountering difficulties in studying expression constructs (Lostao et al., 
1995; Martin et al., 1996). In general, all the transporters in this group seem to work by 
the same mechanism, in which the rate or direction of transport depends purely on the
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number of ligands on each side of the plasma membrane and the membrane potential 
(Parent et al., 1992; Hirayama et al., 1997; Meinild et al., 2002). They transport substrate 
in an “alternative access” manner (Loo et al., 1998), with a maximal turnover rate of 1- 
100 per second at room temperature (Wright and Turk, 2004).
SGLT1. Rabbit SGLT1 was the first isoform to be cloned. It is responsible for high 
affinity, low capacity glucose cotransport in the rabbit intestine (Hediger et al., 1987). Its 
human homologue was cloned two years later (Hediger et al., 1989), and found to possess 
a nucleotide similarity of 71% (Wood and Trayhum, 2003). It expressed predominantly 
in the absorptive epithelial cells of the small intestine, where it mediates D-glucose and 
D-galactose absorption from the gut lumen (Takata, 1996; Ferraris, 2001; Wright et al., 
2003). In addition, it also performs glucose reabsorption in the late proximal tubules to 
prevent glucose loss (Cramer et al., 1992; Lee et al., 1994; Takata, 1996) and is known to 
bear a 2:1 stoichiometry between sodium and glucose (Panayotova-Heiermann et al., 
1995; Mackenzie et al., 1998). Although no obvious selectivity has been revealed for 
SGLT1 in transporting different hexoses, differences in selectivity do exist between 
species (Hirayama et al., 1996). In the absence of glucose, SGLT1 also acts as a uniporter 
of sodium ions, water pump (Loo et al., 1996; Meinild et al, 1998), urea channel or 
cotransporter for both water and urea (Leung et al., 2000b).
Freeze-fracture electron microscopy has confirmed that SGLT1 functions as a 14-helical 
monomer in the plasma membrane (Turk et al., 2000). Further studies also suggest that 
helices 10-13 of GLUT1 form the sugar permeation pathway (Panayotova-Heiermann et 
al., 1997), while channels for small molecules such as urea have also been observed for
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rabbit SGLT1 when expressed in oocytes (Panayotova-Heiermann and Wright, 2001). 
Malabsorption of glucose and galactose was reported to be related to mutations of human 
SGLT1 (Turk et al.f 1991). The disease was caused by improper trafficking of the 
mutated SGLT1 to the plasma membrane, which impaired transport activity and 
decreased transport affinity (Martin et al., 1996). Fortunately, the disorder could be 
corrected by substituting dietary glucose with fructose (Wood and Trayhum, 2003).
SGLT2, SGLT2 is a low-affinity glucose cotransporter predominantly expressed in the 
kidney (Oulianova and Berteloot, 1996). Controversy has surrounded whether SGLT2 is 
the major SGLT isoform in the kidney, rather than SGLT1 (Wright, 2001; van den 
Heuvel et al., 2002). SGLT2 is expressed in the convoluted proximal tubules (Kanai et 
al., 1994) where it is believed to play an important role in bulk glucose transport from the 
glomerular filtrate back to the blood stream (Oulianova and Berteloot, 1996). It is a low 
affinity, but high capacity transporter with a stoichiometry between sodium and glucose 
of 1:1 (Diez-Sampedro et al., 2001). However, unlike SGLT1, it functions as a more 
selective transporter that prefers D-glucose to D-galactose as a substrate (Mackenzie et 
al, 1994). In addition, its transport affinity is much lower (-10 fold) than that of SGLT1 
(Wright, 2001).
SGLT3. SGLT3, formerly named as pig-SGLT2, is a SGLT isoform that demonstrates 
the same stoichiometry and affinity as SGLT1 (2:1), but has a specificity similar to that 
of SGLT2 (Mackenzie et al., 1996). It shares 70% amino acid identity with human 
SGLT1, and is expressed in small intestine and skeletal muscles (Diez-Sampedro et al.,
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2003). Its transport process is phlorizin-sensitive, which is a common feature 
demonstrated in SGLT1 and SGLT2 (Oulianova and Berteloot, 1996; Loo et al., 1998; 
Diez-Sampedro et al., 2003). However, the functional role of SGLT3 is suggested to be 
one of glucose sensing, rather than glucose transport (Diez-Sampedro et al., 2003).
SGLT4, SGLTS and SGLT6. SGLT4 is widely expressed in the body, while SGLT5 is 
expressed exclusively in the kidney. Further functional characteristics are not yet 
available for these two isoforms (Wright and Turk, 2004). SGLT6 is a high affinity 
cotransporter for myo-inositol, but with a lower affinity for D-glucose, as demonstrated in 
the rabbit (Nagata et al, 1999; Coady et al, 2002). SGLT6 is widely expressed in human 
tissues (Roll et al, 2002; Wright and Turk, 2004).
Sodium-dependent myo-inositol transport (SMIT). This is the last member in the 
superfamily thought to possess glucose transport function. It is widely expressed (Kwon 
et al, 1992) and suggested to play a crucial role in the pathogenesis of Down syndrome 
(Berry et a l, 1995). It demonstrated a relatively high affinity in transporting /wyo-inositol, 
but also different sugars, including D-glucose at a lower affinity (Hager et al., 1995).
25
Isoform Geae
name
Amino
acid
residues
Class M ain tissue expression M ajor biological roles
Transport
Properties*
Primary
references
GLUT1 SLC2A1 492 I
Erythrocytes, brain, 
ubiquitous in different 
tissues
General basal glucose transport, 
blood-tissue barriers glucose 
transport
Km glucose ~ 20mM 
IQ ~ 0.08-0.19mM
(Mueckler et a l,  1985; 
Harik et al., 1990; Takata 
et al., 1990; Gould et al., 
1991; Hellwig and Joost, 
1991)
GLUT2 SLC2A2 523 I Pancreas, liver, small intestine, kidney
Pancreatic and hepatic glucose 
homeostasis, intestinal hexose 
(including glucose, fructose and 
galactose) transport and renal 
reabsorption
Km glucose ~ 40mM 
IQ ~l.7-l.8m M
(Thorens etal., 1988; 
Fukumoto et al., 1988b; 
Gould etal., 1991; 
Wandel etal., 1996)
GLUT3 SLC2A3 496 I Brain (neurons) Glucose transport in the brain neurons Km glucose ~ lOmM
(Kayano eta l., 1988; 
Gould etal., 1991; 
Nagamatsu etal., 1992)
GLUT4 SLC2A4 510 I Adipose tissue, cardiac 
muscle, skeletal muscle,
Insulin-dependant glucose 
transport
Km glucose ~ 3mM 
IQ ~ 210±60nM
(Bimbaum, 1989; 
Fukumoto et al., 1989; 
James et al., 1989; 
Wandel etal., 1996)
GLUT5 SLC2A5 501 n Intestine, kidney, testis Fructose absorption, low affinity hexose transport IQ, fructose ~ 11.6mM
(Kayano etal., 1990; 
Burant e tal., 1992; 
Davidson eta l., 1992; 
Shepherd etal., 1992)
GLUT6 SLC2A6 507 m Brain, leukocytes, spleen Low affinity glucose transport IQ~ 210±30nM (Doege et al., 2000b; Lisinski et al.. 2001)
GLUT7 SLC2A7 524 ii Small intestine, colon, 
testis, and prostate Glucose and fructose transport
IQ, glucose ~ 0.3mM 
Km fructose ~ 0.06mM
(Li eta l., 2004)
GLUT8 SLC2A8 477 hi Testes, brain, 
insulin-sensitive cells
Glucose homeostasis, 
insulin-stimulated glucose 
transport
Km 2-deoxy-D-glucose 
~2.4mM 
IQ~56.6±18nM
(Ibberson et al., 2000; 
Doege et al., 2000a)
GLUT9 SLC2A9 540 n Kidney, liver Low affinity deoxy-D-glucose transport IQ~ 105.2±16nM
(Phay et al., 2000; 
Augustin et al., 2004)
GLUT 10 SLC2A10 541 hi Liver, pancreas
2-deoxy-D-glucose, D-glucose, 
D-galactose transport
IQ, 2-deoxy-D-glucose 
~0.3mM
(Dawson et al., 2001; 
Me Vie-Wylie etal., 
2001)
GLUT 11 SLC2A11 503/499/496 ii
Cardiac muscle, 
Skeletal muscle
Fructose transport, 
low affinity to glucose IQ~ 196.6±29.7nM
(Doege et al.. 2001; 
Sasaki e tal., 2001; Wu et 
al., 2002)
GLUT 12 SLC2A12 617 m Heart, prostate D-glucose transport — (Rogers et al.. 2002; Rogers et al., 2003b)
HMIT SLC2A13 629 m Brain myo-inositol transport
Km myo-inositol 
~ O.lmM (Joost and Thorens, 2001; Uldry eta l., 2001)
GLUT 14 SLC2A14 497/520 — Testis — — (Wu and Freeze, 2002)
Table 1.1 Characteristics of the SLC2 family. Please see remarks on the following page.
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Isoform Genename
Amino
acid
residues
Main tissue expression Major biological roles Transportproperties* Primary references
SGLT1 SLC5A1 664 Small intestine, kidney, heart
Sodium-dependant intestinal glucose 
and galactose uptake, 
renal reabsorption
Km D-glucose ~ 0.2-0.4mM 
Km sodium ions ~ 3mM
(Lee etal., 1994; 
Hirayama et al., 1996; 
Oulianova and 
Berteloot, 1996)
SGLT2 SLC5A2 672 Kidney
Sodium-dependant renal glucose 
reabsorption
Kra D-glucose ~ 2mM 
Km sodium ions ~ lOOmM
(Kanai et a l, 1994;
Oulianova and 
Berteloot, 1996)}
SMIT SLC5A3 718 Brain, heart, 
kidney, lung
Sodium-dependant myo-inositol and 
glucose transport Km myoinositol ~ 0.05mM
(Hager et al., 1995)
SGLT3 SLC5A4 660 Small intestine, 
skeletal muscle
Glucose activated sodium channels Km D-glucose ~ 6mM Km sodium ions ~ 1.5mM
(Mackenzie et al., 1996; 
Diez-Sampedro et al., 
2001)
SGLT4 SLC5A8 659 Brain, liver, lung, kidney, 
small intestine
— —
(Li et al., 2003; Wright 
and Turk, 2004)
SGLT5 SLC5A9 681 Kidney — — (Wright and Turk, 2004)
SGLT6 SGL5A10 673 Brain, heart, liver, lung, small intestine
myoinositol, glucose transport myoinositol ~ 0.25mM Km sodium ions ~ 12.5mM
(Nagata et al., 1999; 
Wright and Turk, 2004)
Table 1.2 Characteristics of the SLC5 family members. *Km is the Michaelis-Menten constant, which indicates the substrate transport
affinity of the transporter; The dissociation constant (Kd) indicates the binding affinity of the transporters to cytochalasin-B. A 
high K<j indicates high substrate transport capacity, but low substrate affinity.
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1.2.4 Glucose transport in blood-tissue barriers
In the body, most substrates can exchange freely between blood vessels and tissue cells. 
However, specific organs and tissues have developed a barrier which is selectively 
impermeable to certain substrates. For example, the BAB in the eye is impermeable to 
proteins, so as to maintain ocular transparency (Bill, 1986). In this section, some tissue 
barriers which possess a similar functional structure to the BAB are introduced.
1.2.4.1 Blood-brain barrier (BBB)
The brain comprises ~ 2% of body weight but accounts for ~ 20% of total glucose 
consumption in humans. It has one of the highest metabolic rates of any organ (Sokoloff, 
1973). In the BBB, tight junctions are present between endothelial cells, to hinder free 
substrate exchange (Stewart et al., 1994). Intravenous injection experiments have 
demonstrated these barrier properties; thus tracers (such as horseradish peroxidase) 
remain in the lumen of blood vessels, unable to diffuse beyond the vascular endothelium 
(Reese and Kamovsky, 1967). Since glucose is the primary energy source for the brain, a 
specific mechanism to ensure continuous glucose supply is clearly necessary.
Glucose transport into brain cells occurs through a series of steps, with a decrease in 
concentration gradient, but an increase in transporter affinity at each step. From the blood 
plasma to the extracellular cerebral fluids, the glucose gradient decreased from 6 mM to 4 
mM. Further to cerebral cells, the glucose concentration reduced to 0.5 mM. This 
reduction in glucose concentration was compensated by a general increase in transport 
affinity against the concentration gradient e.g. the kinetic constant (Km) of blood 
capillaries is 8 mM, while at the cellular cells is 5 mM. This increase in transporter
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affinity compensates for the falling glucose concentration and helps to maintain an 
adequate glucose level for cerebral metabolism (Crone, 1965; Bachelard, 1971; 
Pappenheimer and Setchell, 1973). Currently, GLUT1 is believed to be the predominant 
form of glucose transporter in the brain. This has been confirmed by immunoblotting 
(Takata et al., 1990; Pardridge et al., 1990b), northern blotting (Boado and Pardridge, 
1990; Kamei et al., 1999) and cytochalasin B-binding assay (Kalaria et al., 1988; Dwyer 
and Pardridge, 1993). In addition, GLUT3 is also abundantly expressed in brain neurons 
(Nagamatsu et al., 1992; Nagamatsu et al., 1993; Vannucci et al., 1998a) and GLUT5 in 
microglia (Maher et al., 1994; Horikoshi et al., 2003). In addition to the facilitated 
diffusion system, immunohistochemical, immunoblotting (Nishizaki et al., 1995) and 
tracer studies (Lee et al., 1997; Nishizaki and Matsuoka, 1998) have suggested the 
presence of SGLT in bovine cortical vessels and BBB respectively. Since the glucose 
concentration in the brain is only -20% to that of plasma (Raichle et a l, 1975; Gruetter et 
al., 1992), the presence of SGLTs would seems unnecessary, yet its functional role in the 
brain has not been investigated.
1.2.4.2 Blood-placental barrier (BPB)
The placenta is an important organ for the exchange of gases, nutrients and metabolites 
between maternal and fetal blood. Fetal blood is bounded inside a continuous endothelial 
layer with tight junctions (Heinrich et al., 1976). However, these tight junctions are of the 
discontinuous type, which indicates the possibility of paracellular transport (Leach and 
Firth, 1992). The syncytiotrophoblast layer, a continuous single cell layer, is the main 
BPB component which separates the maternal and fetal circulation (Johnson and Smith,
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1985). In order for glucose to reach the fetal circulation, it must pass this syncytial layer. 
Currently, it is widely accepted that glucose transport across the placenta is by the action 
of facilitated diffusion transport machinery. Kinetic studies (using the GLUT inhibitors 
phloretin and cytochalasin B) (Johnson and Smith, 1985), as well as northern blotting, in 
situ hybridization (Kamei et al., 1999; Illsley, 2000), and immunoblotting (Takata et al., 
1992; Hahn et al., 1995) studies all suggest the existence of GLUTs, especially GLUT1 
and GLUT3 in the placenta. The highest level of GLUT1 expression was found along the 
syncytiotrophoblast and localized heavily at its microvillous apical membrane (Jansson et 
al., 1993). In addition, the gap junction protein connexin 26 was found between the 
double-layered syncytiotrophoblast in rats (Metz et al., 1978; Risek and Gilula, 1991). 
The protein may act as an intercellular hydrophilic channel for small molecules including 
glucose (Spray and Bennett, 1985). Similar to CBE, it has been suggested that 
transplacental glucose transfer begins with glucose entering the cytoplasm of the 
syncytial layer at the apical side via GLUT1. After passing through the gap junctions and 
reaching the basal side of the membrane, it also leaves by export through GLUT1 
transporters (Takata, 1996). Similar to CBE, GLUT transporters together with gap 
junctions have been proposed as the major route of BPB glucose transport in human and 
rat (Takata et al., 1994; Takata, 1996).
1.2.4.3 Ocular barriers
The eyes can be regarded as an extension of the central nervous system (CNS) for they 
are developed from the neural tube. The blood ocular barrier, including the blood-retinal 
barrier (BRB) and BAB, is suggested to be comparable to the BBB. The BRB comprises
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the retinal microvasculature and the RPE. The former component has the property of the 
brain barrier (Bill et al., 1980), since tracers such as horseradish peroxidase (Raviola, 
1977), or endogenous serum proteins like albumin and immunoglobulin (Pino and 
Thouron, 1983), fail to cross it. The RPE constitutes the outermost layer of the retina and 
possesses both tight junctions and gap junctions (Hudspeth and Yee, 1973; Raviola,
1977). This barrier contributes significantly to the provision of nutrition to the outer 
retina (Ames, 1992), and separates the retina from the choroidal capillaries. Tight 
junctions in the RPE, make paracellular diffusion of glucose impossible (Ban and 
Rizzolo, 1997; Rizzolo, 1997). Since retina is one of the highest metabolically active 
tissues (Sharma and Ehinger, 2002), and derives most of its energy from glycolysis 
(Krebs, 1972), mechanisms must be present to allow glucose to diffuse across the RPE to 
the retina.
Transport of glucose in the RPE was found to occur by passive facilitated diffusion, since 
it was sensitive to inhibitors of facilitative glucose transport (DiMattio and Zadunaisky, 
1981; Stramm and Pautler, 1982; To and Hodson, 1998b) and provided rich 
immunohistochemical staining for GLUT1 (Harik et al., 1990; Mantych et al., 1993b). In 
the retinal capillaries, GLUT1 was expressed at the barrier site (i.e. the endothelial cells) 
and also intracellularly and on the cellular membranes (Takata et al., 1990; Kumagai et 
al., 1996). In general, GLUT1 is believed to be the major barrier glucose transporter 
present in the retina, whilst intra-retinal glucose distribution is carried out by GLUT 2 
(Watanabe et al., 1994) and GLUT3 (Mantych et al., 1993b).
The BAB is the barrier separating the blood plasma and aqueous humor at the anterior 
part of the eye. The aqueous humor is the major nutrient source (including glucose) for
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many avascular ocular tissues such as the cornea and crystalline lens (Chylack and 
Cheng, 1978; DiMattio, 1984a; Thies and Mandel, 1985). The aqueous glucose 
concentration is comparable to that of blood (Cole, 1984): approximately 81% of that of 
plasma (Abdel-Latif, 1997). As illustrated in figure 1.2, glucose transport in the 
mammalian CE is accomplished by firstly transport from the blood plasma to the stromal 
layer, then into the PE cells via GLUTs. Then, it diffuses through the gap junctions, 
which connect the PE and NPE. Finally, it is transported into the aqueous humor by 
GLUTs (Takata et al., 1997). In this case, GLUT1 acts as a selective gate, whilst the gap 
junctions act as non-selective channels (Shin et al., 1996). Immunocytochemical studies 
have revealed heavy staining for GLUT1 in both the PE and NPE cells (Takata et al., 
1990; Takata et al., 1991), especially along the basal infoldings in these layers (Takata et 
al, 1997). These observations support the previous model described for the glucose 
transport across this part of the BAB.
Endothelial cells of the blood vessels in the iris stroma constitute the other part of the 
BAB. As the continuation of the CBE (Raviola, 1977), the iridial epithelium shows 
similar structures or features, such as tight junctions and inter-cellular gap junctions 
(Freddo, 1984). Heavy labeling was observed for GLUT1 in both the luminal and 
contraluminal plasma membranes (Takata et al., 1991) and it is possible that glucose uses 
a similar pathway to enter and leave the iridial layers as it does in the CBE (Takata et al., 
1997).
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1.3 Diabetes Mellitus (DM)
1.3.1 Prevalence
In the past 20 years, the increasing prevalence of DM and its related systemic 
complications have drawn the attention of researchers worldwide (Leung and Lam, 
2000a). In 1997, an estimated 124 millions people were suffering from DM worldwide, 
with 97% of them having non-insulin dependent DM (NIDDM). Among all, 46% of 
diabetes are from the Asia-Pacific region. By the year 2010, this figure is expected to 
climb to 221 millions (Amos et al., 1997). Since diabetic patients are at risk of various 
acute (e.g. diabetic ketoacidosis) and chronic complications (e.g. nephropathy), it is 
regarded, therefore, as a major source of mortality (Gu et al., 1998; Tseng, 2004) and 
economic burden to the society (American Diabetes Association, 1998; Clarke et al., 
2003).
1.3.2 Cause of DM
DM is a disorder of carbohydrate metabolism, which also affects protein and lipid 
metabolism. It is characterized by excess urine excretion, hyperglycemia and a set of 
systemic complications that primarily affect the blood vessels of the brain, kidney, eyes 
and limbs. Two main theories have been proposed to explain the cause of DM. They are 
the “idiopathic” theory and the “secondary” theory. Idiopathic DM can be further 
categorized into two types: type 1, also known as insulin dependent DM (IDDM) and 
type 2, also named NIDDM. Type 1 DM is caused by an autoimmune destruction of the 
beta-cells in the pancreas, and is manifested at the age of 20 or earlier, so it is also named 
juvenile onset diabetes. It is a rarer type of DM compared to type 2, yet it more often
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develops into ketoacidosis. Type 2 DM is the more common type, which presents with 
milder hyperglycemia and seldom leads to ketoacidosis. It is mostly in adult onset (thus it 
is sometimes called adult-onset diabetes). It usually manifests after the age of 40 and has 
been suggested to be a result of a genetic defect, which causes both insulin resistance and 
insulin deficiency (Galuk, 1991; Avery, 1998). It can be caused by insufficient number of 
functional insulin receptors on the surface of plasma membrane, which thus fail to 
provide adequate glucose uptake under normal conditions (Lonnroth, 1991; Lebovitz, 
2001). Hales and co-workers proposed the ‘Thrifty Phenotype Hypothesis’ for NIDDM in 
1992. This is based on the conflict between malnutrition at a certain stage of fetal 
development and over-nutrition in adulthood (Hales and Barker, 1992). The postnatal 
over-nutrition conflicts with the early metabolic programming, which finally leads to 
consequences like NIDDM, ischaemic heart disease and hypertension. This hypothesis 
has been tested and supported with studies in both humans (e.g. twin studies) (Poulsen et 
al., 1997; Ravelli et al, 1998) and rats (Snoeck et al., 1990; Hales et al., 1996), both of 
which indicate the importance of in utero conditioning in determining susceptibility to 
type 2 DM.
There are many disorders that could manifest DM as a secondary illness. These 
conditions include pancreatic disease, endocrine disease (Yajnik et al., 1990; Watson, 
2003), mutations in the insulin or insulin receptor genes (Vaxillaire et al., 1999) and 
pregnancy (Homnes, 1985; Godwin et al., 1999). Other genetic syndromes such as 
Down’s syndrome or Walffam syndrome (Robinson and Kessling, 1992; Ristow, 2004) 
also appear to increase the risk of diabetes or impaired glucose tolerance.
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1.3.3 Mechanisms of DM pathogenicity
Various mechanisms have been proposed to explain the pathogenesis of diabetic 
complications. In general, five major theories have been suggested: the increased rate of 
polyol metabolism (Gillis and Chylack, 1982; Gaynes and Watkins, 1989), increased 
protein glycation (Forbes et al., 2004; Zieman and Kass, 2004), activation of protein 
kinase C (PKC) (Inoguchi et al., 2003; Setter et al., 2003), increased flux in hexosamine 
metabolism (Kaneto et al., 2001; Bosch et al., 2003) and increased oxidative stress 
(Dominguez et al., 1998; Ha and Kim, 1999).
1.3.3.1 Polyol pathway
The polyol pathway is a two-step pathway involving the conversion of glucose and 
galactose into sorbitol and galactitol, respectively, as the first step, and from sorbitol to 
fructose as the second step. For the first reaction to occur, aldose reductase (AR) must 
catalyse the NADPH-dependent reduction of the carbonyl compounds (i.e. glucose). In 
hyperglycemic conditions, AR is activated rapidly, so that glucose is oxidized into 
sorbitol, which is in turn oxidized to fructose by sorbitol dehydrogenase (Brownlee, 2001; 
Setter et al., 2003). An excess of glucose increases the rate of the polyol pathway, and 
accounts for almost one-third of total glucose turnover. Indeed the rate of fructose 
metabolism is too slow to keep pace, which results in the build-up of sorbitol (Gonzalez 
et al., 1984). The induced osmotic stress leads to cell swelling and cell disruption (Hotta, 
1997; Oates, 2002). The polyol pathway also generates intracellular conditions (high 
NADH/NAD+ and low NADPH levels) which lead to further hyperglycemic damage to 
the cells via protein glycation and oxidation (Brownlee, 2001).
35
Introduction
1.3.3.2 Protein glycation
Glycation is the process by which non-enzymatic reactions occur between reducing 
sugars and proteins, leading to the formation of advanced glycation end-products (AGEs) 
(Stitt, 2001). High concentrations of NADH/NAD+resulting from the polyol pathway 
increase the amount of triose phosphate through inhibition of the glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) enzyme (Brownlee, 2001). The elevated triose 
phosphate stimulates the production of methylglyoxal, a precursor of AGEs (Ahmed et 
al., 2003). This not only assists the formation of AGEs, but also generates diacylglycerol 
(DAG), which activates PKC (Xia et al., 1994; Koya and King, 1998). Other potential 
promoters of AGE formation are glyoxal from glucose degradation (Welten et al., 2003) 
and 3-deoxyglucosone from the decomposition of the Amadori product (Schalkwijk et al.,
1999). These reducing sugars bind to proteins, causing functional alterations and 
irreversible damage. Studies using inhibitors of AGEs in animal models have shown their 
preventative role against diabetic complications in kidney (Nakamura et al., 1997) and 
retina (Hammes et al., 1991). This confirms the critical role of AGEs in hyperglycemic 
conditions. In general, AGEs interfere with matrix-to-matrix or matrix-to-cell interactions 
(Haitoglou et al., 1992), which finally lead to altered functions e.g. loss of elasticity in 
blood vessels due to impairment of Type 1 collagen function (Tanaka et al., 1988; 
Huijberts et al., 1993). In addition, AGEs can further stimulate cytokine and reactive 
oxygen species (ROS) production through AGE-specific receptors, and intracellular 
proteins modifications (Brownlee, 1995), which cause marked diabetic damage.
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1.3.3.3 Activation of PKC
Hyperglycemia can increase the level of DAG as it has been revealed in cultured 
microvascular cells (Xia et al., 1994; Koya and King, 1998). Besides, DAG can also be 
generated from indirect polyol pathway in hyperglycemic conditions. As a lipid second 
messenger, DAG can activate nine out of the eleven isoforms of PKC (Brownlee, 2001). 
Abnormal activation of PKC is known to cause blood-flow abnormalities in kidney 
(Koya et al., 1997) and decreased production of nitric oxide (Craven et al., 1994). It also 
inhibits transcription of endothelial nitric oxide synthase (Kuboki et al., 2000) but 
increases the transcription of vascular endothelial growth factor (VEGF) (Williams et al.,
1997), which results in elevated permeability of endothelial cells. Moreover, activated 
PKC increases microvascular matrix protein accumulation, due to the increased 
expression of transforming growth factor-beta (TGF-P), fibronectin and type IV collagen 
(Studer et a l, 1993; Phillips et al., 1999). Treatment of diabetic animals using inhibitors 
for PKC-beta (PKC- p) has greatly reduced the PKC activity and diabetic damage in 
retina (Nonaka et al., 2000) and renal glomeruli (Koya et al., 2000; Kelly et al., 2003). 
This shows that activation of the PKC pathway has a crucial role in the pathogenesis of 
diabetes.
1.3.3.4 Hexosamine pathway
During hyperglycemia, the excess intracellular glucose is shunted to the hexosamine 
pathway, which causes measurable insulin resistance in diabetic rats (Robinson et al., 
1995). It has been suggested that the hexosamine pathway is one of the major 
mechanisms responsible for insulin resistance in NIDDM (Zraika et al., 2002). However,
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it has also been proposed that the activated hexosamine pathway actually causes adverse 
pancreatic beta-cell function via oxidation (i.e. over-production of hydrogen peroxide) 
and a reduction in the expression of several beta-cell specific genes (Kaneto et al., 2001). 
Also, an increase in glutamine:fructose-6-phospate amidotransferase (GFAT), the 
enzyme that regulates the conversion of glucose to glucosamine in this pathway, has been 
found to attenuate cellular glucose uptake via activation of the PKC pathway (Bosch et 
al., 2003). Despite the controversy in the exact underlying mechanism, it is generally 
believed that activation of the hexosamine pathway could cause various changes in gene 
expression and protein function, leading to the observed diabetic manifestations, such as 
diabetic nephropathy (Schleicher and Weigert, 2000; Brownlee, 2001).
1.3.3.5 Oxidative stress
Chronic hyperglycemia induces oxidative stress, which is characterized by an increased 
level of reactive oxygen species (ROS) and a deficiency in antioxidative defence 
(Bonnefont-Rousselot et al., 2000). In diabetes, hyperglycemia causes increased ROS 
levels at the mitochondrial complex II (Nishikawa et al., 2000), where they modulate and 
affect various biological signal pathways (Suzuki et al., 1997). Excess superoxide 
production via oxidative phosphorylation in hyperglycemic conditions induces 
endothelial dysfunction that results in cardiovascular complications (Doi et al., 2001), 
which is now a leading cause of morbidity and mortality in diabetic patients (Bonnefont- 
Rousselot et al., 2000). Furthermore, ROS contribute in the formation of atherosclerosis 
in diabetic patients by activating extracellular matrix metalloproteinases (Uemura et al.,
2001). Consumption of NADPH in the polyol pathway causes NADPH depletion and
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leads to poor regeneration of glutathione (Brownlee, 2001) which weakens the 
antioxidative system. Excessive production of AGEs, on the other hand, produces ROS 
via several complex biochemical mechanisms (Mullarkey et a l , 1990) such as reduced 
signalling through the endothelial receptor of AGE (RAGE) (Heidland et al., 2001). This 
in turn causes reduced production or activation of transcription factors such as nuclear 
factor kappa B (Nishio et al., 1998), resulting in vascular abnormalities e.g. inflammatory 
reactions, smooth muscle cell proliferation, and angiogenesis (De Martin et al., 2000; 
Collins and Cybulsky, 2001) due to release of pro-inflammatory cytokines or adhesion 
molecules (Heidland et al., 2001).
Apparently, all of these mechanisms interact with one another. However, recent reports 
have suggested that the overproduction of superoxide by the mitochondrial electron- 
transport chain is the common process shared by these pathogenic mechanisms 
(Nishikawa et al., 2000; Brownlee, 2001; Du et al, 2003). Interruption of the intracellular 
overproduction of superoxide suppressed cellular damages induced by the activation of 
polyol pathway, increased AGEs formation, activation of the PKC pathway and 
hexosamine pathway (Nishikawa et al, 2000; Brownlee, 2001; Hammes, 2003). This 
demonstrated the crucial role of oxidative stress in diabetic complications and provides a 
new insight in the treatment of hyperglycaemic-related disorders.
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1.3.4 DM induced ocular manifestations
DM can lead to different ocular complications such as diabetic keratopathy (Schultz et 
al., 1983), iris neovascularization (Femandez-Vigo et al, 1997; Tolentino and Adamis,
1998), diabetic cataract (Altomare et a l, 1995; Duhaiman, 1995; Lee and Chung, 1999; 
Kyselova et al, 2004), diabetic vitreopathy (Sebag, 1996; Stitt et al, 1998), diabetic 
retinopathy (DR) (Ciulla et al, 2003; Khan and Chakrabarti, 2003; Rotimi et al, 2003; 
Turczynski et al, 2003; Frank, 2004) and diabetic maculopathy (Giovannini et al, 1999; 
Ikeda, 2000; Misra et al, 2004). Among all, DR and diabetic cataract are the most 
common visual disabilities and cause the highest visual impairment rates (Seyoum et al, 
2001; Rotimi et al, 2003).
1.3.4.1 Diabetic retinopathy (DR)
The deterioration in the retinal blood vessels due to diabetes is known as DR. It is the 
most common ocular manifestation in diabetic patients (Ciulla et a l, 2002; Ciulla et al,
2003) and is the leading cause of blindness in the working age population in the 
industrialized world (Stanga et al, 1999; Ciulla et al, 2002). DR is characterized by loss 
of retinal pericytes, retinal capillary closure, ischaemia (Archer, 1999), and 
neovascularization (Aiello, 1997). Recently, loss of neurons by apoptosis and activation 
of glial cells were also observed in human DR and in animal models (Barber et a l, 1998; 
Zeng et al, 2000). The prevalence of DR was investigated in diabetic patients, with no 
significant difference found between type 1 DM and type 2 DM subjects (Seyoum et al, 
2001; Hammes et al, 2004). Similar to other diabetic complications, DR is caused by 
more than single pathogenic mechanism. Increased oxidative stress, promotion of PKC
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pathway, increased formation of AGE and more contribute in causing retinal blood 
vessels abnormalities e.g. blockage, leakage or dilation (Van den Enden et al., 1995; Ono 
et al., 1998; Chakrabarti et al., 2000; Stitt, 2001). Besides, VEGF is thought to promote 
retinal leukostasis via induction of intercellular adhesion molecule-1 (ICAM-1) (Lu et al.,
1999). This is a process in which leukocytes tend to stick to the vascular endothelium and 
results in vascular blockage and free radical (i.e. superoxide) generation (Miyamoto et
al., 1999).
The loss in vascular permeability has been suggested to be complicated by the down- 
regulation of membrane barrier transporter GLUT1 (Kumagai et al., 1994; Badr et al.,
2000). However, other researchers have found no such changes (Fernandes et al., 2003) 
or even an increase (Kumagai et a l , 1996) in inner GLUT1 level in hyperglycemia. 
Recent research also suggested another hypothesis, in which the insulin-like growth 
factor-1 (IGF-1) plays a pathological role. By inhibiting IGF-1, vascular damage and 
proliferation were diminished (Kuang et al., 2003; Poulaki et al., 2004).
1.3.4.2 Diabetic cataract
Cataractogenesis is one of the most common secondary DM complications (Nielsen and 
Vinding, 1984; Leske et a l , 1991). The explanation for diabetic cataract formation can be 
traced back as early as in 1959, when the osmotic hypothesis was proposed (van 
Heyningen, 1959). As mentioned in section 1.3.3.1, a high glucose concentration 
stimulates AR and promotes an osmotic challenge. Hyperglycemia in the lens causes 
excess glucose to pass through the polyol pathway, which leads to sorbitol accumulation 
(Kinoshita et a l , 1963). Sorbitol, as an osmotically active substance, causes excessive
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water uptake into the lens and results in cell turgidity and fiber cell disruption, thus loss 
of transparency (Kador et al., 1985; Swamy-Mruthinti et al., 1999). Although this 
hypothesis has been successfully demonstrated in several animal models (Kuriyama et 
al., 1983; Richter et al., 2002), researchers who used animal models with a greater 
similarity to human (i.e. low AR level in the lens) failed to demonstrate a significant level 
of sorbitol-induced osmotic damage (Varma and Kinoshita, 1974; Garadi and Lou, 1989; 
Hegde et al., 2003). In mouse lenses, inappropriate addition of GLUT1 in fiber cells was 
also suggested as the major cause in cataract formation (Gong et al., 2001). Nevertheless, 
it is still believed that by acting synergistically with other mechanisms, the activation of 
AR through the polyol pathway could still cause severe damage in DM (Hegde et al.,
2003). Other hypotheses, such as those relating to oxidative stress and glycation (Sensi et 
al., 1995), have also been suggested to be responsible for diabetic cataract formation 
(Obrosova et al., 1998; Donma et al., 2002; Franke et al., 2003; Pokupec et al., 2003). It 
is believed that AR can indirectly generate ROS (as revealed by AR inhibition study 
(Suzen and Buyukbingol, 2003)) and also diminish the antioxidative defence capability 
by lowering the amount of glutathione (Donma et al., 2002). With high exposure to ultra­
violet light, oxidative stress in the crystalline lens may be an important issue, especially 
in pathological conditions such as DM (Gamer et al., 2000). Furthermore, AGEs can 
induce oxidative stress through chemical and cellular mechanisms e.g. the Fenton 
reaction (Lin, 1997), which has been found to contribute to cataract formation in both 
ageing and diabetic lenses (Pokupec et al., 2003). These AGEs can cross-link alpha- 
crystallins, the basic structural protein in the lens, resulting in loss of chaperone activity 
and dense protein aggregation (Chellan and Nagaraj, 1999; Derham and Harding, 1999).
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A newer proposal has also been suggested by Kistler and others in 1999 for diabetic 
cataract formation. They believed that the increase in intracellular glucose level induced 
an elevated anaerobic metabolism, thus leading to an increase in lactate production and 
reduction in pH. This reduction of pH closed the pH-sensitive gap junctions between 
cortical cells and hindered cell-to-cell communication. Consequently, normal circulation 
within lens was blocked and resulted in fluid accumulation and loss of transparency 
(Kistler etal., 1999).
1.3.5 Glycemic control
Glycemic control is always a major concern in DM patients, as it is regarded to be 
important in delaying or preventing secondary diabetic complications. Currently, the 
most effective treatment is subcutaneous insulin delivery, together with a real-time blood 
glucose measurement using an implanted glucose-oxidase sensor (Renard, 2002). Studies 
on glycemic control have shown the regain of a good glycemic control, after a period of 
poor control might not always be helpful in preventing the progress of hyperglycemia- 
induced complications (The Diabetes Control and Complications Trial Research Group, 
1993; Kowluru, 2003a). Earlier diagnosis and treatment is therefore necessary in order to 
promote a successful healing rate (Stanga et al., 1999). Since good glycemic control is 
not always easily established, pharmacological studies have been carried out to 
specifically target certain diabetic complications (Harding, 2001; Kowluru and Koppolu, 
2002; Kowluru et al., 2003b). For diabetic cataract, various preventive approaches have 
been tested and these include glycation inhibitors (Lewis and Harding, 1990; Swamy- 
Mruthinti et al., 1996), antioxidants (Cao and Phillis, 1995; Evans and Goldfme, 2000)
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and AR inhibitors (Beyer-Mears et al., 1996; Suryanarayana et al., 2004). However, they 
are still at an experimental state, with further development necessary in order for a safe 
treatment with minimal adverse effects to be found.
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1.4 Proj ect obj ectives and significance
Diabetic patients are more susceptible to cataract development than non-diabetic patients 
(Kuriyama et al,, 1983; Nielsen and Vinding, 1984; Di Benedetto et al., 1999; Kyselova 
et al., 2004). Therefore, good aqueous glycemic control should help in the prevention of 
diabetic cataract formation. Since the CBE is responsible for transporting glucose into the 
aqueous chamber, studies on the glucose transport mechanism across the CBE might help 
in deriving a strategy to maintain a healthy aqueous glycemic level in DM patients. 
Furthermore, it might directly contribute to a decreased risk of diabetic cataract formation. 
Physiologically, it would provide the basic understanding on how glucose transport into 
the aqueous is achieved and how such transport can be regulated at the transcriptional or 
translational level.
In this study, an investigation of glucose transport, and its regulation, across the bovine 
CBE was carried out. This knowledge provides insight into the control of aqueous 
glycemic level, which may help eventually in the prevention of diabetic cataract 
formation.
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2.1 Introduction
In the present study, glucose transport across the bovine CBE was characterised using a 
modified Ussing-type chamber. Glucose fluxes across the tissue were measured under 
control and inhibited conditions, in both cases with equal glucose concentrations bathing 
the NPE and PE sides of the preparation. Four inhibitors were used, in order to evaluate 
the glucose transport mechanism across the bovine CBE, since the inhibitors inhibit 
different types or aspects of glucose transport. Thus, the aim of this investigation was to 
reveal the presence of different glucose transport mechanisms in the bovine CBE.
In this study, the use of the modified Ussing chamber eliminates the influence of systemic 
circulation, hydrostatic pressure and hormonal changes on glucose flux measurements. 
Therefore, any change in the rate of glucose transport under inhibited condition could be 
assumed to relate purely to the interaction between the drug and the CBE preparation.
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2.1.1 Overview of experimental design
2.1.1.1 Ussing-type chamber
An “Ussing-type chamber” is a simplified term of “Ussing-Zerahn-type chamber”, a 
chamber named after its designers, Ussing and Zerahn (1951), who firstly applied this 
technique in the measurement of sodium ions across frog skin (Ussing and Zerahn, 1951). 
All the later modified version of the Ussing-type chambers are named “Modified Ussing- 
type chamber”. Nowadays, this technique has been widely adopted in different ion (e.g. 
chloride and potassium ions) and solute transport studies (e.g. glucose and ascorbate)
(Chu and Candia, 1988; To and Hodson, 1998b; To et al., 2001; Candia et al., 2002).
Electrical
param eter
m easurem ents
CBE
Ringer
solution
Fig. 2.1 Simplified diagram of an Ussing-Zerahn type chamber.
A simplified diagram is shown to illustrate the schematic configuration of an Ussing-type 
chamber with a CBE tissue preparation. As seen in figure 2.1, tissue is mounted in- 
between the chambers, so as to separate the chamber into two halves. The partition allows
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the change of solution on one side without affecting the solution on the other side. By 
changing the chemical content in the Ringer solution, different ionic conditions can easily 
be established and corresponding effects can be examined. In addition, two sets of 
electrodes are introduced into the chambers, thus allowing measurements of the electrical 
parameters across the tissue. The first pair of electrodes ( W ’), situated closer to the 
tissues, measures the transepithelial potential difference (PDt). The second set of 
electrodes (II’) is for measuring the resistance to current passage. Both electrode sets are 
connected to voltage monitoring devices for consistent measurement of electrical 
parameters. Details of the measurement of the electrical parameters will be given in the 
following sections:
2.1.1.2 Transepithelial electrical parameters
In the present study, three electrical parameters were analyzed. Descriptions of each of 
these electrical parameters are given below:
PDt, The PDt is an indicator of the difference in electrical charge across a cellular 
membrane. Its polarity is determined by the direction and valence of ions being 
transported, and is the result of a slight excess of cation or anion at one side compared to 
the other. In CBE, an aqueous-side negative potential is widely accepted, and is believed 
to relate to a predominance of active anion transport towards the aqueous (Matsui et al., 
1996; Crook et al., 2000; To et al., 2001; Wu et al., 2003). In bovine CBE, the negative 
ion gradient is believed to be generated mainly by active chloride ion transport from
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stromal to aqueous (To et al., 1998a; Do and To, 2000). Such a net ion transport has also 
been observed in rabbit (Crook et al., 2000).
As illustrated in figure 2.1, PDt can be measured via electrode set W ’, which are placed 
closely aside the tissue to minimise any blank resistance generated by the Ringer 
solution. In voltage clamp mode, the voltage across the tissue is set to zero. At this point, 
one can read the current which is necessary to pass through the tissue in order to short- 
circuit it (Lewis, 1996) (see below).
Transepithelial resistance (RJ. The Rt is a measurement of the resistance across the 
tissue of interest, and is composed of two major components. These comprise the 
paracellular resistance (Rp) and the transcellular resistance (Rtc). The former indicates the 
resistance generated by the tight junctions and intercellular spaces, for a solute to pass via 
the paracellular route. The latter describes the resistance contributed by the cell 
membranes.
By the use of the Ohm’s law, one can easily calculate the Rt across a tissue. It is achieved 
by passing a known current across the tissue and observing the voltage change. 
Alternatively, the tissue can be “clamped” to a new voltage and the observed current 
change can be used to calculate Rt, again using Ohm’s law. The first method was used in 
the present study (a detailed description can be found in section 2.2.7). In general, Rt is 
directly and inversely related to ionic permeability. Researchers have realised that Rt is 
useful in categorizing whether an epithelium is of the “tight” or “leaky” types (Diamond, 
1974). Epithelia are termed as “leaky”, if their Rt is lower than 100 Qcm2, while they are 
termed as “tight” for a Rt higher than 500 Qcm2 (Fromter and Diamond, 1972; Diamond,
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1974). A stable Rt is regarded as a viability check in the present study, since only a 
physiologically intact preparation can generate a stable resistance (Hodson and Wigham, 
1987).
Short-circuit current (Isc). The I,* is an external current that is passed across the 
epithelium, so as to reduce the voltage to zero. It is applied to remove any external 
driving force that is facilitating active transport across a membrane. Any net movement 
of solute under the short-circuit conditions reveals the active transport activity (Ussing 
and Zerahn, 1951). Isc is determined by the sum of all the ions that are actively 
transported across the membrane. It is possible to calculate the Isc if one knows the net 
ion flux of all ions across the membrane under short-circuit conditions (Koefoed-Johnsen 
and Ussing, 1958). Isc can then be deduced by the following equation:
1*= Y V z-F
1
Where Ji is the net flux of ion i, z  is the valence of ion i (i.e. the number and polarity of 
an ion), while F is Faraday’s constant. Alternatively, Isc can be determined by the use of 
Ohm’s law, since the PDt and Rt are continuously measured throughout the experiment. 
Therefore, short-circuit conditions can be used to determine whether there is any active 
ion or solute transport across the tissue. The 1  ^is regarded as an index of the net 
electrogenic ion transfer across the epithelium (Krupin and Civan, 1996). In CBE, a 
negative L* was observed along with a consistently negative PDt across the CBE (To et 
al., 1998a; Do and To, 2000; To et al., 2001).
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2.1.2 Inhibitors
Four inhibitors were chosen for use in this study. They are inhibitors which have been 
widely accepted to cause inhibition of particular transporter proteins. Phloretin and 
cytochalasin B are specific inhibitors of the GLUT family, while phlorizin and ouabain 
target the SGLTs, directly and indirectly, respectively.
2.1.2.1 Phloretin
Phloretin, is a competitive inhibitor of glucose transport via facilitated-diffusion. Its 
inhibitory effect on glucose transport has been shown in a number of tissues, including 
red blood cells (Jennings and Solomon, 1976; Krupka, 1985), smooth muscle (Dresel and 
Knickle, 1987), brain (Halton et al., 1980; Roeder et al., 1985) and small intestine 
(Alcalde et al., 1986). It is a non-penetrating molecule, which suggests that it exerts its 
inhibitory effect by binding onto the extracellular side of the transporter proteins 
(Masterson and Chader, 1981). It was found to exert its action on GLUTs by binding to 
the phenol site of the transporter and thus the binding of phloretin would be expect to 
hinder (Alvarado and Crane, 1964; Alvarado, 1978). The phenol site is situated next to 
the glucose receptor site in the transporter, and thus the binding of phloretin would be 
expect to hinder glucose binding (Alvarado, 1978). In other words, phloretin lowers 
glucose transport capacity by slightly altering the transporter configuration (Betz et a l ,
1975). In the intestinal system, phloretin was not a potent inhibitor (Alvarado and Crane, 
1964), since SGLTs but not GLUTs, are the predominant type of glucose transporters for 
the daily glucose uptake in this organ (Lee et al., 1994; Nagata et al., 1999; Ferraris,
2001; Wright et al., 2003). In other words, phloretin is a potent inhibitor specifically for
52
Glucose transport kinetics: Ussing-type chamber experiments
GLUTs, as demonstrated in rat lens (Elbrink and Bihler, 1972) and bovine RPE (To and 
Hodson, 1998b). However, counter-arguments have been made, as an increase of 
conductance resulted after the addition of phloretin in frog lens (Lucas and Duncan,
1983) and in lipid bilayer membranes (Melnik et al., 1977). It has been also suggested 
that the inhibitory effect exerted by phloretin might be a secondary effect following the 
altered intracellular sodium level (Lucas and Duncan, 1983).
2.1.2.2 Cytochalasin B
Cytochalasin B is a potent inhibitor for monosaccharide transport, as demonstrated in 
tissues such as smooth muscles (Dresel and Knickle, 1987), red blood cells (Lin and 
Spudich, 1974a), heart (Clow et al., 2004) and brain (Nishizaki and Matsuoka, 1998). It 
is a fungal metabolite (Bloch, 1973), that is regarded as a highly competitive inhibitor 
(Lin and Spudich, 1974a), and binds directly to the glucose binding site of the transporter 
(Lin et al., 1974b; Silverman, 1991). It has emerged as the more potent and specific 
inhibitor in lowering bi-directional glucose transport across the frog lens, when compared 
with phloretin (Lucas and Duncan, 1983). However, again, counter arguments have been 
raised, since cytochalasin B also inhibits various cellular movements by interacting with 
microfilaments (Wessells et al., 1971), which result in alterations to cell locomotion and 
cytokinesis (Krishan, 1972). However, even this notion has been challenged by other 
studies (Bluemink, 1971; Goldman, 1972), which has left the argument unsettled. 
“Cytochalasin B-binding” activity has been widely used to assess the transport capacity 
or affinity of a glucose transport system (Wheeler and Hauck, 1985; Hellwig and Joost, 
1991; Wandel et al., 1996). Cytochalasin B is a photolabile molecule and can form a
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covalent bond with the transporter, and according to the extent of binding, the transport 
kinetics can be deduced (table 1.1, p.26). In human red blood cells, high and low-affinity 
binding sites have been revealed for cytochalasin B (Lin and Spudich, 1974a; Lin et a l , 
1974b). Their binding with cytochalasin B could be inhibited up to 80 to 90 % in the 
presence of D-glucose, especially at the high-affinity site. This indicates a clear 
competitiveness of this inhibitor. Furthermore, the inhibitory effect of cytochalasin B in 
these samples was not affected by pH, in the range 5.0 to 9.0, which agreed with a 
previous study using D-glucose in the red blood cell membranes (Kahlenberg et al.,
1971). However, cytochalasin B binding activity decreases with increasing ionic strength 
(Brekkan et al., 1996). In addition, the binding of cytochalasin B to GLUT1 was found to 
occur in two different states, which might exist at equilibrium under normal conditions, 
but interchange according to surrounding environmental conditions (Gottschalk et al., 
2000).
2.1.2.3 Phlorizin
Phlorizin is a natural plant glucoside (Malathi and Crane, 1969). It has long been used as 
a potent and specific inhibitor for the SGLTs, mainly SGLT1, in kidney (Silverman,
1976; Turner and Moran, 1982a; Miller et al., 1992; Oku et al., 2000) and small intestine 
(Jervis et al., 1956; Despopoulos, 1966; Tsujihara et al., 1996; Hirsh et al, 1997) to 
reduce active glucose transport. It is regarded as a competitive inhibitor, as it has been 
found to directly compete for the glucose binding site with D-glucose (Betz et al., 1975) 
and even to be transported by the SGLT (Walle and Walle, 2003). More recently, 
researchers have revealed the mechanism of phlorizin binding (Koepsell et al., 1990;
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Veyhl et a l , 1993; Oulianova et al., 2001). They suggest that there are two phases in 
phlorizin binding, composed of a first “fast-binding phase” and a “slower equilibration 
phase”. The heterogeneity observed in previous studies (Turner and Moran, 1982a;
Turner and Moran, 1982b), in which high and low-affinity transport pathways were 
observed in the brush border membrane vesicle, was argued to have been purely due to 
the presence of these complex transport properties of SGLT1 (Oulianova and Berteloot,
1996). However, whether this is valid argument in other species has yet to be elucidated, 
since SGLT2 was found widely expressed in kidney in many later studies (Mackenzie et 
al, 1996; Wright, 2001).
Although generally believed to be an inhibitor of SGLTs, phlorizin also exerts an 
inhibitory effect on the facilitated-carrier system, as seen in tumour cells (Nelson and 
Falk, 1993) and cardiac tissues (Clow et al., 2004). This might be explained by the 
formation of phloretin due to phlorizin hydrolysis (Malathi and Crane, 1969) (Fig. 2.2). 
Phlorizin also inhibits ascorbate transport across the rabbit CBE, as well as glucose (Chu 
and Candia, 1988). In recent years, a number of different sodium-dependent vitamin C 
transporters have been identified (Tsukaguchi et al., 1999; Castro et al., 2001), yet 
whether phlorizin has direct interaction with all of these transporters remains to be 
elucidated.
S p x  Hydrolysis
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Fig. 2.2 Chemical transition between phloretin and phlorizin in hydrolysis.
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In the lens, phlorizin demonstrated a reversible but non-specific glucose transport 
inhibition, with a concurrent influence on the sodium ionic level (Lucas and Duncan, 
1983). In addition, it caused a significant reduction in glucose transport of the 
conjunctiva, when it was added to the mucosal side (Hosoya et al., 1996; Horibe et al.,
1997). Although there are many unsettled arguments about the specificity of phlorizin 
towards SGLTs, it is still a commonly used inhibitor in this type of study.
2.1.2.4 Ouabain
The Na+, K+-ATPase, also named the Na+/K+-pump, is an integral membrane protein, 
ubiquitously distributed in cellular epithelia (Lingrel and Kuntzweiler, 1994). It 
transports two potassium ions from the interstitial fluid into the cytoplasm and three 
sodium ions in the opposite direction, in every cycle. It, therefore, generates chemical and 
electrical gradients across cell membranes (Pedemonte and Kaplan, 1990). The driving 
force for each of the cationic exchange cycles requires the hydrolysis of ATP (i.e. energy 
consumption) (Ohtsubo et a l , 1990). Any transport processes dependent upon the 
chemical and electrical gradients set up by the Na+, K+-ATPase are named energy-driven 
or simply “active”. These include the transport of glucose against a concentration 
gradient, which make use of the sodium gradient firstly built up by the Na+, K+-ATPase 
(Hirayama et al., 1996; Turk and Wright, 1997).
Ouabain is a cardiac glycoside, which is a specific inhibitor of the Na+, K+-ATPase 
(Lingrel and Kuntzweiler, 1994). It exerts its inhibitory effect by binding to the 
extracellular surface of the Na+, K+-ATPase. The binding strategy was found to be very 
complex, involving the alpha-subunit as the primary binding site, but the beta-subunit
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was reported to be involved too (Hansen, 1984). In addition, different extracellular and 
transmembrane amino acids, were also found to be important in determining the affinity 
of the drug towards the sodium-pump (Bums and Price, 1993; Schultheis and Lingrel, 
1993). Therefore, ouabain can be used to inhibit active glucose transport indirectly, by 
dissipating the sodium gradient across a membrane, via the functional abolition of Na+/K+ 
exchange. Without the sodium concentration gradient (Diez-Sampedro et al., 2001), 
glucose cannot be transported across the membrane against its own concentration 
gradient. In the eye, ouabain has been used in several studies to help elucidate the 
corresponding glucose transport mechanism, e.g. in the RPE and lens (Stramm and 
Pautler, 1982; Lucas and Duncan, 1983; Roeder et a/., 1985; To and Hodson, 1998b).
2.1.3 Glucose transport in the eyes
Various ocular tissues have been investigated to find out their mode of glucose transport. 
The Ussing chamber technique has been a commonly employed method (Hosoya et al., 
1996; Horibe et al., 1997; To and Hodson, 1998b; To et al., 1998c), while bolus injection 
(DiMattio and Zadunaisky, 1981; DiMattio et al., 1984b), and glucose or cytochalasin B- 
binding assay techniques have also been tested (Stramm and Pautler, 1982; Lucas and 
Duncan, 1983; Vilchis and Salceda, 1996).
In general, the facilitated-carrier or passive transport mechanism has been found to be the 
predominant mode of glucose transport in ocular tissues. The tissues which possess a 
facilitated glucose transport system include bovine RPE (Crosson and Pautler, 1982; To 
and Hodson, 1998b; To et al., 1998c), rat retina and RPE (Dollery et al., 1971; Stramm 
and Pautler, 1982; Vilchis and Salceda, 1996), frog RPE (Miller and Steinberg, 1976;
57
Glucose transport kinetics: Ussing-type chamber experiments
DiMattio and Streitman, 1986), chick RPE (Masterson and Chader, 1981), rat blood- 
ocular barriers including BAB (DiMattio and Zadunaisky, 1981), rabbit corneal 
endothelium (Hale and Maurice, 1969) and rat lens (DiMattio, 1984a). Active or sodium- 
dependent glucose transport has been reported in rabbit conjunctiva (from mucosal side) 
(Hosoya et al., 1996; Horibe et al., 1997), and sheep RPE, from the retinal to choroidal 
direction (Pascuzzo et al., 1980). It is interesting to note that the sheep RPE operated 
using a different mechanism to the other species investigated, since facilitated-carrier 
transport has been found in all other mammals. This finding might have resulted from a 
technical difference in experimental design specifically, the mounting of the choroidal 
layer, which was not done in other studies of RPE.
Studies into the glucose transport of the retina and RPE have been popular (Vinores et al., 
1988; Stitt et al., 1994; Badr et al., 2000), possibly since DR is such a common cause of 
blindness (please refer to section 1.3.4). In contrast, studies on more anterior ocular 
tissues are scarce. Since, glucose transport across the CBE would directly affect the 
extent of glucose reaching the aqueous humor, a thorough study of this issue would be 
meaningful, for some new insights into how best to achieve good ocular glycemic 
control.
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2.2 Methodology
2.2.1 Materials and bathing solution
The composition of the HEPES-bufFered Ringer solution was (in mM) 113.0 NaCl, 4.6 
KC1, 21.0 NaHCC>3, 0.6 MgSCU, 7.5 D-glucose, 1.0 glutathione (reduced form), 1.0 
Na2HP0 4 , 10.0 HEPES, and 1.4 CaCL. The pH of the solution was adjusted to 7.4.
The 3-0-[Methyl-14C]-D-glucose (MDG) was purchased from NEN Life Science 
Products, Inc. (Boston, MA), while the L-[3H]-glucose (LG), phloretin, phlorizin, 
cytochalasin B, ouabain, dimethyl sulfoxide (DMSO) and all other chemicals were 
purchased from Sigma-Aldrich Company (St. Louis, MO).
2.2.2 Tissue preparation and selection
Fresh bovine eyes were taken from a local abattoir, having been enucleated immediately 
post mortem. They were transported to the laboratory, within an hour, in ice box and kept 
at 4°C. Eyes were chosen for an experiment if they were externally intact without leakage 
of aqueous or vitreous caused by external damage and possessed a smooth and clear 
cornea and lens. They exhibited a regular iridial shape, and the texture of the vitreous was 
rigid, not dissolved.
2.2.3 Tissue dissection
The bovine CBE was isolated according to the method devised by To and colleagues (To 
et al., 2001). Connective and extraocular muscles around the globe were removed with a 
razor blade. Two radial incisions (Fig. 2.3a) were made through the limbus to the equator. 
The cornea was cut from the incision points to the center and a flap lifted (Fig.
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Fig. 2.3
The dissection procedures 
used in the isolation of a 
CBE preparation, a) 
Incisions were made 
through limbus to 
equator, b) Part of the 
cornea was cut and 
flipped over, c), d) tissues 
were carefully trimmed 
off from sclera and 
vitreous, e) A sector of 
CBE ready to mount on 
the Ussing chamber.
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2.3b). Caution was taken not to apply excess pressure to the globe since this could 
damage the ciliary body, especially near the incision breaks. Under a dissecting 
microscope (EMZ-5 with MA502 SWF 10X eyepieces; Meiji Techno Co. Ltd., Japan), 
the CBE was carefully isolated anteriorly from the sclera (Fig. 2.3c) and posteriorly from 
the vitreous (Fig. 2.3d). During this process, the anterior aspect of the crystalline lens 
capsule was used as a “handle” for holding the ciliary body since it is firmly attached to 
the CBE. Finally, the sector of CBE was isolated at a point around 0.5 cm behind the pars 
plana (Fig. 2.3e). The preparation was then soaked in Ringer solution for 10 minutes 
before mounting. Throughout the dissection process, Ringer solution was applied 
constantly to the exposed surface to prevent the tissue from desiccation.
2.2.4 Ussing-type chamber configuration
The Ussing chambers used in this study were a continuous-perfusion type that was 
specifically designed for bovine CBE preparations. Configurations are shown in figure 
2.4. Each of the chambers consisted of two Perspex rectangular half chambers that fitted 
perfectly together with the assistance of the sliding base unit, flat-screws and wing nuts. 
The chamber cavities were of 0.30 cm2 in cross-sectional area and had a depth of 0.60 
cm, on top of which lay an 0.1 cm thick layer of silicone plate. The silicone plate acted as 
a cushion support in clamping tissues, in order to reduce solution leakage due to edge 
damage.
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Perfusion inlet
a) Front view of the Ussing-type half-chambers.
Perfusion outlets
Wire for. 
current passage
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b) Side view of the Ussing chambers. The sliding base and platform, 
together with the flat-screws are crucial in holding the preparation in place.
Fig. 2.4 Configurations of the continuous-perfusing type Ussing chamber. 
Please refer to figure 2.5 for the final setup.
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2.2.5 Chamber preparation
Before mounting, silicone lubricant (Dow Coming Corporation, USA) was applied on the 
silicon plates to enhance sealing and prevent slippage of the tissue in the chamber during 
the experiment. In addition, Ringer solution was continuously perfused through the 
chambers before mounting the tissues, to ensure that all bubbles were completely 
removed, and thus would not interfere with the electrical parameter measurements. The 
solution pumped into the chambers was collected into a glass container. Throughout the 
experiment, Ringer solution was pumped into the chambers (via the perfusate inlets) at a 
rate of 10 ml per hour, under the control of a microprocessor-controlled syringe infusion 
pump (Cole-Parmer Instrument Ltd., USA). Since the volume of the chamber cavity was 
210 pi, the turnover time of the solution in the chamber would be 75.6 seconds, assuming 
perfect mixing.
2.2.6 Tissue mounting
After 10 minutes immersion in Ringer, the CBE preparation was sandwiched into the 
modified Ussing chamber. Briefly, one of the half chambers was laid flat and tissue was 
placed with only the CBE, not the iris, exposed to the chamber cavity. Great care was 
taken in the mounting process to achieve “minimal pressure without leak” clamping, 
since excess pressure would cause mechanical damage to the preparation. It was achieved 
by slowly tightening the chamber screws and nuts until the first point where there was no 
solution dripping out of the chamber-tissues sandwiches. The temperature of the 
preparation was maintained at 35-37°C by wrapping pre-calibrated heating cloths around 
the chambers. Since two CBE tissues were isolated from the same bovine eye in every
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experiment, these tissues were mounted into two different chambers to allow 
measurement of glucose flux in both directions simultaneously.
2.2.7 Electrical parameters measurement
Electrical parameters, the PDt and R*, were monitored using the Dual Voltage Clamp- 
1000 unit (World Precision Instruments, Sarasota, FL, USA). Concurrently, a dual­
channel flatbed chart recorder (BD-12E; Kipp & Aonen Inc., Saskatoon, SK, Canada) 
was used to record the voltage and current output of the preparation (Fig. 2.5).
Just before the experiment, the PD-sensing tubes and by-pass arms were filled with 
Ringer solution. They were made with polyethylene tubes (PE90; CLAY ADAMS®, 
Becton, Dickinson, and Company, USA) and were inserted into the PD-sensing inlets of 
the chambers. Caution was again taken to expel all bubbles trapped inside chamber 
cavities, PD-sensing tubes and by-pass arms, as this would have resulted in a short circuit, 
which would generate electrical noise or mask the true potentials. By changing the three- 
way stopcocks’ position, the Ag/AgCI electrodes could either connect to the by-pass arm 
or the PD-sensing tubes independently. Therefore, the unit allowed a “zero-check” and a 
voltage measurement of the preparation, respectively. “Zero-check” was done at regular 
intervals throughout the experiment to correct any drifting of the zero reference and 
assure that the correct PD was recorded.
During the experiment, a known current was passed across the tissue through the 
Ag/AgCI electrodes every 5 minutes. This was done by setting the dual-voltage clamp 
into “timer” mode, at which it was cycled between zero current clamp and current clamp 
for 5 minutes and 3 seconds respectively. The changes in potential difference were
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recorded on the chart recorder and the total resistance (R) was calculated by using Ohm’s 
law:
Where AV is the change of potential when a known current passed across the preparation; 
AI is the known current used, which was 10 pA in this study and A is the cross sectional 
area of the exposed tissue, which was 0.30 cm2.
Since R is composed of both the fluid resistance (Rf) and the Rt, the exact value of Rt can 
be deduced by the subtraction of Rf from R:
Rt = R - R f
Rf could be obtained by measuring the resistance across the chamber with only the fluid 
perfused through the cavity, without tissue in place.
Probe
unit
Salt-bridges^ 
containing 0.9% 
sodium-chloride 
solution By-pass
arm
PD-sensing
tubes
CBE
tissue
- 3-way 
stopcock
C hart
recorder
Dual-Voltage 
Clamp-1000 unit
Fig. 2.5 Schematic diagram showing the experimental setup for the
electrophysiological study of Ussing chamber. “I” and “V” indicate the 
unit for applying current clamp and voltage clamp respectively.
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2.2.8 Test of viability
The preparations were considered to be viable by three criteria. These include 1) constant 
PDt and Rt greater than -0.2 mV and 70 Qcm2, respectively before addition of any drug, 2) 
low diffusional LG flux (i.e. lower than 70 nmolhr'cm2), and 3) biphasic response to 
ouabain when it is added to the aqueous side of the preparation as suggested by To et al. 
(1998a). Preparations were rejected if they failed in one of these criteria.
2.2.9 Glucose flux measurement
2.2.9.1 Basal flux measurement
After being sandwiched into the chamber, the tissue was left for 60 minutes for 
stabilization. The tightness of the chamber clamp sometimes needed adjustment during 
this period. This was because the thin layer of vitreous on the tissue surface could loosen 
the clamping, which would then affect the standing potential and result in a leak. When 
the electrical parameters were stable (i.e. a similar PDt and Rt were generated for more 
than 15 minutes), background radioactivity was measured by collecting perfusates for 2 
intervals of 12 minutes. These counts were averaged to give the control activity. The 
experiment was only included in the analysis if this value was below 100 counts per 
minute. Then, Ringer solution containing 0.5 pM 3H-LG (4 pCi) and 0.5 pM 14C-MDG (5 
pCi) were loaded to either the stromal or aqueous side (referred to as the “hot” side). 
Concurrently, normal Ringer solution was perfused to the opposite side (i.e. the “cold” 
side). After a 90 minute stabilization period, sample collection was begun, under short- 
circuited conditions. Perfusates (2 ml) were collected from both sides in clear glass 
scintillation vials (Wheaton, USA) at a 12-minutes interval, four times. They were mixed
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with 15 ml of biodegradable scintillation cocktail (NBCS104; Amersham Radiochemicals,
England). Radioactivity of samples was measured with a liquid scintillation counter
(Wallac 1414 Winspectral DSA; Wallace, Helsinki, Finland). The counting windows
allowed the discrimination of 3H and 14C decays, and the values were determined by
averaging consecutive counts for correspondent side samples. The final count data
allowed the calculation of bi-directional glucose fluxes from paired preparations, thereby
indicating the existence of any active glucose transport in the CBE preparations. The
unidirectional flux (J) was calculated using the following equation:
r _ C I V  
~ H A T
Where C is cold side radioactivity (cpm); I is concentration of the solute-of-interest in the 
Ringer solution (mM); V is the volume of perfusate collected in each interval (ml); H is 
the hot side radioactivity (cpm); A is the cross-sectional area of the chamber cavity (cm2) 
and T is the collection time for each sample (hour).
The unidirectional fluxes were calculated from the specific activity of the “hot side’ and 
the rate of radioactive tracer appearance on the “cold side” as the experiment progressed. 
The flux value was expressed in nmolh^cm'2.
2.2.9.2 Effects of inhibitors
Phloretin, cytochalasin B, phlorizin and ouabain are organic chemicals that have poor 
solubility in water. Hence, they were dissolved in DMSO before use, to give a final 
concentration of 0.1% in Ringer solution. After the first stabilization period of 60 minutes 
with normal Ringer solution, Ringer solution with inhibitor (0.1 mM phloretin, 0.01 mM 
cytochalasin B, 0.1 mM phlorizin or 0.1 mM ouabain) was perfused to both sides of the
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preparation for another 60 minutes. Again, background radioactivity counts were done as 
described earlier. After the completion of background perfusate collection, solution with 
both radioactive tracers and an inhibitor was perfused to one side of the preparation (i.e. 
the hot side) and Ringer solution containing only the inhibitor, but not radioisotopes, was 
perfused to the opposite side (i.e. the cold side). Ninety minutes was allowed for final 
equilibration before sample collection. Perfusates were collected under short-circuited 
conditions and then analyzed as described in section 2.2.9.1.
2.2.10 Statistical analysis
All the statistical calculations were performed by using Excel (Miscrosoft) or GraphPad 
Prism (version 3.02). All data were expressed as mean ± S.E.M. and p < 0.05 was 
considered as statistically significance. The paired Student’s t-test was used to analyze 
the basal flux measurements and the effect of inhibitors, whilst the impaired Student’s t- 
test and one-way ANOVA with Dunnett’s post-hoc test were used to compare the results 
from different studies and to evaluate variations within a set of tissue samples, 
respectively.
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2.3 Results
2.3.1 Baseline measurement
2.3.1.1 Electrical parameters
Preliminary experiments showed that the preparations were viable for at least five hours 
with consistent PDt, Isc and Rt. All of the preparations tested responded to 1 mM ouabain 
added to aqueous side of the chamber at the end of the experiment (Fig. 2.6). The average 
PDt , Isc and Rt of the bovine CBE was -0.47 ± 0.09 mV (with the aqueous side 
consistently negative), -4.94 ± 0.54 pAcm2 and 98.50 ± 7.20 Hem'2 (mean ± S.E.M., n = 
9), respectively. After the addition of ouabain, PDt and Isc increased transiently for a 
period o f25-30 minutes. This was followed by a depolarization which abolished them to 
nearly zero after another 120 minutes (Fig. 2.6). The maximum PDt and Isc attained 
during ouabain’s transient stimulatory phase was 157 ± 12% of the baseline (p < 0.05, n = 
9) while Rt eventually decreased by 10.8 ± 5.8% after the addition of ouabain (p > 0.05, n 
= 9) for 30 minutes.
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Fig. 2.6 Changes of PDt over time and in response to the addition of ouabain 
at the aqueous side (indicated by the arrow) in an control experiment.
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For the inhibition study, electrical parameters were significantly affected by the addition 
of ouabain (Dunnett’s post-hoc test, p < 0.05), while phloretin, cytochalasin B and 
phlorizin (Dunnett's post-hoc test, p > 0.05) showed no significant influences (Table 2.1). 
The electrical parameters presented in table 2.1 are the data taken around 150 minutes 
from the time at which the preparations were mounted. Significant changes were 
observed in PDt (ANOVA, F = 4.55, p < 0.05) and I* (ANOVA, F = 11.1, p < 0.001) 
with bilateral ouabain addition (Figs. 2.7 and 2.8). The maximum stimulation was 140 ±
11 % (p < 0.05, n = 16) and the reduction of Rt was 7.5 ± 6.2 % (p > 0.05, n = 16).
Condition PDt (mV) R, (Hem2) Isc (pAcm2) n
Baseline -0.52 ±0.08 95.14 ± 6.17 -5.73 ±1.07 20
Phloretin -0.42 ± 0.05 91.95 ±5.77 -4.64 ± 0.48 22
Cytochalasin B -0.43 ±0.18 99.70 ±11.86 -4.37 ±1.72 18
Phlorizin -0.46 ± 0.03 104.40 ±8.45 -4.44 ± 0.27 16
Ouabain -0.14 ± 0.03* 88.99 ±6.13 -1.63 ±0.35* 16
Table 2.1 Electrical parameters of baseline measurement and inhibition studies.
Data were taken around 150 minutes from the time at which the 
preparations were mounted, n represents the sample size. * indicates 
statistical significance level of p < 0.05 when compared to the baseline 
readings. Data are presented as mean ± S.E.M..
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Fig. 2.7 The effect of bilateral ouabain addition (indicated by the arrow) on PDt 
values of a CBE preparations.
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Fig. 2.8 Changes of IK before and after the bilateral addition of ouabain 
(indicated by the arrow) in both sides of the chambers.
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2.3.1.2 Glucose flux measurement
The glucose flux measurements, under normal and inhibited conditions, are summarised 
in table 2.2. Bovine CBE demonstrated stereospecificity for MDG, with a D-glucose to 
L-glucose transport ratio of 6.3-6.5 under an equal concentration gradient. No significant 
net flux was observed for either MDG or LG across the CBE under basal conditions (p > 
0.05, n = 10), or after the addition of phloretin (p > 0.05, n = 11), cytochalasin B (p >
0.05, n = 9), phlorizin (p > 0.05, n = 8) or ouabain (p > 0.05, n = 8). The corrected MDG 
(CMDG) flux was deduced by subtraction of the LG flux from the MDG flux to 
determine the transcellular rate of MDG movement across the bovine CBE. The CMDG 
flux was drastically decreased with the bilateral addition of cytochalasin B.
Comparatively more modest reductions were observed after the addition of phloretin or 
phlorizin. Ouabain did not cause a significant reduction in the glucose flux. Moreover,
LG fluxes were not significantly affected by any of the drugs used (Table 2.2), but 
decreased steadily as Rt increased, with a correlation factor of 0.71 (Fig. 2.9).
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Fig. 2.9 The plot of LG flux against Rt.
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Condition Flux
direction
LG MDG CMDG
CMGD flux 
inhibition (%)
Baseline
measurement
Jsa (10) 25.8+2.0 189.5115.1 163.8114.2 —
Jas (10) 26.3+2.3 196.1 + 14.7 169.8113.2 —
Phloretin
Jsa (11) 24.711.9 91.2 + 3.5* 66.513.2* 59.4
Jas (11) 24.612.1 93.8 1 53* 69.213.7* 59.3
Cytochalasin B
Jsa (9) 27.414.5 60.919.0* 33.519.2* 79.6
Jas (9) 26.014.6 58.2 1 11.8* 32.11 10.2* 81.1
Phlorizin
Jsa (8) 22.011.9 149.419.4* 127.417.6* 22.2
Jas (8) 21.312.7 155.719.6* 134.418.3* 20.8
Ouabain
Jsa (8) 28.412.5 169.5118.5 141.1 + 16.4 13.9
Jas (8) 27.5 + 2.7 173.3110.6 145.819.5 14.1
Table 2.2 Glucose flux measurements under basal and inhibited conditions.
* indicates statistical significance with p < 0.05. Fluxes are presented in 
nmolhr^cm'2 (mean ± S.E.M). Jsa is the influx, which is the glucose flux 
measured from stroma to aqueous and vice versa for Jas (i.e. the efflux). 
Sample size is indicated in parenthesis.
73
Glucose transport kinetics: Ussing-type chamber experiments
2.4 Discussion
2.4.1 Bovine CBE in Ussing chamber
Bovine eyes were used in this study for they have much larger CBE area when compared 
to other animal models such as rabbit (Kishida et al., 1982; Krupin et al., 1984) which 
facilitates their manipulation. Also, they are readily available in local abattoirs. One could 
easily distinguish the CBE sector from other ocular tissues in the bovine eye, which made 
tissue mounting in the Ussing chamber (without iris) highly reliable. This issue is 
important, as it assures that any electrical parameter and transport rate measurements or 
changes were purely demonstrated by the CBE, and not adjacent tissue(s). Such 
assurance is not possible when smaller-sized models are used in this type of study (Iizuka 
et al., 1984; Krupin et al., 1984; Wiederholt and Zadunaisky, 1987), in which the iris is 
often exposed to the tissue cavity.
2.4.2 Baseline and control electrical parameters
The consistently negative PDt across the CBE observed in the present study is consistent 
with findings from previous studies (To et al., 1998a; Do and To, 2000). A negative PD 
has been found commonly in iris-ciliary body preparations from a range of different 
mammalian species, such as monkey (Chu et al., 1987b), cat (Holland and Gipson, 1970), 
dog (Iizuka et al., 1984) and rabbit (Kishida et al., 1982; Krupin et al., 1984). Such a 
constant negative potential indicates a predominance of anion transport in the direction 
from stroma to aqueous, .and has been suggested to be the result of the relative transport 
activities of sodium and chloride ions across the tissue (Wiederholt and Zadunaisky, 
1987). Recently, a net chloride flux was revealed in bovine CBE, but not a net sodium
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flux (To et al., 1998a). This demonstrates the crucial role of chloride ions in the 
maintenance of the negative PD across the CBE, and suggests that it might be an 
important component in driving fluid transport (i.e. aqueous humor production) (Do and 
To, 2000).
The magnitude of Rt found in the present study is difficult to compare with that in other 
mammalian species, since Rt varies widely (Holland and Gipson, 1970; Kishida et al., 
1982; Iizuka et al., 1984). For example, a study on monkey reported a Rt of 185 Gem 
(Chu et al., 1987b), while 31 Gem was reported for shark (Wiederholt and Zadunaisky, 
1987). When considering only the bovine studies, a range from 61 to 124 Gem has been 
reported (To et al., 1998a; Do and To, 2000; To et al., 2001). Reassuringly, this included 
the range we found in the present study.
2.4.3 The biphasic response to ouabain addition
As described in Chapter 1 (section 1.1.2), the NPE and PE possess different densities of 
Na+, K+ -ATPase (Riley and Kishida, 1986), with the NPE possessing approximately eight 
times more Na+, K+-ATPase catalytic alpha subunit protein than the PE (Dunn et al., 
2001). Since Na+, K+-ATPase is located in abundance on the basolateral side of both 
layers, but working in opposite directions, sodium ions are constantly being pumped out 
of the CBE in exchange for potassium.
When ouabain was added to the aqueous side, it would inhibit the Na+, K+-ATPase 
located on the basolateral side of the NPE cell layer. The exchange (3 Na+ for 2 K+) 
across the NPE basolateral side would thus be reduced or arrested, leading to a reduction 
in sodium ions in the aqueous side and producing a hyperpolarization of the PDt. In
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theory, the active chloride ion transport across the CBE would play a role in the change in 
PDt after ouabain. The active chloride flow is dependent on the sodium-potassium- 
chloride cotransporter (Na+/K+/2C1* cotransporter) located on the basolateral side of PE 
which moves the chloride into the PE. This uptake process is driven by sodium gradient 
generated by the Na+, K+-ATPase. The subsequent efflux of chloride ions from the 
bilayers to the aqueous humor is via the chloride channels down its electrochemical 
gradient (Do and To, 2000). Initially, as the Na+, K+-ATPase was inhibited by ouabain, 
the chloride ion movement into the CBE was not immediately affected as the sodium 
gradient still remained intact but started to dissipate. Therefore, the chloride transport 
may not have been contributing to the PDt changes immediately after ouabain addition. 
Afterwards, the ouabain either reached the PE from the stromal application or diffused 
across the bilayer to the stromal side so that the Na+, K+-ATPase in the basolateral 
membrane of PE was subsequently inhibited. This produced the observed depolarization 
of the PDt. Finally, all active transport functions were abolished, sodium gradient 
dissipated and the PDt decreased slowly towards zero with time. This phenomenon has 
been widely reported and established in other CBE transport models (Wiederholt and 
Zadunaisky, 1987; Chu et al., 1987b ). The biphasic response observed in the present 
study is consistent with other studies (Krupin et al., 1984; Wiederholt and Zadunaisky, 
1987; Chu et al., 1987b) and has also been used to test tissue viability involving Ussing 
chamber experiments of the bovine CBE (To et al., 1998a).
In the inhibition study, when ouabain was added bilaterally, the maximal stimulation of 
PDt (and Isc) was slightly lower than that when ouabain was added only on the aqueous 
side. It might be because that in the bilateral application, ouabain reached the PE
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basolateral membrane from the bathing solution shortly after it acted on the NPE. The 
inhibition of the Na+, K+-ATPase at the PE side produced depolarization which may have 
depressed the hyperpolarization peak as observed when ouabain was applied at the 
aqueous side alone. In both cases, the PD and Isc eventually decreased towards zero and 
became stable. Measurement of ouabain’s effect on glucose transport was started from 
this point onwards.
2.4.4 L-glucose (LG)
In the present study, LG was used as a difftisional control. This substrate is biologically 
inactive, and its movement into a tissue is purely dependent on passive paracellular 
diffusion (DiMattio and Streitman, 1986; To and Hodson, 1998b). This finding has been 
confirmed by other studies, in which LG was observed to enter into ocular compartments 
using the same mechanism as urea and sucrose, which also move via passive diffusion 
(DiMattio and Zadunaisky, 1981). The rate of LG diffusion is a good indicator with 
which to quantify physical damage of the tissue upon mounting, and to evaluate the 
physical integrity of the bovine CBE as a measure of its “tightness” as an aqueous barrier. 
Thus, a low permeability of LG indicates the barrier is tight with low leakiness.
Moreover, a low permeability of LG also meant the absence of severe edge damage to 
tissues, caused by chamber mounting. Since LG passes through cell layers in a 
paracellular manner or via edge damage during tissue mounting, the subtraction of the 
LG flux from the MDG flux gives the transcellular glucose flux that is the rate of glucose 
transport across the membrane by glucose transporters. Figure 2.9 revealed the 
relationship between LG and Rt: they correlated linearly and inversely.
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In the present study, no significant net LG flux was found in any of the experiments. The 
measured LG fluxes were slightly lower than those reported by others (To et al., 1998a), 
which indicates that the selected tissue preparations had good integrity and that edge 
damage was minimal. This discrepancy with previous findings might be due to the 
modifications that had been made to the chambers, which made the tissue preparation 
more stable and edge damage less severe. In addition, the lower permeability of CBE 
towards LG implies that the bovine CBE is generally tight, not leaky.
For the calculation of the glucose flux, the area of the tissue cavity (i.e. 0.30 cm2) was 
used as if the tissue surface was flat. However, this would be the maximum estimation of 
LG flux for the bovine CBE, since the CBE surface is far from flat in reality. The CBE is 
in fact highly convoluted, yet the actual surface area is hard to estimate. Therefore, the 
actual LG flux per cm must be smaller than that estimated in the present study, for the 
convoluted surface area will possess a larger surface area. This issue also applies to the 
MDG flux calculation.
2.4.5 Passive versus active transport
In this study, MDG was used in an attempt to eliminate the influence of metabolism.
MDG is a non-metabolizable sugar, but which is otherwise very similar to D-glucose 
(DiMattio and Zadunaisky, 1981; DiMattio and Zadunaisky, 1982). MDG would pass 
through the cell membrane in both a paracellular and a transcellular manner. Thus, the 
subtraction of the LG flux from the MDG flux gives the transcellular glucose flux. In the 
present study, no significant net flux (i.e the difference between Jsa and Jas for each eye) 
was observed for MDG. Therefore, the chance of having active glucose transport in the
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bovine CBE seems unlikely. This agrees with previous assumption based on the fact that 
the concentration of glucose in the aqueous humor is lower than that of the blood stream 
(DiMattio et al., 1984b; Abdel-Latif, 1997). Hence active transport of glucose across the 
CBE would be unnecessary, since it could simply move down its concentration gradient.
2.4.6 Stereospecificity
The present study demonstrated that MDG was transported into the aqueous humor more 
readily than its stereoisomer, LG. This finding is consistent with other studies in which D- 
glucose also crossed cells more readily (DiMattio and Zadunaisky, 1982; Stramm and 
Pautler, 1982; DiMattio and Streitman, 1986). This clearly shows that the glucose 
transport mechanism across the bovine CBE exhibits stereospecificity. However, the D- to 
L-glucose transport ratio of 6.3-6.5 in the bovine CBE might somewhat underestimate the 
true value. Although MDG has been widely used to evaluate D-glucose transport in 
different tissues (Stramm and Pautler, 1982; DiMattio, 1984a), it does possess an 
additional methyl group not present in D-glucose itself. This modification has been 
suggested to hinder the transport efficiency of MDG as compared to D-glucose (DiMattio 
and Zadunaisky, 1981). It has been shown that the transport rate of MDG is slower than 
that of D-glucose, but faster than urea in ocular epithelia (DiMattio and Zadunaisky,
1981). This result contradicted an early finding in frog RPE, in which MDG was 
transported at a faster rate than D-glucose (Zadunaisky and Degnan, 1976). Therefore, 
there may be a slight difference in the transport rate between D-glucose and MDG across 
the bovine CBE in vivo. However, MGD was used in this study because the metabolism
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of D-glucose can be variable, relatively complex (DiMattio and Zadunaisky, 1981) and 
would have been a difficult factor to control in experiments.
The stereospecificity of glucose transport has been demonstrated in aqueous and vitreous 
barriers of Sprague-Dawley rats (DiMattio and Zadunaisky, 1981). D-glucose was found 
to transport into the aqueous and vitreous at a higher rate than LG. However, exact 
stereospecificity between D-glucose and LG was difficult to determine because of the 
metabolism of D-glucose. Glucose transport stereospecificity has also been investigated 
for bovine, bullfrog and rat RPE, using D-glucose and also for rat lens by using MDG. 
The bovine RPE possessed a D- to LG transport ratio of 2.2 (To and Hodson, 1998b) 
while a ratio of 13.0 was observed in bullfrog RPE (DiMattio and Streitman, 1986). A 
ratio of 4.6 was found for rat RPE (DiMattio and Zadunaisky, 1983) and of 3.0 in the rat 
lens (DiMattio, 1984a). Apparently, species and cellular differences are present in 
glucose transport stereospecificity, and the stereospecificity in bovine CBE is somewhat 
higher that that measured in bovine RPE (with a ratio of 2.2) (To and Hodson, 1998b). 
Surprisingly, no stereospecificity of glucose transport was found in the rat cornea 
(DiMattio, 1984a).
2.4.7 Glucose transport mechanism in the bovine CBE
This study demonstrated that the transport mechanism of glucose across the bovine CBE 
is primarily via facilitated passive transport. The application of phloretin exhibited a 60% 
inhibition of the MDG flux and cytochalasin B caused an ~ 80% reduction. These 
inhibitors are highly specific for GLUTs, which suggested the presence of passive 
facilitated transport as the major route for glucose transport in the bovine CBE. The
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greater potency of cytochalasin B, compared to phloretin, agrees with previous studies in 
bovine RPE (To and Hodson, 1998b) and frog lens (Lucas and Duncan, 1983). Both 
phloretin and cytochalasin B did not cause any significant change in LG flux. This 
suggests that LG diffuses across cell membrane in a paracellular manner, and thus is not 
affected by these inhibitors.
The significant inhibition by phlorizin (~ 20%) and the mild inhibition by ouabain were 
unexpected, since facilitative type glucose transport has been presumed to be the only 
glucose transport mechanism in the CBE, as it is constantly under a stable glucose 
gradient (Cole, 1984; Abdel-Latif, 1997). Since passive facilitative glucose transport 
does not require a transmembrane sodium gradient (To and Hodson, 1998b), the 
dissipation of the sodium gradient with ouabain should not have direct effect on the 
glucose transport across the bovine CBE.
The binding conditions and inhibitory effects of glucose transport with phlorizin have 
been widely investigated (Stramm and Pautler, 1982; Lucas and Duncan, 1983; Hosoya et 
al., 1996; Oulianova and Berteloot, 1996). The significant reduction of glucose flux 
across CBE by phlorizin might be explained by two possibilities. Firstly, phlorizin could 
have inhibited a SGLT present in the bovine CBE membrane by binding directly to its 
glucose binding site. Secondly, phlorizin could have inhibited the GLUTs present in the 
CBE by transforming (via hydrolysis) into phloretin (Malathi and Crane, 1969). For 
example, phlorizin caused significant reduction of glucose transport in human tumour 
cells (Nelson and Falk, 1993), when GLUTs are widely known to be the commonest 
glucose transporter isoform in the tumour cells (Das, 1999; Kato et al., 2002). In brain 
tissues, phlorizin’s inhibitory effect was significant too (Betz et al., 1975), even though it
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is known that GLUT1 and GLUT3 are the predominant isoforms that exist in the brain 
(Simpson et al., 1994; Vannucci et al., 1997). This evidence of non-specificity of 
phlorizin towards different glucose transporter families therefore complicates our 
interpretation in the present study, since it is not possible to determine the extent to which 
phlorizin was hydrolyzed into phloretin. There were no significant changes in electrical 
parameters during the bilateral phlorizin addition, which argues against a major 
contribution by the SGLTs. This is because the inhibition of SGLTs by phlorizin should 
result in a change in the sodium gradient and potential across the membrane (Hosoya et 
al., 1996; Horibe et al., 1997). However, we could not rule out the presence of a minor 
contribution by SGLTs which may produce very small changes in the PDt or Isc during 
phlorizin addition. To investigate this issue further, expression studies on transporter 
genes and proteins were carried out in Chapters 4 and 5.
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2.5 Conclusion
This study suggested that the glucose transport across the bovine CBE was via a bi­
directional carrier-facilitated transport mechanism. A similar mechanism has been 
reported in the BRB (Takata et al., 1997; Busik et al., 2002) which shares the same 
embryological origin as the BAB during development. Active glucose transport, if 
present, is unlikely to play a major role in the physiological glucose transport across the 
bovine CBE.
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3.1 Introduction
3.1.1 Overview of experiments
In this chapter, the glucose flux (i.e. Jsa) under various glucose concentration gradients 
was investigated. Five different glucose concentration gradients were established across 
the bovine CBE, with the stromal side having the higher concentration, and the 
osmolarity balanced by the addition of sorbitol on the aqueous side. Modifications were 
made to the modified Ussing-type chambers to reduce tissue damage and improve 
functional stability.
If glucose transport across the bovine CBE occurs by a carrier-mediated system, it should 
be saturable -  given a sufficiently high plasma glucose concentration. Therefore, there 
should be a point at which further increases above this saturating plasma glucose 
concentration would cause no further increase in the glucose flux. To examine this issue, 
a series of experiments were performed in which the stromal glucose concentration was 
varied. The change of the glucose transport rate was observed, and the transport kinetic 
parameters, the Michaelis constant (K„,) and maximum velocity (Vmax), were estimated 
by the use of an Eadie-Hofstee plot.
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3.1.2 The Michaelis-Menten equation
The enzyme kinetic model is a biochemical scheme, which describes the enzyme- 
substrate catalytic reaction. It represents an overall reaction composed of two sub­
reactions in which enzyme (E) and substrate (S) bind to each other to form an enzyme- 
substrate complex (ES) and at the same time, the complex is decomposing into product 
(P) and E:
ki k2
E + S r  - ES-----------► P + E
k.,
Where kjt k.j and k2 are the rate constants of corresponding reactions. According to this 
model, the second reaction would become the limiting step of the overall reaction when 
the substrate concentration ([S]) was high enough to bind all enzymes into ES complex.
A further increase in the substrate concentration would have no effect on the overall 
reaction rate. In other words, it is a model used to explain why, when at low [S], the 
initial reaction velocity (V 0) is directly proportional to [S], while reaction velocity tends 
to reach a maximum (V max) that is independent of [S] at high [S]. It is a common concept 
applied to describe the substrate affinity or transport velocity of a biological system, such 
as ascorbate transport in the isolated rabbit CE (Chu and Candia, 1988), sugar transport in 
the dog kidney (Turner and Silverman, 1978) and bovine BBB (Lee et al., 1997). In order 
to make it useful to use in experimental quantitation, the enzyme-kinetic model can be 
formulated using the Michaelis-Menten equation:
y  _  V m ax • [ S ]
° "  K m + [ S ]
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which is a description of the hyperbolic curve of V0 against [S]. The Michaelis constant 
(Km) is defined as:
_ k - \  + ki
/Cm — ----------------
k\
and is the sum of the rates of binding and dissociation of substrate and enzyme, compared 
to the rate of complex formation. Experimentally, it can be determined as the 
concentration at which a transport system is half-saturated (i.e. Vmax/2). It is also a 
measure of the affinity of a transporter or enzyme for its substrate. A high Km indicates 
weak binding and thus, low affinity of the system. A low Km indicates strong binding and 
therefore, high affinity of the system.
In general, two transformations of the Michaelis-Menten equation are commonly used in 
describing transport kinetics, these include the Lineweaver-Burk plot and the Eadie- 
Hofstee plot.
3.1.2.1 The Lineweaver-Burke plot
The Lineweaver-Burke plot, also called the “double reciprocal plot” is a graphical
representation of enzyme kinetics. It is one of the transformations of the Michaelis-
Menten equation, which is commonly used in the analysis of transport kinetics, e.g. in
frog RPE (DiMattio and Streitman, 1986), rat retina and RPE (Vilchis and Salceda,
1996), where it was adapted for characterizing the tissues’ carrier-mediated glucose
transport. The Lineweaver-Burk equation is:
1 K m  1 1+
V o  V m ax [ S ]  V m ax
Figure 3.1 illustrates an example double reciprocal plot. The y-intercept represents 1/Vr 
and the x-intercept represents -1/Km.
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1
Km
1/[S]
Figure 3.1 An illustration of a Lineweaver-Burk plot.
Despite its useful attributes, the Lineweaver Burk plot is regarded as an inferior method 
to Eadie-Hofstee plot, since it tends to overweight the contribution of data taken at low 
substrate concentrations.
3.1.2.2 Eadie-Hofstee plot
The Eadie-Hofstee diagram, also called Woolf-Eadie-Augustinsson-Hofstee or Eadie- 
Augustinsson plot, is another commonly used linear presentation of the Michaelis- 
Menten Equation. Similar to the Lineweaver-Burk plot, it is a graphical presentation of 
enzyme-substrate kinetics, which allows rapid determination of the Km and Vmax. The 
kinetic terms can be deduced by plotting the reaction velocity, which is the transport rate 
(Jsa) in this study, as a function of the velocity-per-unit-substrate concentration. The 
Eadie-Hofstee equation is:
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This transformation has been used in a variety of kinetic analysis studies, such as the 
glucose transport in chick RPE (Masterson and Chader, 1981) and bovine RPE (To et al., 
1998c). It is considered to be superior to the Lineweaver-Burk plot because it gives equal 
weight to every data point. An illustration of an Eadie-Hofstee plot is given in figure 3.2. 
Transport kinetics can simply be deduced according to the slope (-Km) and y-intercept
<y*md-
V
max
V/fSl
Figure 3.2 An illustration of an Eadie-Hofstee plot.
3.1.3 Saturation studies
Table 3.1 summarises the glucose transport kinetic studies that have been carried out for 
ocular tissues. Inter-species differences clearly exist. It is noted that only a single study 
has been carried out in characterizing the glucose transport across the CBE (DiMattio and 
Zadunaisky, 1981).
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Ocular
tissues Species Substrate Km (mM) v max Reference
BAB Rat D-glucose 6.1 22.5 nmol/min
(DiMattio and 
Zadunaisky, 
1981)
BRB Rat D-glucose 0.2 & 7.8 — (Ennis et al., 1982)
BVB Rat D-glucose 4.6 23.8 nmol/min
(DiMattio and 
Zadunaisky, 
1981)
Retina
Rat 2-deoxy-D-glucose 2.0 750 nmol/g/min
(Vilchis and 
Salceda, 1996)
Rat
(diabetic)
2-deoxy-D-
glucose 5.0 1500 nmol/g/min
(Vilchis and 
Salceda, 1996)
Frog 2-deoxy-D-glucose 5.1 699 nmol/mg/min
(Witkovsky and 
Yang, 1982)
RCP Bovineculture MDG 1.53
0.50 mmol /
(pg DNA)/ min at 37°C
(Li et al., 1985)
RPE
Bovine D-glucose
27 (C-»R) 
9.5 (R->C)
2100 nmo/cm2/hr 
(C->R)
710 nmol/cm2/hr 
(R-*C )
(Crosson and 
Pautler, 1982)
Bovine MDG 30.8 (C->R) 2452nm ol/cm 2/h r (C ^ R ) (T o e / al., 1998c)
Chick
culture
2-deoxy-D-
glucose 2.7
22 nmol/min/mg 
protein
(Masterson and 
Chader, 1981)
MDG 4.5 27.7 nmol/min/ mg protein
(Masterson and 
Chader, 1981)
Frog MDG
19.3 (C-»R) 
16.2 (R-»C)
1050 nmol/cm2/hr 
(C -»R )
952 nmol/cm2/hr 
(R ^ C )
(DiMattio and 
Streitman, 1986)
Human
culture MDG 5.6
0.45 nmol/ 
mg protein/min
(Busik et al., 
2002)
Rat (Diabetic) 2-deoxy-D-glucose 20.0 750 nmol/g/min
(Vilchis and 
Salceda, 1996)
Rat MDG
1.9
&
640
12.0 nmol/ 
mg protein/min 
&
12.2 
nmol/ 
mg protein/min
(Stramm and 
Pautler, 1982)
RVE
Human
culture MDG 6.3
1.4 nmol/ 
mg protein/min
(Busik et al., 
2002)
Rat culture MDG 5.56 ±0.51
45.3 ±  2.6 
nmol/ 
mg protein/ min
(Hosoya et al., 
2001)
Table 3.1 Transport kinetic studies in different ocular tissues. BVB: blood vitreous 
barrier, RCP: retinal capillary pericytes, RVE: retinal vascular 
endothelium, (C->R): from choroid to retina direction, (R->C): from 
retina to choroid direction.
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As well as difference between species, e.g. frog retina (Witkovsky and Yang, 1982) was 
of lower affinity to 2-deoxy-D-glucose than that of rat (Vilchis and Salceda, 1996), 
studies in the same species also show high variability. These differences vary with the 
ocular tissues being investigated and the substrates being used. Therefore, a general 
conclusion cannot be drawn unequivocally due to this variability.
In rat RPE, high- and low-affinity transport systems were found to co-exist (Stramm and 
Pautler, 1982), and similar transport mechanisms were also observed in the rat BRB 
(Ennis et al.t 1982). This type of high and low-affinity mechanism is not uncommon: 
different transport affinities have been demonstrated in kidney (Mackenzie et al., 1996; 
Oulianova and Berteloot, 1996). This was recognised as being the result of the presence 
of different glucose transporters, which possess their maximum transport capacity at 
differing glucose concentrations.
In two studies of the bovine RPE, the glucose transport kinetics in the direction choroid- 
to-retina were comparable, as were the transport capacities (Crosson and Pautler, 1982;
To et al., 1998c). MDG was said to be a good substitute for D-glucose in transport kinetic 
studies, since the results based on MDG alone did not deviate greatly from that of the D- 
glucose. The bovine RPE revealed a low affinity but high capacity, suggesting that the 
retina is a highly metabolic tissue (Miceli et al., 1990). Because of its requirements in this 
regard, a system that does not saturate under physiological conditions is beneficial.
In diabetic models, tissues typically demonstrate a significant decrease in glucose 
transport affinity (Vilchis and Salceda, 1996). In the rat retina, an increase of 2.5-fold of 
Km resulted after exposure to simulated diabetic conditions, and double the amount of 
glucose could be transported across the cell membrane. This finding agreed with previous
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work based on comparisons between normal and diabetic rats (Ennis et al., 1982), and 
clearly showed that exposure to diabetic conditions can change the normal glucose 
transport properties of an organ (Ennis et al., 1982; Mandarino et al., 1994).
As shown in table 3.1, previous studies have focused mostly on the retina and RPE, hence 
little information is available regarding the saturation characteristic in BAB, or the CBE. 
The present study aimed to investigate these characteristics, and therefore, lead to a better 
understanding of the mode of glucose transport across the CBE.
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3.2 Methodology
3.2.1 Materials and bathing solution
All the materials and the Ringer solution used in this part of the project were the same as 
in the previous chapter (section 2.2.1), with an additional chemical, sorbitol, which was 
purchased from Sigma-Aldrich Company (St. Louis, MO). The D-glucose concentration 
in the Ringer solution was varied, as described below.
3.2.2 Tissue preparation, selection and dissection
Please refer to sections 2.2.2 and 2.2.3 for details.
3.2.3 Ussing-type chamber configuration and modification
Continuous-perfusion-type Ussing chambers, similar to those described in the previous
chapter were used, with minor modifications. Figure 3.3 highlights these changes, 
including newly inserted O-rings surrounding the tissue cavity and also pins introduced 
between the silicone plates. The modifications provided the advantage of decreased edge 
damage of tissues upon mounting and therefore decreased leakage. Furthermore, the pins 
on the silicone plates held the tissues in place in a tighter manner which increased the 
stability of tissue mounting.
3.2.4 Chamber preparation and tissue mounting
The chamber preparation was similar to that described in section 2.2.5, except that an O- 
Ring was placed on top of the O-Ring groove after application of silicone lubricant on the 
silicone plate. After the O-Rings were in place, silicone grease was applied again to seal
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a) Front view of the modified Ussing-type half-chambers.
Pins
b) Side view of the modified Ussing-type half-chambers.
Fig. 3.3 Configurations of the modified Ussing-type chambers.
Pin slots
.m.Jm.A
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the gap between the chambers and the rings. This was to ensure good sealing and a good 
cushioning effect for the CBE preparations.
The tissue mounting procedure used was also altered slightly. Since pins were included as 
one of the modifications to the chambers, CBE tissues could only be placed on the side of 
chambers without pins. In this case, the CBE tissues could lie flat and carefully exposed 
to the cavity. The other half chamber was then slid gently into place and the tissue was 
clamped tightly by adjusting the screws and nuts. Extra care was taken when tightening 
the chamber halves since the pins from the top chamber would go through the tissues 
which lay outside the tissue cavity area, and then fitted into the pin slots of the lower 
chamber. The final tightness was adjusted slowly by turning the wing nuts as described in 
2.2.6.
3.2.5 Glucose flux measurement
Electrical parameters were measured as described in details in section 2.2.7. For glucose 
flux measurement, the radioactive tracer method used in the previous section was again 
employed. Varying concentration gradients were set up by elevating the glucose 
concentration on the stromal side. Studies were performed for different stromal glucose 
concentrations of 7.5, 15, 30,45, 60 mM, while the aqueous glucose level was 
maintained at 7.5 mM. The Jsa at these five gradients was studied. Osmolarity at the 
aqueous side was balanced by the addition of sorbitol, a chemical that possesses similar 
molecular weight to glucose (MW 181.6 versus 181.0), but which is not transported by 
any of the known glucose transporters. For example, in the experiment involving a 7.5 
mM concentration gradient, 15 mM D-glucose Ringer solution was perfused to the 
stromal side, and 7.5 mM of D-glucose plus 7.5 mM sorbitol Ringer solution to the
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aqueous side. Initial stabilization was allowed for 60 minutes and background 
radioactivity and further radioactive measurement were performed as described in section 
2.2.9.1. However, for concentration gradients higher than 15 mM, it was necessary to 
increase the concentration in a stepwise manner, using 15.0 or 7.5 mM steps, until the 
desired concentration was reached (Table 3.1). For example, a concentration gradient of 
45 mM was started at 15 mM at the stromal side and 7.5 mM D-glucose at the aqueous 
side. After 30 minutes stabilization, Ringer solution containing 22.5 mM glucose was 
perfused to the stromal side of the preparation and allowed to equilibrate for another 30 
minutes. This resulted in a concentration gradient of 15 mM across the CBE preparation. 
Then, two more 15 mM changes were performed, with 52.5 mM Ringer perfusing into 
the stromal side eventually, which produced a 45 mM glucose concentration gradient. 
After the desired gradient was reached, the preparation was left to stabilise for another 60
minutes and control perfusates were collected. A change of solution to those containing 
radioactive isotopes was then carried out, and preparations were stabilised for another 
hour. Finally, radioactive perfusates were collected and analyzed as described earlier.
Change of 
solutions
D-glucose concentration ( mM )
S A S A S A S A S A
Initial 15 7.5 15 7.5 15 7.5 15 7.5 15 7.5
1st — — 22.5 7.5 22.5 7.5 22.5 7.5 22.5 7.5
2nd — — — — 37.5 7.5 37.5 7.5 37.5 7.5
3rd — — — — — — 52.5 7.5 52.5 7.5
4th — — — — — — — — 67.5 7.5
Final
concentration
gradient
7.5 15 30 45 60
Table 3.2 Stepwise build-up of the glucose concentration gradient across the bovine
CBE. S is the stromal side, A is the aqueous side.
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Glucose flux results were calculated and plotted in an Eadie-Hofstee relationship, to 
allow the deduction of transport kinetics for CMDG to be determined. The properties, Km 
and Vmax, of the bovine CBE were deduced as described in section 3.1.2.2.
3.2.6 Test of viability
In this part of the study, preparations were considered to be viable if they fulfilled the 
same criteria as described in Chapter 2 (section 2.2.8): 1) a stable PDt and Rt greater than 
-0.2 mV and 70 Gem2 respectively, before the first change of Ringer solution to higher
1 *7concentration, 2) a low diffusional LG flux (i.e. lower than 70 nmolhr cm ), and 3) a 
biphasic response to ouabain, when added to the aqueous side. Again, preparations were 
rejected if they failed in any one of these criteria.
3.2.7 Statistical analysis
Statistical calculations were performed by using Excel (Microsoft) or GraphPad Prism 
(version 3.02). All data were expressed as mean ± S.E.M. and p < 0.05 was considered as 
statistically significance. The unpaired Student’s t-test was used to compare the results 
between different tissue samples. One-way ANOVA with Tukeys multiple comparison 
test or Dunnett’s post-hoc test was performed to evaluate variations within a set of tissue 
samples.
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3.3 Results
3.3.1 Glucose influx across the bovine CBE
Glucose fluxes from stromal to aqueous side were measured and analyzed for five 
different concentration gradients (Table 3.2). The stereospecificity of CBE in transporting 
glucose was maintained across a wide range of concentration gradients, with the highest 
recorded at 30 mM. When compared to 7.5 mM, 30 mM or higher gradients caused a 
significant increase in both MDG influx and CMDG fluxes (Dunnett’s post-hoc test, p < 
0.01, n = 6-8). The LG influx, on the other hand, increased steadily but slowly with the 
increase of concentration gradient. When compared to 7.5 mM, 45 mM or higher 
gradients caused a drastic increase in LG flux (Dunnett’s post-hoc test, p < 0.05, fig. 3.4).
Concentration
gradient
(mM)
Jsa (nmolhr' cm' ) D- to L-
glucose
ratioLG MDG CMDG
7.5(10) 36.2 ± 8.6 236.6 ± 24.0 200.4 ±23.6 5.5
15(6) 39.6 ±6.1 306.0 ±28.0 266.4 ±27.3 6.7
30 (6) 44.2 ± 7.6 353.6 ±31.2 309.4 ± 27.9 7.0
45 (6) 49.1 ±3.7 347.1 ±40.3 298.1 ±36.4 6.0
60 (8) 62.4 ±10.1 383.9 ±40.6 321.4 ±34.6 5.2
Table 3.3 Glucose fluxes under different concentration gradients. Numbers
of completed experiments are in parenthesis. Flux data are all 
expressed as mean ± S.E.M..
3.3.1.1 Saturation characteristics
An Eadie-Hofstee plot of the CMDG was used to analyze the transport kinetics of 
glucose across the CBE. The Eadie-Hofstee plot of CMDG showed high linearity, with 
Km and Vmax equal to 5.3 mM and 349.5 nmolh'1 cm'2 respectively (Fig. 3.5).
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Fig. 3.4 Influx measurements in five glucose concentration gradients.
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Fig. 3.5 Eadie-Hofstee plot of CMDG (r2 = 0.93, mean ± S.E.M.).
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3.3.2 Electrical param eter measurements
In this study, electrical parameters including PDt, Rt and Isc were monitored as in the last 
chapter (Table 3.3). Only a borderline statistically significant influence was observed 
with different glucose concentration gradients on Rt (Dunnett’s post-hoc test, p > 0.05, n 
= 6-8). However, significant influences were noted on PDt and Isc with concentration 
gradients of 30 mM (Dunnett’s post-hoc, p < 0.001, n = 8), 45 mM (Dunnett’s post-hoc 
test, p < 0.001, n = 8) and 60 mM (Tukey’s post-hoc, p < 0.001, n = 8), when compared 
to the 7.5 mM concentration gradient. Representative plots of the changes in PDt and Isc 
with concentration gradients and addition of ouabain are given in figures 3.6 and 3.7. A 
summary of the changes measured at gradients of 30, 45 and 60 (in mM) are shown in 
figures 3.8-3.10.
Concentration 
gradient ( mM) PDt (mV) Rt (Hem2) Isc (pAcm2) n
7.5 -0.39 ± 0.08 107.7 ±4.8 -3.54 ±0.58 10
15 -0.20 ± 0.03 93.8 ±5.1 -2.12 ±0.29 6
30 -0.12 ±0.03 112.0 ±4.4 -1.01 ±0.22 6
45 0.16 ±0.04 102.3 ±4.3 1.50 ±0.36 6
60 0.34 ±0.06 104.6 ±4.8 3.30 ±0.63 8
Table 3.3 Electrical parameters of the CBE preparations under different
concentration gradients. All the data stated above are data calculated at 
60 minutes after the desired concentration gradients were reached. 
Results are presented as mean ± S.E.M..
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Fig. 3.6 Changes of PDt with a final glucose concentration of 60 mM. The 
data indicated the PDt of the aqueous side with respect to that of 
stroma across the bovine CBE. Each change in concentration is 
indicated with an arrow. The broken arrow indicates the addition of 
ouabain. Please refer to table 3.1 for details.
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Fig. 3.7 Changes of Isc across CBE with a final glucose concentration
gradient of 60 mM. The data indicated the resultant ion transport 
into the aqueous with reference to the stromal side. Each change is 
indicated with an arrow. The broken arrow indicates the addition of 
ouabain.
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Fig. 3.8 PDt changes in experiments up to 30 mM concentration gradients (r2= 0. 78).
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Fig. 3.9 PDt changes in experiments up to 45 mM concentration gradients (r2 = 0. 77).
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Fig. 3.10 PDt changes in experiments up to 60 mM concentration gradients (r2 = 0. 74).
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3.4 Discussion
3.4.1 Glucose saturation characteristics of bovine CBE
The glucose transport kinetics across the bovine CBE were determined by using an 
Eadie-Hofstee plot. The Km and Vmax were 5.3 mM and 349.5 nmolh'1 cm'2 respectively, 
and indicated that the glucose transport across the bovine CBE would be likely to saturate 
at a stromal glucose concentration of » 10.6 mM (i.e. double the Km value) with a 
maximum glucose transport rate of 349.5 nmolh'1 cm'2. Previous studies on bovine RPE 
demonstrated a lower affinity, but much higher capacity in transporting glucose into the 
retina (Crosson and Pautler, 1982; To et al., 1998c) than across the CBE. These studies 
revealed that glucose transport across the RPE is not limiting at normal plasma glucose 
concentrations. This would be beneficial, since the RPE is crucial in transporting glucose 
into the retina, in order to ensure an adequate glucose supply to meet the needs of the 
highly metabolically-active retinal tissues, including the photoreceptors (Adler and 
Southwick, 1992; To et al., 1998c).
As mentioned above, the experimental work carried out in this chapter suggests that 
glucose transport across the bovine CBE will saturate at a stromal glucose concentration 
of » 10.6mM. It should be noted that this finding may not necessarily reflect the diabetic 
condition, since it was an acute rather than a chronic alteration of glucose levels. It is 
known that tissues which have been exposed to elevated glucose concentrations can 
become leaky (through an increase in paracellular glucose movement) and that 
hyperglycemia can affect the glucose transport rate. Similar changes in the transport 
characteristics of “diabetic exposed” tissues have been reported in rat retina and RPE 
(Vilchis and Salceda, 1996). These alterations in glucose transport might result from
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glucose toxicity (Gaynes and Watkins, 1989; Unger, 1991) and other hyperglycemic 
complications.
3.4.2 Viability of preparations
3.4.2.1 L-glucose (LG)
LG was again used as the diffusional control. The general LG influx in the present study 
was low and indicated the new Ussing-type chamber was not leaky. Similar to the last 
study (Chapter 2), the subtraction of the LG flux from the MDG flux enabled the 
transcellular glucose flux to be calculated. This (indirectly) caused a reduction of the 
MDG flux increase at higher glucose concentration gradients. The fact that the LG fluxes 
were lower than the preset criteria and also smaller than those measured in a previous 
study (To et al., 1998a), indicated that the preparations were not leaky, and therefore that 
passive diffusion was not the dominant mode of glucose transport.
3.4.2.2 Ouabain response
At the end of each experiment, ouabain was added to the aqueous side as a final check of 
viability. Only those preparations (~ 80%) that gave a biphasic response to ouabain were 
included in the final analysis. Preparations might also be rejected when no stable 
electrical parameters could be obtained after the first stabilization period (Please refer to 
Chapter 2 (section 2.4.3) for details).
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3.4.2.3 Electrical parameters
All of the results included in the present study were collected from preparations, showing 
a consistently negative PDt before the first change of solution. Other electrical parameter 
changes with the increase of glucose concentration are discussed below.
3.4.3 Electrical parameter changes with glucose concentration
Figures 3.6 and 3.7 illustrate the electrical parameter changes upon increments of plasma-
side glucose level. It was noted that a plasma glucose concentration higher than 30 mM 
caused a polarity change, with the aqueous side becoming positive. In a previous study, 
significant changes of PD and 1  ^were also reported at very high glucose concentrations 
(i.e. 205 mM) in frog RPE and glucose fluxes were affected too with a concentration of 
100 mM (DiMattio and Streitman, 1986). However, a glucose concentration as high as 
100 mM has been suggested to be detrimental to the RPE (DiMattio and Streitman, 1986; 
To et a l , 1998c). Yet, these concentrations are far higher than those used in the present 
study, and the preparations studied here were still responsive to ouabain. One could 
postulate that the tissues were alive, but their electrical characteristics were somehow 
altered in response to the increase in extracellular osmolarity.
3.4.3.1 Cell volume regulation
Most living cells have the ability to self-regulate their volume, in order to counter balance 
alterations in extra- or intra-cellular solute content ratio (Rink, 1984). In general, an 
increase in extracellular osmolarity induces cell volume increase through water 
absorption, and vice versa. Such compensatory mechanisms, which act to restore proper
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cell size and functions, are called regulatory volume increases (RVI) or decreases (RVD) 
(Civan et a l, 1996).
In the bovine CBE, constant ionic and electrochemical gradients are maintained by the 
actions of various ion transporters and channels (Do and To, 2000). In the present study, 
the increase in the extracellular solute concentration led to a change in transmembrane 
polarity. It indicated that there was a net increase either in cation movement in the 
aqueous direction or anion movement in the stroma direction. Although, the exact ion 
mechanism for the observed changes in PDt is unknown, hyperosmotic stress and volume 
regulation can lead to changes in the potential difference via activations of various ion 
transporters or channels. Hyperosmotic shrinking has been demonstrated to activate the 
Na+/K+/2C1' cotransporter and sodium-proton exchanger (Na+/H+ exchanger) to restore 
the cell volume by water absorption as a secondary effect (Burg, 1995; Lang et al., 1998; 
Wehner and Tinel, 1998). Activation of chloride and other channels has also been shown 
in kidney tissues and several cell lines, due to intracellular hypertonicity (Kawahara and 
Matsuzaki, 1993; Hardy et al., 1995; Kanzaki et al., 1999). In rat muscles, an increase of 
20 mM glucose or mannitol activated Na+/K+/2C1' cotransporter activity, which 
subsequently induced water absorption into the cells (Gosmanov et al., 2003).
In the ciliary body, potassium channels and chloride channels were found to be activated 
separately in RVD in human, with or without the help of ion transporters (Yantomo et al., 
1989). A study of the NPE demonstrated its ability to induce RVI by activation of four 
different mechanisms, which mainly stimulated the uptake of sodium and chloride ions 
from the aqueous humor (Civan et al., 1996).
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In the present study, it is possible that the hyperosmolarity altered the transmembrane 
polarity through complex activation of the Na+/K+/2C1‘ cotransporter, sodium-proton and 
chloride-bicarbonate antiporter (Na+/H+ and CITHCCV antiporter) activities. These may 
have promoted the accumulation of sodium and chloride ions into NPE and PE cells, 
whilst effecting volume changes (Strange, 1992; Hardy et al., 1995; Civan et al., 1996).
A study into the mechanism of self-regulatory volume in NPE cells also showed that the 
process of RVD was mediated by separate K+ and Cl' conductances. Moreover, the 
change in the NPE cell volume also induced a change in intracellular calcium (Ca*) 
concentration, which facilitated the modulation of cell regulation during RVD (Adorante 
and Cala, 1995). In cardiac myocytes, high glucose induced a rise in the intracellular Ca+ 
concentration (Smogorzewski et al., 1998), which also could be one possible change 
responsible for the polarity alteration of CBE.
In addition, an increase in the active transport of osmolytes into the epithelial bilayer 
would be another explanation, since many Na+-solute transporters including the 
Na+/myo-inositol cotransporter (Morimura et al., 1997), Na+-ascorbate cotransporter 
(Helbig et al., 1989) and SGLT (details are discussed in Chapter 4) have been found in 
the CBE. These mechanisms are used in the brain to counter balance any extracellular 
deviations by actively transporting osmolytes including taurine, glutamate, or myo­
inositol (Strange, 1992). Therefore, the changes in the rate of ion, and/or solute transport 
could have induced an accumulation of sodium in the epithelial bilayers. At higher 
intracellular sodium ions concentration, the transport rate of the Na+, K+-ATPase of the 
CBE may be increased (such an effect has been demonstrated in Ehrlich ascites tumour 
cells, in which the sodium efflux increased 2.5 to 3 times in glucose-treated cells (Laris
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and Henius, 1982)). This could increase the vectorial transport of sodium into the 
aqueous and therefore induce a depolarization across the CBE. However, exactly how 
different ions contributed to the change is yet to be elucidated. In any case, apparently, 
the Na+, K+-ATPases remained unchanged in high-glucose condition, since the biphasic 
response was still present after the addition of ouabain (Fig. 3.6).
3.5 Conclusion
The present study has demonstrated the glucose transport kinetics across the bovine CBE 
using a wide range of glucose gradients. The results indicate that glucose transport across 
the bovine CBE is saturable and it is also consistent with a facilitated and carrier- 
mediated model of glucose transport mechanism.
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4.1 Introduction
In this study, RT-PCR was used to screen the mRNA expression of seven glucose 
transporters (GLUT1-5 and SGLT1-2) in the bovine CBE. Possible expression 
differences between the pars plana and pars plicata regions of the CBE were also 
investigated.
Firstly, bovine glucose transporter mRNA sequences were retrieved from GenBank for 
primer design. Bovine CBE tissues were isolated and RNA extraction was performed. 
The RNA samples were reverse-transcripted into cDNA templates and PCR was carried 
out with the isoform-specific primers. Amplified DNA samples were analyzed by gel 
electrophoresis and sequencing, for molecular weight determination and identity 
confirmation, respectively.
The kinetic study (Chapter 2) showed that glucose transport across the bovine CBE is 
driven mainly by a facilitative mechanism. The present set of experiments was designed 
to investigate the mRNA expression of the two major transporter families (GLUTs and 
SGLTs) to elucidate the molecular basis of glucose transport in this tissue.
A previous study suggested that glucose transport across the bovine CBE is likely to be 
facilitative/passive, as active glucose transport seems unnecessary under the natural 
glucose concentration gradient (Takata et al., 1991). However, the kinetic study of this 
project suggested a slightly different point of view, since phlorizin, a specific SGLT 
inhibitor, reduced the trans-CBE glucose flux significantly. With this molecular study, a 
clearer picture on the glucose transport across bovine CBE could be drawn.
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4.1.1 G ene expression  o f g lucose transporters in the eye
Numerous studies have demonstrated GLUT and SGLT mRNA expression in ocular
tissues including the cornea, lens, RPE and retina. Details o f gene expression findings on
ocular tissues are summarised in table 4.1. However, detailed investigation on their
expression in CBE has not been reported previously.
Gene Ocular tissues M ethods
Gene size 
(kbp)
Species Reference
Conjunctiva Northern blotting . . .
Human
culture
(Gherzi et al., 
1991)
Corneal epithelium
RT-PCR 
Northern blotting
2.8 Rat
(Takahashi et 
al., 1996)
RT-PCR _ Rat
(Takahashi et 
al., 2000)
Corneal epithelium and 
endothelium
Nuclease protection 
assay
. . . Bovine
(Bildin et al., 
2001)
Comeal endothelial cells Northern blotting 2.8
Bovine
culture
(Ishida et al., 
1995)
Lens epithelium
RT-PCR 
Northern blotting 
In situ hybridization
2.9 Rat
(Merriman- 
Smith et a l., 
1999)
GLUT1
Northern blotting 
Quantitative RT-PCR
2.2 Rat
(Merriman- 
Smith et a l., 
2003)
Retinal capillary 
endothelial cells and 
pericytes
Northern blotting 2.8
Bovine
culture
(Mandarino et 
al., 1994)
Retinal endothelial cells Northern blotting 2.8
Human
culture
(Knott et al., 
1996)
Retinal
microvasculature
Northern blotting 
Quantitative RE-PCR 2.8
Human
culture
(Badr et al., 
1999)
BRB,
RVE cells and RPE
Northern blotting 2.8
Human
culture
(Busik et al., 
2002)
RPE
PCR 
Southern blotting 
Northern blotting
2.8
Human
culture
(Takagi et al., 
1994)
RT-PCR 
Northern blotting
3.2
Chick
culture
(Ban and 
Rizzolo, 2000)
GLUT2 Retinal Muller cells
RT-PCR 
Southern blotting — Rat
(Watanabe et al., 
1994)
Lens - cortical fiber cells
RT-PCR 
Northern blotting 
In situ  hybridization
4.0 Rat
(Merriman- 
Smith et al., 
1999)
Lens - epithelial cells
Northern blotting 
Quantitative RT-PCR 4.0
Rat
(Merriman- 
Smith et al., 
2003)
GLUT3 Retinal endothelial cells Northern blotting 4 .1 ,3 .2
Human
culture
(Knott e ta l.,  
1996)
Retinal microvasculature
Northern blotting 
Quantitative RT-PCR —
Rat
(Badr et al., 
1999)
RPE
PCR 
Southern blotting
. . . Human
culture
(Takagi et al., 
1994)
RT-PCR . . .
Chick
culture
(Ban and 
Rizzolo, 2000)
GLUT5 RPE
PCR 
Southern blotting
. . . Human
culture
(Takagi et al., 
1994)
Table 4.1 G ene expression  o f  glucose transporters in ocu lar tissues.
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4.1.2 Regulation of glucose transporter gene expression 
Growth factors. Several growth factors have been found to be effective in regulating 
certain glucose transporter gene expression, including platelet-derived growth factor 
(PDGF), endothelial growth factor (EGF), and IGF-1. PDGF can stabilise GLUT1 
mRNA by increasing its half-life by four-fold (Rollins et al., 1988), while EGF 
upregulated GLUT1 expression by activating the PKC pathway. However, the effect of 
certain growth factors has been more controversial. Isliida et al. (1995) found that 
GLUT1 mRNA expression was not affected by IGF-1 in bovine cornea, while Masters et 
al. (1991) found the cells were IGF-1 responsive in their study. Other growth factors such 
as transforming growth factor-/?l (TGF- p \)  have been found to work synergistically with 
others (e.g. serum, fibroblast growth factor (FGF), PDGF) to increase glucose uptake and 
GLUT1 gene expression by increasing the level of transcription (Kitagawa et al., 1991). 
For human RPE cells, EGF caused a significant increase of GLUT1 mRNA expression, 
but PDGF, IGF-1, and FGF were ineffective (Takagi et al., 1994). However, FGF was 
effective in upregulating GLUT1 mRNA in rat fibroblasts (Hiraki et al., 1988), while 
IGF-1 stimulated GLUT1 expression in brain astrocytes (Masters et al., 1991). Further 
evidence of species variations have also been demonstrated in a carcinoma study, in 
which the same signaling pathway that upregulates GLUT1 in rodents (Flier et al., 1987) 
could only upregulate GLUT3 in chick (Wagstaff et al., 1995; Steane et al., 1998). These 
studies clearly demonstrated inter-species and tissue differences in gene regulation 
mechanisms, which might be highly dependent on the relevant intracellular signal 
transduction pathways or cell surface receptor expression.
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Transcriptional factors. Nuclear factors Spl and Sp3 were found to be important in 
GLUT3 mRNA regulation, since the former mediated suppression, while the latter 
resulted in activation of GLUT3 mRNA transcription in mouse neuroblasts and 
trophoblasts (Rajakumar et al., 1998). In addition, the transcription factor KLF15 was 
found to mediate regulation of GLUT4 in cardiac muscle tissues by binding to specific 
DNA response elements (Gray et al., 2002).
Insulin, Short-term insulin therapy in diabetic rats normalises the GLUT1 mRNA level, 
yet cannot normalise the GLUT1 protein level (Lutz and Pardridge, 1993). In vivo, 
hyperinsulinaemia caused an inhibitory effect on GLUT2 mRNA expression in rat 
hepatocytes, but it was partially prevented or dominated by the presence of 
hyperglycemia (Postic et al., 1993). Furthermore, studies of human subjects suggested 
that insulin was only useful in upregulating the GLUT4 mRNA level in normal subjects 
and acute stimulation of GLUT4 mRNA seemed to be altered in diabetic patients 
(Schalin-Jantti et al., 1994). However, it was found useful to regain the normal level of 
GLUT4 mRNA in insulin-deficient rats in the adipose tissues (Sivitz et al., 1989). 
Therefore, effect of insulin on GLUT4 mRNA level remains controversial.
Hypoxia or ischemia. Apart from being regulated by growth factors, certain conditional 
changes can also change the expression pattern of glucose transporter genes. In a rat liver 
cell line, GLUT1 mRNA expression was found to be upregulated during inhibition of 
oxidative phosphorylation, which resulted from an increase in gene transcription and a 
decrease in mRNA degradation (Shetty et al., 1993). Chronic hypoxic exposure 
stimulated both GLUT1 and GLUT3 gene expression in both gerbil and rat brain (Lee
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and Bondy, 1993; Gerhart et al., 1994) such as in microvessels, which resulted in a 60% 
increase in capillary density of the cerebrum together with an increase in glucose 
transport capacity of the brain (Shetty et al., 1993). For GLUT3 and GLUT4, hypoxia 
also induced an increase of mRNA transcriptional levels in fetal rat brain (Royer et al., 
2000), which further indicates responsiveness to hypoxia.
Glucose deprivation. Glucose deprivation was found to increase GLUT1 gene expression 
in brain capillary endothelial cells, via stabilization of its mRNA (Boado and Pardridge, 
1993). Such a mechanism, which was previously postulated to be mediated by PKC, was 
also found to be related to the participation of a cis-acting regulatory element (CAE). The 
CAE served to increase the GLUT1 mRNA expression during glucose deprivation, as 
judged by elevation of a GLUTl-luciferase reporter gene and a decrease in the rate of 
mRNA decay (Boado and Pardridge, 2002). For GLUT4, glucose deprivation caused a 
decrease in its mRNA in rat adipose and muscle tissues, while the condition was 
reversible by glucose intake (Sivitz et al., 1989).
Hyperglycemia or glucose toxicity. Elevated glucose levels or simulated diabetic 
conditions can alter GLUT2 mRNA expression both in vitro and in vivo. In an in vivo 
diabetic model, a decrease in GLUT2 expression was seen in pancreatic P-cells, but not in 
cells of the liver, intestine or kidney (Orci et al., 1990; Ohneda et al., 1993). In in vitro 
cell culture, on the other hand, an increase in GLUT2 mRNA expression was seen in 
response to high glucose exposure (Waeber et al., 1994). In skeletal muscles, GLUT4 
mRNA expression was downregulated in hyperglycemia, and only partly reversible with 
glycemic correction. In the same study, GLUT1 was upregulated directly with glucose
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concentration. This revealed incomplete restoration ability of the insulin responsive 
system, but not in the basal uptake system (Dimitrakoudis et al., 1992).
Toxic agents. Glucose transporter gene expression changes were found after exposure to 
agents such as cobalt chloride (II) [Co(II)] and cadmium. After 10-12 days exposed to 
Co(II), an agent that stimulates hypoxia-responsive genes (Watanabe et al., 1996),
GLUT1 and GLUT3 mRNA expression in rat retina were increased by 2.48 fold and 1.5 
fold, respectively (Badr et al., 1999). This is consistent with previous studies on GLUT 
mRNA expression in response to hypoxia. Cadmium, a toxic agent that can cause renal 
glycosuria, induced different or opposite effects on SGLT expression, with both SGLT1 
and SGLT2, expression being reduced. The response, however, was dose-dependent for 
SGLT1, but not for SGLT2. For SGLT3, expression was increased by five-fold in the 
kidney as a result of cadmium toxicity (Tabatabai et al., 2001). Not only does this imply 
that SGLT3 is a stress-response gene, it also indicates response variation within the same 
transporter family.
4.1.3 RT-PCR and related concepts
GenBank Database. The GenBank database is a repository for known nucleotide and 
protein sequences, and is hosted by the National Center for Biotechnology Information 
(NCBI). Newly discovered gene sequence must be submitted to Genbank (or its European 
or Japanese equivalents) as a normal prerequisite to journal publication. GenBank also 
contains expressed sequence tag (EST) sequences contributed by numerous authors and 
sequencing centers (Benson et al., 1999; Stoesser et al., 1999).
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Polymerase chain reaction (PCR). PCR was invented by Kary Mullis in 1984 with the 
first description of this method published in 1985, for its use in amplifying Beta-globin 
sequences in sickle cell anemia (Saiki et al., 1985). This technique allows in vitro 
amplification of a specific region of DNA, which generates numerous copies of DNA that 
could be used for further purposes e.g. cloning and sequencing.
In general, a basic PCR reaction involves two oligonucleotide primers that flank the 
template sequence that is to be amplified. After denaturation of the DNA, the primers 
hybridise to opposite single-strand DNA. The Taq Polymerase then proceeds through the 
region in between the primers, in the presence of deoxynucleotide triphosphates (dNTPs: 
dATP, dCTP, dGTP and dTTP), for DNA synthesis. The resulting double-stranded DNA 
acts as new templates for the next thermal cycle. Amplification of the DNA sequence is 
achieved by repeat cycles of heat denaturation, primer hybridization and sequence 
extension. This reaction can generate up to 105-106 fold amplification of the original 
target DNA after 20-30 successive cycles (Mueller and Young, 2001).
Primer design. A primer is a short oligonucleotide, which is designed to recognise its 
complementary sequence on a cDNA template. Two PCR primers are used in a molar 
excess for each PCR reaction, to provide the specificity of the reaction. After the primers 
anneal to the heat-denatured DNA template strands, two complete complementary 
sequences (the region to be amplified) are synthesized. The pair of primers for a target 
sequence should have: similar GC content, such that they possess a similar melting 
temperature; minimal secondary structure, to prevent self-complementarity, and low 
complementarity to each other at their 3’ends. In this study, all primers were designed 
based on the bovine glucose transporter mRNA sequences present in GenBank. Before
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primer design, sequences were aligned with all other mammalian glucose transporter 
sequences retrieved from GenBank to limit the chances of including sequence errors. 
After a short oligonucleotide was chosen as primer, it was checked against other glucose 
transport sequences to avoid non-specific hybridization (cross-reactivity) with non­
targeted transporters. In this study, the program Clustal W provided by the EMBL-EBI 
(European Bioinformatic Institute) was used for sequence alignment, since it allows 
multiple-sequence alignment so that identities, similarities and differences can be seen.
Melting and annealing temperature. The melting temperature (Tm) of a primer is 
dependent on its constitution of different bases. The Tm can be determined by using the 
following equation for 20 or less base pairs primer:
[(number of base (A + T) x 2°C) + (number of base (G + C) x 4°C)] 
or by using the nearest-neighbour method (Breslauer et al., 1986). The annealing 
temperature of the PCR reaction is usually chosen to be 3-5°C lower than the Tm.
RNA extraction. Extraction of RNA involves the removal of protein and DNA from 
samples using organic solvents (e.g. phenol or chloroform containing 4% isoamyl 
alcohol) and alcohol. Phenol is an oily chemical that is partly miscible with water. In the 
presence of 20% water, it forms an aqueous solution that contains phenol micelles 
surrounded by water molecules. Proteins, which are mainly hydrophobic molecules, can 
partly dissolve in this organic solvent. When mixing equal volumes of phenol and 
aqueous protein samples, most of the phenol molecules tend to dissolve in the 
hydrophobic core of protein. The protein then swells and denatures. Denatured proteins 
gather more micelles of phenol and dissolve more readily in the phenol phase as a result
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of their stronger hydrophobic bonding. The use of both chloroform and phenol helps to 
unfold proteins and to expose the hydrophobic regions so they can bind more readily to 
phenol micelles. Thus, proteins can be completely denatured and removed by repeated 
phenol-chloroform extraction. Since nucleic acids are hydrophilic and highly soluble in 
water, they stay in the aqueous phase. They can be precipitated with high-salt in the 
presence of alcohol (i.e. ethanol or isopropanol). In this study, TRI reagent (Sigma- 
Aldrich Co. Ltd., Dorset) was used for the RNA extraction. It is a mono-phase solution of 
phenol, guanidine thiocyanate, buffer and solubilizing agents. Guanidine thiocyanate is 
an effective reagent that inhibits ribonuclease (RNase) activity (Chomczynski and Sacchi, 
1987) by denaturing all cellular proteins, including RNase (Chan, 1992).
RNA or DNA quantification. The nucleic acid concentration of a sample can be 
determined by using spectrophotometry. One unit absorbance at 260 nm corresponds to 
approximately 50 pg/ml and 44 pg/ml of double-strand DNA and single stranded RNA, 
respectively. Resonance structures of pyrimidine and purines bases are responsible for the 
absorbance, while it is also affected by the amount of base ionization and the sample pH 
(Wilfinger et al., 1997). The absorbance at 260 nm (A260) and 280 nm (A280) can be used 
as a ratio (A260/A280 ratio) for sample purity estimation. In general, pure preparation of 
DNA and RNA have ratios of 1.8 or 2.0, respectively (Chan, 1992). If ratio is less than 
the suggested values, it indicates that the samples are contaminated with protein or 
phenol, which would affect the concentration calculation. Under these circumstances, 
RNA extraction should be repeated.
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RNA integrity. Cellular RNA is mainly comprised of ribosomal (rRNA). Messenger 
RNA (mRNA) constitutes only a small portion of the total RNA (2-5% of RNA).
Through electrophoresis in a 1% formaldehyde agarose gel, good quality RNA should 
reveal 2 major bands, corresponding to ribosomal units 28S and 18S, or sometimes 3 
bands (including the minor 5.8S unit), with the intensity of 28S band double that of 18S. 
In other words, good quality RNA would show 2 or 3 bright bands against a faint smear 
of mRNA.
Agarose gel electrophoresis can be used to separate RNA and double-stranded DNA 
fragments according to their molecular weight. The agarose gel is a complex network of 
pores, which allows RNA or DNA molecules to travel according to their molecular sizes. 
Gels can be stained with ethidium bromide after electrophoresis, allowing bands to be 
visualised. Molecular weight estimation can be done by comparison of a band in a sample 
lane with a series of molecular weight marker bands.
Reverse Transcription (RT), PCR requires a DNA template for amplification (RNA is a 
poor substrate). Thus, to facilitate PCR, RNA is reverse-transcribed into complementary- 
DNA (cDNA), using the enzyme reverse transciptase. This enzyme syntheses a cDNA 
template by polymerization of dNTPs using the RNA as template. Reverse transcriptase 
adds nucleotides starting from the 3’end, by making use of a pre-existing primer base 
paired to the template. As almost all eukaryotic mRNAs possess a string of 50-250 
adenine residues at their 3’ end, a short string of thymidine (oligo-dT) bases targeted to 
this poly(A) tail makes a good primer for RT.
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HotStar Taq Polymerase. The Taq DNA polymerase from the thermophilic bacterium 
Thermus aquaticus was first introduced in 1988 (Saiki et al., 1988). HotStar Taq 
Polymerase, a modified form of the recombinant 94 kDa Taq DNA Polymerase, is 
inactive at ambient temperature, which prevents mis-priming during the initial 
denaturation step of PCR (Chou et al., 1992). It is activated at 95°C, by means of an 
extended incubation during this initial denaturation phase.
DNA Sequencing. In general, DNA sequencing employs a “chain termination method”, 
which involves the synthesis of a single-stranded DNA template in the presence of 
limiting amounts of 2’,3’-dideoxynucleotides (ddNTPs). In practice, a primer which is 
annealed close to the sequence is used to initiate the synthesis in the presence of Klenow 
fragment of DNA polymerase and the four deoxy-nucleoside 5’-triphosphates (dNTPs). 
Fluorescent tags are attached to the chain-terminating nucleotides, with each of the four 
ddNTPs carrying a different fluorophore. When the ddNTP attaches to the chain, the 
chain can no longer be extended. The resulting DNA fragments can be run on a high- 
resolution gel, at the bottom of which is a detector, which scans for the fluorescent tags.
4.1.4 Available methods for gene expression study
In situ hybridization, northern blotting and RNase-protection assays are common methods 
used in RNA expression studies. This section will briefly describe each method and 
compare their strengths and weaknesses to each other, and to RT-PCR.
In situ hybridization (ISH). It is a technique developed to localise nucleic acid in cells or 
tissues and was firstly introduced by Paradue and Gall in 1969 (Gall and Pardue, 1969).
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A nucleic acid probe is used in the same way as labeled antibodies, to hybridise with the 
in situ nucleic acid of interest and generate a signal. It provides additional information 
compared to samples extracted using homogenization. The use of ISH in RNA expression 
studies was firstly introduced by Harrison et al. in 1974, who used a DNA probe for RNA 
detection in liver (Harrison et al., 1974). Later in 1984, Cox et al. (Cox et al., 1984) 
designed an RNA probe for embryonic RNA detection. In general, tissues are gently 
fixed with the RNA exposed at its original position. The probe and target hybridise and 
generate a pattern of gene expression in the tissue. This allows insights on differential 
gene expression in cell compartments that help in explaining functional differences 
between cells (Alberts et al., 2002).
Northern blotting. A  technique named with regard to Southern blotting (which itself was 
named after its inventor, Edwin Southern), Northern blotting is used to detect and 
quantify a particular RNA sequence in a complex RNA mixture. Total cellular RNAs are 
denatured by reagents such as formaldehyde to assure a linear conformation of the RNA 
molecules by breaking hydrogen bonds between base pairs. The individual RNA 
molecules are then separated by gel electrophoresis according to their size, and 
transferred onto nitrocellulose or nylon membranes and exposed to a labeled single 
stranded-nucleic acid probe. The labeled probe used can be purified RNA, cDNA or a 
cloned fragment of genomic DNA and acts similarly to antibodies at this point (Darbre, 
1999). The size of the targeted RNA molecule can be determined by reference to known 
RNA standards. With this method, one can get an estimation on the molecular weight as 
well as comparing the amount (quantity) of the RNA of interest in different samples.
121
Glucose transporter gene expression in the CBE
RNase protection Assay, In this method, hybridization is carried out directly in cell 
lysates, which precludes the need for membrane transfer from gels (Bildin et al., 2001).
In general, it involves the hybridization of mRNA with a single stranded RNA or DNA 
probe in solution. Excess probe and imperfect duplexes are digested by single-strand 
specific nucleases. The RNA-DNA or RNA-RNA hybrids are finally analyzed by gel 
electrophoresis (Raval, 1994).
4.1.4.1 Comparison of RT-PCR with other methods
The major advantage of PCR is its sensitivity. In particular, a sample size as small as one 
single cell can be used as the starting template. It has much higher in sensitivity than 
Northern blotting and RNase protection assays and can detect copy number in the 
attomolar (10'2IM) range (Miller et al., 1997). In addition, RT of mRNA for RT-PCR can 
be used to stabilise sample material for long periods. Therefore, RT-PCR is the optimal 
method in most screening applications, especially in the situation when sample supply is 
limited.
For questions concerning the level or regulation of mRNA expression, standard RT-PCR 
alone is inadequate to provide the necessary answers. Quantification of expression can be 
done by Northern blotting, RNase protection assay or quantitative RT-PCR (Ji et al.,
1990; Jindal et al., 1995). Although northern blotting is labour intensive and requires 
significant amount of starting RNA, it has the advantage that once produced, membrane 
can be stripped and reprobed many times. The RNase protection assay technique allows 
multiple transcripts to be screened simultaneously, but the use of high doses of 
radioactivity is a disadvantage. Among all, only ISH provides resolution at the cellular 
level, regarding the site of gene expression.
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Since information about glucose transporter gene expression in CBE is not yet available, 
a method that can be used for quick screening was desirable. Thus, RT-PCR is very 
suitable to be used in this study for it provides a rapid way to determine the presence of 
certain genes, especially in the case of limited sample quantity.
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4.2 Methodology
4.2.1 Basic principles
In this study, RNA samples were taken from bovine CBE, and kidney, which were then 
reverse transcribed into cDNA templates. For each gene whose expression was 
investigated, a pair of gene-specific primers was designed and tested to ensure successful 
amplification of mRNA from the “positive control tissue” (kidney). RT-PCR was then 
carried out on RNA from bovine CBE. PCR products were purified and sent for 
sequencing for confirmation of amplification specificity.
4.2.2 Tissue preparation
Dissection instruments were baked at 200°C overnight to destroy any contaminating 
RNase activity. Fresh tissues were obtained from the abattoir and immediately dissected 
as described in the following sections:
4.2.2.1 Ciliary processes/ pars plicata
Eyes were positioned with the cornea facing upwards (Fig. 4.1a). One comer of the 
cornea (adjacent to the limbal region) was cut with an RNase-free razor blade. The whole 
cornea was carefully trimmed off (Fig. 4.1b) with RNase-free scissors started at the cut 
comer, leaving the underlying structures including the lens (Fig. 4.1c) and ciliary 
processes exposed (Fig. 4. Id). The ciliary processes’ tissues were carefully tom off with 
RNase-free forceps and submerged in RNAlater (Ambion European Ltd.,
Cambridgeshire, UK). This agent is used to preserve RNA quality (Gong et al., 2001). 
Upon arrival in the laboratory, tissues were immediately frozen in liquid nitrogen and 
stored at -80°C.
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Corner
Sclera-
a) Eyes were positioned upwards.
b) The whole cornea was trimmed off.
Iris
Iris
Crystalline 
lens
c) The iris was exposed after the 
removal of cornea (top view).
d) The ciliary processes were exposed after the 
removal of iris (top view). Forceps can be used 
to tear off the tissues at this stage.
Ciliary
process
Iris
Retina
Ora serrata
e) An area of pars plana was cut from 
the whole CBE (back view).
Anterior lens capsule
Pars plicata 
(ciliary process)
Pars plana
Fig 4.1 Dissection of tissues from bovine eyes.
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4.2.2.2 CBE pars plana
The CBE was isolated as described in section 2.2.3. A 0.5cm x 0.5cm area of pars plana 
tissue was cut from the whole CBE pars plana (Fig. 4.1e) with a sterile scalpel. The tissue 
was submerged in RNA/ater, frozen immediately in liquid nitrogen and stored at -80°C.
4.2.2.3 Bovine kidney
Two methods were used for the isolation of bovine kidney samples. In the first approach, 
tissues were dissected in the laboratory, frozen in liquid nitrogen and stored at -80°C. 
Briefly, a sterile scalpel was used to remove the outer cortex. A new scalpel was then 
used to cut 0.5cm x 0.5cm pieces of tissue from the inner cortex of kidney. Tissues were 
frozen in liquid nitrogen and stored at -80°C for later use. For the second method, small 
pieces of kidney tissues were transferred to RNAJater at the abattoir, similar to the 
protocol for ciliary body tissue as described in sections 4.2.2.1 and 4.2.2.2. They were 
frozen in liquid nitrogen and stored at -80°C on arrival at the laboratory.
4.2.3 RNA extraction
Frozen tissues were powdered at liquid nitrogen temperature using a dismembrator 
(Mikro-Dismembrator U, B. Braun Biotech International) at 1600 rpm for 2 mins. The 
isolation of RNA was performed using TRI reagent (Sigma-Aldrich Co. Ltd., Dorset). 
Dismembrated samples were mixed with 100 pi TRI reagent at 1600 rpm for 2 mins. An 
800 pi aliquot of TRI reagent was further mixed with samples at 1600 rpm for 5 mins. 
Solubilised samples were transferred into a sterile Eppendorf tube. The dismembrator 
tissue container was finally washed with 100 pi TRI reagent at 1600 rpm for 30 seconds 
with the washed sample also transferred into the same Eppendorf tube. Lysed samples
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were centrifuged at 13,500 x g for 5 mins at room temperature to pellet any insoluble 
material. Supernatants were transferred to fresh Eppendorf tubes containing an aliquot of 
silicon grease, and mixed with 200 pi chloroform by vortexing for 1 min. They were left 
to stand for 10 mins at room temperature before centrifugation at 13,500 x g for 10 mins. 
After centrifugation, an interface was formed by the silicon grease with a clear upper 
aqueous phase containing RNA, and a lower phase containing the phenol-chloroform and 
proteins. The upper aqueous phase was carefully transferred to a fresh Eppendorf tube. It 
was mixed with 500 pi isopropanol by vortexing and was allowed to stand at -20°C for 
15 mins. Centrifugation at 13,500 x g at room temperature was performed again for 10 
mins. The supernatant was discarded and the RNA pellet was washed with 1 ml ice-cold 
70% ethanol. The mixture was centrifuged at 13,500 x g again for 2 mins and the ethanol 
was removed. The pellet was partially air-dry by standing at room temperature for 5 
mins. To dissolve the pellet, 51 pi sterilised water was added and incubated for 10 mins 
at 37°C with periodical mixing. DNase treatment was carried out by adding 6 pi 1 OX 
DNase reaction buffer, 1 pi RNase OUT, 2 pi DNase I, which was thoroughly mixed with 
the samples. The DNase reaction mix was incubated at 37°C for one hour. This step was 
designed to degrade residual DNA that had co-purified with the RNA.
4.2.3.1 Pigment removal from RNA preparations
CBE is enriched with melanin, a pigment which gives the tissues a distinct brownish 
colour. Melanin, which co-purifies with RNA, is known to inhibit RT as well as PCR 
reactions (Giambemardi et al., 1998). In this study, the RNAeasy mini kit (Qiagen Ltd., 
West Sussex, UK) was employed to remove the pigment from the samples (following the 
manufacturer’s instructions). It is kit consisted of filtered-type column which samples can
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pass through the sieve-like membrane easily but not the pigment molecules. Kidney 
samples, as the positive control, were also treated using the same method to ensure 
experimental consistency. The final RNA sample was eluted in 100 pi RNase-free water. 
Samples were quantified with a GeneQuant instrument for absorbance at 260 nm, 280 nm 
and 320 nm. The typical yield of total RNA was ~30 pg for CBE and ~60 pg for kidney 
tissues.
4.2.3.2 RNA integrity
After extraction, 2 pg of each RNA sample was analyzed by agarose gel electrophoresis. 
The gel mixture was made by dissolving 1 g agarose in 100 ml lx MOPS buffer (20 mM 
MOPS, 8 mM sodium acetate, 2 mM EDTA, pH 7.0). After complete dissolution and de­
gasing of the gel mixture, it was allowed to cool to 55°C at room temperature. 
Formaldehyde was added to a final concentration of 0.7M shortly before the pouring of 
the mixture into the gel tray.
Before sample loading, 6 pi volume RNA samples were mixed with 14 pi loading buffer 
(10 pi 20X MOPS; 70 pi 37% Formaldehyde; 200 pi 100% Formamide; 10 pi Ficoll- 
EDTA). Samples were denatured by heat at 55°C for 15 mins before loading onto the gel. 
Electrophoresis was carried out at 80 V for 80 mins and the gel was stained with IX 
SYBR-GOLD (Molecular Probes, Inc., Eugene, USA) for 20 mins. The gel was 
examined using a dual-intensity transilluminator (UVP, USA) and photo-documented 
with a DS34 Direct screen instant camera (Polaroid, UK). Only samples showing high 
quality rRNA bands were used in the subsequent experiments.
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4.2.4 Reverse transcription (RT)
RNA samples were transcribed into cDNA as follows. Initially, samples (5 pg) were 
mixed with 0.5 pg Oligo (dT)i2-i8, 0.7 mM dNTP mix in water in a final volume of 13 pi, 
and overlaid with 20 pi of RNase-free mineral oil to prevent evaporation. Samples were 
then heated at 65°C for 5 mins and cooled to 4°C for 5 mins. Then, 7 pi master mix was 
added to each sample to give a final concentration of IX First Strand Buffer; 5 mM DTT; 
2U RNase OUT; 10U Superscript III RT (Invitrogen life technologies, USA). Mixtures 
were heated at 50°C for another 60 mins. After incubation, mineral oil was removed from 
all samples and QIAQuick Purification (Qiagen Ltd., West Sussex, UK) was performed. 
Samples were eluted in 100 pi 10 mM Tris-HCl buffer (pH 8.0). The efficiency of RT is 
around 30%, which meant the total yield of cDNA samples was expected to be ~1.5pg.
4.2.5 Polymerase chain reaction (PCR)
4.2.5.1 Primer design
In the design of primers, an mRNA sequence search was performed in the GenBank 
database (http://www.ncbi.nlm.nih.gov). Bovine sequences were the prioritised choices to 
retrieve (Table 4.2), while other mammalian glucose transporters sequences were also 
retrieved to ensure the identity of bovine sequences in Clustal alignments. Primers were 
designed from the bovine mRNA sequences according to the following criteria: i) length 
of 18-25 base pairs (bp); ii) percentage of GC composition ranged from 50% to 60%; iii) 
Tm range of 60°C to 75°C, calculated according to Breslauer et al. (1986); iv) beginning 
with one to two G or C nucleotides and ending with one to three A or T nucleotides; v) 
avoid stretches of four or more identical bases; vi) prevent self-complementarity, since 
formation of secondary structure would hinder normal PCR reaction.
129
Glucose transporter gene expression in the CBE
GLUT1
UCaIl£li
NM 174602 F 2533
GLUT2 AF308828 P 427
GLUT3 NM 174603 P 1793
GLUT4 D63150 F 2642
GLUTS AF308830 P 617
SGLT1 AF508807 F 2248
SGLT2 AY208941 F 2275
SGLT2-like 
bovine EST* AV605490
— 553
Table 4.2 Bovine mRNA sequences used for primer design.
Clustal alignments (http://www.ebi.ac.uk/clustalw/) were performed for all mammalian 
glucose transporter mRNA sequences retrieved in order to check for mis-specification. 
Some sequences for SGLT2 were found to be mis-specified (Appendix I).
* Before the bovine SGLT2 sequence was published in early 2004, a bovine EST 
sequence was found in GenBank, which aligned well at certain regions with other 
mammalian SGLT sequences (Appendix II). A pair of primers was designed based on 
this sequence.
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In general, 2 sets of primers were designed for each glucose transporter member with the 
better performing set chosen depending on the PCR results. The optimised primers used 
in this study are summarised in Table 4.3.
* will
’5^3^ | l §
*
58$ ft®wm Product s ize (bp)
GLUT1-UP CACCAGCTAGGCATCGTCGT 60.0 68.7 64 548
GLUT1-DN GATGGTCATGAGCACTGCACA 52.4 68.8
GLUT2-UP CAGCTCTTCACCAATGCCA 52.6 66.4 62 296GLUT2-DN CTCAGGAGCACAAGTCCCA 57.9 65.4
GLUT3-UP CCAGTTTGGCTACAACACTGGA 50.0 67.1 63 532GLUT3-DN GCACTGGATGATGGCTGGT 57.9 67.6
GLUT4-UP CCATCTTGATGACTGTGGCT 50.0 63.9 63 621GLUT4-DN CCACTGCTAACCACAACACA 50.0 63.4
GLUT5-UP GCTTCATCTCCGTGCTGA 55.6 64.1 59 495GLUT5-DN CAGTGAAGTTGGAGAGCCAGT 52.4 64.5
SGLT1-UP GGTATGGTGCCTTCGTGA 55.6 63.4 59 678SGLT1-DN GGTGGTCCCAAGTAACTGGT 55.0 63.7
SGLT2-UP CCATCCTGCTCTTCGTCTGCT 57.1 69.1 64 460SGLT2-DN ACTGCATTGGACACCCTGAGC 57.1 69.9
SGLT2-like-UP GCACTGATGTACACGGACA 52.6 62.0 58 151SGLT2-Iike-DN TGACGGTATCCGAGGATC 55.6 62.2
Table 4.3 Primers used for PCR in this study. *TA is the annealing temperature.
4.2.S.2 Positive and negative controls
Bovine kidney was used as the positive control in this study as the literature suggested 
that kidney expressed all of the GLUT and SGLT transporters examined.
“Mock” RT reactions were performed as negative controls. In mock RT, the enzyme 
(i.e.Super Script III RT) was substituted by water, while other reagents and experimental 
procedures remained the same. Under such conditions, cDNA template from the desired 
mRNA would not be formed. Thus, any positive PCR results from these mock samples 
would reveal the presence of genomic DNA contamination. This enabled the
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identification of false positive PCR reactions by comparison of the PCR results between 
the normal and mock samples.
Positive controls (i.e. kidney cDNA template) and negative controls (i.e. mock kidney,
CE samples) were used along with the CBE cDNA templates in every PCR experiment.
4.2.5.3 Experimental optimization
Optimization of RT-PCR was carried out by using the bovine kidney samples. 
Unsatisfactory PCR results e.g. faint or no bands, heavy primer dimers or positive results 
on mock samples were optimised by testing different annealing temperatures, use of Q- 
solution (HotStar Taq DNA Polymerase Kit, QIAGEN Ltd.) and trials of different sample 
concentrations. Continual failure in optimization necessitated the redesign of primer sets. 
In this study, the problems encountered were solved by varying the annealing temperature 
(i.e. GLUT4) or re-design of primers (i.e. GLUT2, GLUT3 and SGLT2).
4.2.5.4 PCR protocol
Two microlitres (~ 0.03 pg) of cDNA templates was mixed with an 18 pi PCR reaction 
master mix (IX PCR Buffer (QIAGEN Ltd., West Sussex, UK), 0.2 mM dNTPs, 1 pM 
upstream-primer, 1 pM downstream-primer and 1U of Hotstar Tag DNA Polymerase 
(QIAGEN Ltd., West Sussex, UK)). The mixtures were overlaid with 20 pi mineral oil to 
prevent evaporation. PCR was performed in a Techne Progene PCR machine. Initially, 
mixtures were heated at 95°C for 15 mins to activate the polymerase. A profile of 35 
cycles, comprising heating at 94°C for 1 min for cDNA denaturation, an annealing phase 
at a temperature set according to the primer’s Tm for 1 min and finally an extension phase
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of 72°C heating for 1 min. An additional heating phase (72°C for 5 mins) was performed 
after the 35 cycles to allow any remaining sequence polymerization to complete.
4.2.6 Gel electrophoresis
PCR products were separated on 2% agarose gels for product size determination. In 
general, 5 pi of loading buffer (15% Ficoll 400,10 mM EDTA, 0.13% xylene cyanol FF) 
was added to 20 pi of PCR product and mixed. Ten microlitres of each sample were 
loaded onto the gel for electrophoresis (80 V for 80 mins). Gels were stained with 
ethidium bromide (0.5 mM) for 30 mins and de-stained in distilled water. Some gels were 
stained with SYBR gold dye (0.1 mM), a more sensitive gel stain to ensure negative 
findings (see section 4.3.1.). Gels were examined by the transilluminator and photo­
documented by using the Polaroid DS34 camera.
4.2.7 Sequencing
4.2.7.1 PCR products preparation
Samples were amplified by PCR as described in the previous section. Five replicate PCR 
samples were pooled together to give a total volume of 100 pi and purified using the 
QIAquick kit (Qiagen Ltd.) to remove residual primers and dNTPs. The PCR products 
were eluted in a volume of 180 pi of 2 mM Tris-HCL (pH 8.0). Two microlitres of 
glycogen (2 pg /pi) and 20 pi of 3M sodium acetate solution were added to the 180 pi 
eluant. After mixing and centrifugation, 200 pi of phenol-chloroform was added. The 
samples were mixed thoroughly for 1 min and centrifuged at 13,000 rpm for 2 mins. The 
supernatant was transferred into new tube and 400 pi of ethanol was added. The mixture 
was thoroughly mixed again before it was left to stand at -20°C for 20 mins.
133
Glucose transporter gene expression in the CBE
Centrifugation was carried out at 14,000 rpm for 10 mins and the supernatant was 
discarded. One milliliter of ice-cold 70% ethanol was added to the pellet and the sample 
was centrifuged again at 14,000 rpm for 2 mins. The supernatant was discarded again and 
the pellet left to air-dry for 5 mins. The pellet was re-dissolved in 20 pi water. The 
GeneQuant instrument was used to measure the absorbance at 260 nm (see section 
4.2.3.2) and samples were diluted to a final concentration of 25 ng/pl. Ten microliters of 
each sample was sent to the Cardiff University Sequencing Facility using the ABI Prism 
3100 genetic analyzer (Applied Biosystems).
4.2.7.2 Sequencing results verification
All sequences were viewed using the CHROMAS program (Technelysium Pty Ltd, 
Australia) and exported as a text file. The identity of DNA sequences was examined by 
BLAST searches against the GenBank non-redundant database 
(http://www.ncbi.nlm.nih.gov/BLAST/).
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4.3 Results
4.3.1 RT-PCR
Polymerase chain reaction products were run on a 2% agarose gel and stained with 
ethidium bromide (0.5mM). (For GLUT2 and SGLT2, gels were stained with SYBR gold 
dye in one of the repeated experiment to confirm the presence o f positive finding in the 
positive control only, and rule out the possibility that a very faint band was missed when 
only using the ethidium bromide). Experimental optimization was done when non­
specific bands were visible. Table 4.4 summarises the results using RT-PCR.
Glucose
transporter Kidney Pars Plicata Pars Plana
GLUT1 V V V
GLUT2 S X X
GLUT3 S V V
GLUT4 V V V
GLUT5 S s V
SGLT1 ✓ X X
SGLT2 V V V
SGLT2-like V X s
Table 4.4 The RT-PCR results for bovine kidney, pars plicata and pars plana of 
CBE. S : positive RT-PCR result; *: negative RT-PCR result
4.3.1.1 GLUTs
As seen in fig 4.2a, positive results were found for GLUT1 in both pars plana and pars 
plicata with an expected size of 548 base pair (bp) (n = 3). For GLUT2, only kidney 
samples gave a positive control result o f 296bp but not pars plicata and pars plana (Fig. 
4.2b; n = 4). Figs. 4.2c, 4.2d and 4.2e show the RT-PCR results for GLUT3, GLUT4 and 
GLUT5, respectively. Their mRNAs were found to be expressed in both pars plicata and 
pars plana with expected sizes o f 532bp (n = 3), 621 bp (n = 3) and 495bp (n = 3) 
respectively.
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DL 1 2 3 4 5 6 DL 1 2 3 4 5 6
(d) (e)
Fig. 4.2 Representative gel electrophoresis results of RT-PCR for (a) GLUT1; (b) 
GLUT2; (c) GLUT3; (d) GLUT4; (e) GLUT5. DL: DNA ladder; lane 1: 
bovine kidney; lane 2: mock kidney; lane3: CBE pars plicata; lane 4: mock 
pars plicata; lane 5: pars plana; lane 6: mock pars plana.
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4.3.1.2 SGLTs
There was no SGLT1 mRNA expressed in either pars plicata or pars plana (Fig. 4.3a; n = 
3). However, SGLT2 gene expression was found in both pars plicata and pars plana (Fig. 
4.3b; n = 4).
DL 1 2 3 4 5 6  DL 1 2 3 4 5 6
(a) (b)
Fig. 4.3 Gel electrophoresis result of RT-PCR for (a) SGLT1 and (b) SGLT2.
DL: DNA ladder; lane 1: bovine kidney; lane 2: mock kidney; lane3: CBE 
pars plicata; lane 4: mock pars plicata; lane 5: pars plana; lane 6: mock 
pars plana.
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4.3.1.3 Presence of SGLT2-like mRNA in the pars plicata
The investigation o f glucose transporter mRNA expression was started before the 
publication o f the bovine SGLT2 mRNA sequence in GenBank. A bovine EST sequence 
was found at this time, which aligned well with other SGLT2 mRNA sequences and RT- 
PCR was carried out with primers based on this short EST sequence. Positive signals 
were detected in both kidney and pars plana (Fig 4.4). Its sequencing result produced the 
highest hit against human SGLT2 sequences (prior to the appearance o f the bovine 
SGLT2 sequence in GenBank-the highest score was against the bovine SGLT2 mRNA 
sequence once this was available).
DL 1 2 3 4 5 6
Fig. 4.4 Gel electrophoresis result of the RT-PCR based on the bovine SGLT2-like 
EST. DL: DNA ladder, lane 1: bovine kidney; lane 2: mock kidney; lane 3: 
CBE pars plicata; lane 4: mock pars plicata; lane 5: pars plana; lane 6: 
mock pars plana.
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4.3.2 Sequencing
The PCR products for GLUT 1-5 and SGLT1-2 were sent for automated sequencing. 
Sequenced details are attached in Appendix III. Their identities were confirmed by 
BLAST searches against the GenBank database. Table 4.5 summarises the BLAST search 
results, with the alignment scores.
PCR
sequence
BLAST search alignment results
Accession
number Identification Score*
Nucleotide 
Identity (%)
GLUT1 NM_174602
Bos taurus solute carrier family 2 
(facilitated glucose transporter), 
member 1 (SLC2A1), mRNA
1019 100
GLUT2 AF308828 Bos taurus glucose transporter 2 mRNA 333 98
GLUT3 NM_174603
Bos taurus solute carrier family 2 
(facilitated glucose transporter), 
member 3 (SLC2A3), mRNA
779 99
GLUT4 D63150 Bos taurus mRNA for glucose transporter type4 872 98
GLUT5 AF308830 Bos taurus fructose transporter Glut5 mRNA 898 99
SGLT1 AF508807 Bos taurus Na+/glucose cotransporter (SGLT1) mRNA 1225 99
SGLT2 AY208941 Bos taurus Na+/glucose cotransporter (SGLT2) mRNA 783 100
SGLT2-like AY208941 Bos taurus Na+/glucose cotransporter (SGLT2) mRNA 210 100
Table 4.5 BLAST search results for RT-PCR sequences. * The score is calculated by 
adding all similarities (+1) and differences (-3) between each nucleotide in 
an alignment.
All BLAST search results demonstrated the best alignment with the respective target 
mRNA sequence. All the RT-PCR sequences shared 98 to 100% identity to their target 
sequences. This revealed a highly confident conclusion that all PCR products were 
derived from the desired mRNA sequences.
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4.4 Discussion
4.4.1 Sequence similarity
As mentioned before, all bovine sequences retrieved from GenBank were aligned with all 
other mammalian glucose transporter mRNA sequences to assess their similarity. In this 
study, all bovine sequences aligned well with their orthologues in other mammalian 
groups, which facilitated primer design. However, some sequences previously labeled as 
SGLT2 or low affinity sodium glucose transporter were found to align better with SGLT3 
instead (Appendix I). This might have been due to the period these sequences were 
submitted (around year 2000), when only the SGLT1 mRNA sequence was well- 
established for different species. Therefore, all other similar sequences submitted to 
GenBank were probably named SGLT2.
For the bovine SGLT2-like EST sequence, it was interesting to see how alike it was when 
clustered against other mammalian SGLT2 sequences (Appendix II). However, when 
compared with the true bovine SGLT2 mRNA, the similarity score was only 40. These 2 
sequences aligned very well at the 3’ end of the EST sequence, but poorly at the 5’ end 
(Appendix IV). As shown in appendix IV, the primers designed according to the bovine 
SGLT2-like EST sequence lay at the 5’end of the true bovine SGLT2 mRNA sequence, 
where they showed complete identity. This might explain why positive results were only 
seen on kidney and pars plana samples with the SGLT2-like EST primers. In this study, 
Oligo (dT) primer was used to synthesize cDNA strands. This method tends to over­
represent the 3’end of transcripts, therefore, maximum sensitivity of the cDNA pool will 
lie with the 3’ ends. In this study, primers for the SGLT2-like EST were designed at the 
5’ end region of the true SGLT2 mRNA sequence. With these primers, gene expression 
appeared most abundant in kidney, then pars plana and least in the pars plicata. It is
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possible that there was incomplete copying of the 5’ end of the SGLT2 mRNA in the pars 
plicata samples, for effective PCR amplification. Later, with primers designed at the 
3’end of the complete bovine SGLT2 sequence, the complementary sequences would be 
much better amplified, since the RT method provides the highest sensitivity at the 3’end. 
The observation of a stronger intensity band (with SGLT2 primers) for both kidney and 
pars plana samples might therefore be due to a combination of amplification from both 
the complete bovine SGLT2 and the SGLT2-like EST mRNA in the samples. 
Nevertheless, the presence of SGLT2 in all samples is distinctive. Sadly, there was 
insufficient time to study the SGLT2-like mRNA in further detail.
4.4.1.1 Alternative splicing
In the RT-PCR reaction for SGLT2, a consistent pattern of double bands was seen with 
the expected band showing the higher intensity. Such a pattern was conserved across a 
wide range of PCR annealing temperature (63-68°C), which meant the chance of non­
specific binding resulting in the formation of the minor band was low. This additional 
band might be explained by alternative splicing, a process in which different mRNAs are 
generated by varying the pattern of pre-mRNA splicing. Thus, various mRNAs are 
produced from the same gene and then the mRNAs are templates for different protein 
isoforms. Alternative splicing of GLUT14 has been reported in testis (Wu and Freeze,
2002), but other transporter isoforms have no similar report at the present stage. Alternate 
splicing has been reported to happen in different cell types (Larkin and Park, 1999; Nixon 
et al.y 1999; Omer et al., 2002), yet no direct relationship has been established for 
particular abnormalities or disease.
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To further characterise the splicing pattern for SGLT2 in this study, exon-specific primers 
could be used to identify the extra amplification products, or direct sequencing for the 
RT-PCR product (band) purified out from the gel would be another option.
4.4.2 mRNA expression of glucose transporters in the CBE
As revealed in this study, more than one glucose transporter transcript was present in the 
bovine CBE. The pars plicata and pars plana showed no particular difference in their gene 
expression profile, but the pars plana seemed to have a higher mRNA expression level 
overall. This was especially obvious for GLUT3 (Fig 4.2c) and SGLT2 (fig 4.3b). 
However, as discussed in section 4.1.4.1, RT-PCR is not the best method in assessing 
gene expression level, since there is a need for stringent standardization (Muller and 
Kennedy, 1996) throughout the whole procedure (i.e. proper control for RT, amplification 
and normalization). Thus, simply assessing the staining intensity visually is not sufficient 
to infer accurate quantitative differences. In the past, researchers have combined RT-PCR 
with different methods to make quantitative conclusion. These include the use of enzyme- 
linked immunosorbent assay (ELISA) (Alard et al., 1993; Sabbatini et al., 1993) or 
Southern blotting (Thompson et al., 1992; Doi et al., 1994). Nowadays, real-time 
quantitative RT-PCR, Northern blotting and RNase protection assay would be a better 
choice for accurate mRNA expression quantification. Since the aim of this study was 
simply to screen for the presence of the different glucose transporters in the bovine CBE, 
the use of RT-PCR was appropriate to fulfil this goal.
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4.4.3 Role of glucose transporters in the CBE
Glucose is crucial for every single cell for metabolism and energy supply. Glucose 
transporters in the CBE, therefore, are essential for local and also anterior avascular tissue 
glucose supply. As revealed in this study, the bovine CBE possessed GLUT1, GLUT3, 
GLUT4, GLUT5 and SGLT2 mRNA. It again shows that one kind of tissue carries more 
than one glucose transporter isoform. Other examples can be found in bovine skeletal 
muscle that it has both GLUT3 and GLUT4 mRNA (Zhao et al., 1993); rat placenta, 
which possessed GLUT1 and GLUT3 mRNA (Boileau et a l , 1995); or rat alveolar cells 
have GLUT1, GLUT4, GLUT5 and SGLT1 mRNA (Mamchaoui et al., 2002).
For GLUT1 and GLUT3 mRNAs, their presence were not surprising since they are 
present in many blood-tissue barriers, such as the BBB (Boado and Pardridge, 1990; 
Nagamatsu et al., 1992; Gerhart et al., 1994), BPB (Zhou and Bondy, 1993; Takata et al., 
1994) and BRB (Knott et al., 1996). However, GLUT1 is the glucose transporter isoform 
that is generally recognised to be abundantly expressed in cells with occluding junctions. 
This protein has been found colocalised with occludin and ZO-1 (i.e. a 210-225 kDa 
cytoplasmic protein), which are tight junction constituents and absent in non-barrier cells 
(Tserentsoodol et al., 1998). With its colocalisation with connexin 43, a gap junction 
protein (Shin et al., 1996), the role of GLUT1 was confirmed as one of the biochemical 
signatures of “barrier” tissues (Gherzi et al., 1991) as shown in high metabolic-rated 
tissues like the microvascular endothelium of retina, RPE and CBE (Harik et al., 1990; 
Mantych et al., 1993b). The presence of GLUT1 mRNA in the CBE is very reasonable, 
as the CBE is the blood-aqueous barrier, which is responsible for selective substrate 
transport into the aqueous humor.
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GLUT3 is believed to work with GLUT1 for basal cellular glucose uptake, with the 2 
proteins expressed ubiquitously in mammalian tissues (Mantych et al., 1993b). However, 
in rat lens, GLUT1 was found to be expressed mainly in the epithelium, while GLUT3 
was expressed in cortical fiber cells. It was suggested that GLUT1 was crucial for 
external glucose uptake while GLUT3 was crucial for internal glucose exchange 
(Merriman-Smith et al., 1999; Merriman-Smith et al., 2003). In human retina, GLUT3 
was found localised in the plexiform layers and served to take up glucose into neural cells 
once it had passed the BRB via GLUT1 (Watanabe et al., 1996; Tserentsoodol et al., 
1998). Such an expression pattern was also found in the brain (Nagamatsu et al., 1992) 
and it is therefore not unexpected for the eye to show a similar pattern of expression, 
since it has the same origin as the brain during development (Sharma and Ehinger, 2002). 
Furthermore, the CBE is an extension of the neural retina and is regarded as part of the 
CNS. Thus, the possession of similar glucose transporters as the brain and retina seems 
logical. Similar to the condition in retina, GLUT1 in CBE might be localised at the tight 
junctions (to enable barrier glucose transport), while GLUT3 may have some other 
function. However, such a conclusion cannot be made without further investigation. 
Studies of GLUT4 in ocular tissues are scarce. Researchers could not find any GLUT4 
protein in rabbit iris-ciliary body (Tsukamoto et al., 1995) and retina (Mantych et al., 
1993b). GLUT4 is an insulin responsive glucose transporter, which is widely expressed 
in heart (Abel, 2004), kidney (Marcus et al., 1994), mammary gland (Zhao et al., 1993), 
skeletal muscle (Hocquette et al., 1995) and adipose tissues (Miura et al., 2003). In the 
brain, GLUT4 mRNA was found specifically in the cerebellum, while GLUT1 and 
GLUT3 were found in each brain region including the medulla, midbrain and 
hypothalamus (Rayner et al., 1994). The presence of GLUT4 was suggested to allow for
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insulin-responsive glucose uptake in cerebellum, and suggests that a similar process 
might operate in the bovine CBE. The presence of GLUT4 mRNA in bovine CBE clearly 
reveals the presence of an insulin-response glucose transport system, yet how dominant 
this mechanism is in this tissue has yet to be determined.
GLUT5 is expressed predominantly in small intestine (Burant et al., 1991) and kidney 
(Davidson et al., 1992), for dietary glucose uptake and glucose reabsorption, respectively. 
Northern blotting showed its presence in the small intestine and kidney, yet it is also 
expressed at a very low level in human muscle, adipose tissue (Bell et al., 1990), RPE 
(Takagi et al., 1994) and brain (Mantych et al., 1993b; Payne et al., 1997). It is known 
that GLUT5 has a higher transport capacity for fructose than glucose (Shepherd et al.,
1992), thus the presence of this transporter in the CBE might indicate the existence of 
fructose transport along with glucose transport.
The presence of SGLT2 in the bovine CBE was a surprise in this study, since it was 
assumed that passive transport would be enough to maintain the required glucose flux 
across CBE. However, the existence SGLT2 is consistent with the energy-dependent 
glucose transport that was clearly present in this tissue in the electrophysiological study 
carried out in Chapter 2. Interestingly, similar results have been found in bovine cortical 
arteries, where GLUT1 is responsible for normal glucose transport, while SGLT1 is used 
for dealing with stress conditions like hypoglycemia (Nishizaki and Matsuoka, 1998). 
Therefore, the function of SGLT2 in the CBE might be similar, namely to protect the 
tissues in conditions of stress by ensuring adequate glucose transport.
In this study, neither GLUT2 nor SGLT1 mRNA was found in the bovine CBE. GLUT2 
was not detected in either human (Takagi et al., 1994) or chicken RPE cultures (Ban and 
Rizzolo, 2000) and rat brain (Rayner et al., 1994). However, it was observed in rat retinal
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Muller cells, and is thought to be responsible for intra-retinal glucose homeostasis 
(Watanabe et al., 1994). GLUT2 mRNA was found to be intensely expressed in bovine 
liver, but at a lower abundance in kidney and duodenum (Zhao et al., 1993). GLUT2 is 
not a common GLUT isoform in the CMS, therefore, it is not a surprising result that it is 
absent from the BAB of the CB.
SGLT1 is the high affinity SGLT, which is largely responsible for galactose and glucose 
transport in intestine (Wright, 2001). Absence of SGLT1 mRNA in the bovine CBE 
might indicate that a high affinity glucose transport system is not necessary in the bovine 
CBE.
4.4.4 Implications of mRNA expression of glucose transporters in the CBE
Different species and different tissues respond to glucose insult in distinct ways. Rat lens 
cells respond to hyperglycemia by upregulating the transcription of GLUT3, but not 
GLUT1, by 3.5 fold (Merriman-Smith et al., 2003). Chick RPE increases GLUT1 
expression instead of GLUT3 mRNA, under similar circumstances (Ban and Rizzolo,
2000). In bovine retinal endothelial cells, the amount of GLUT3 mRNA increases 
significantly with increases in glucose levels to physiological concentrations, yet declines 
in response to adverse glucose insult (i.e. hyperglycemia) (Knott et al., 1993). Such a 
pattern of regulation is not seen in bovine cultured cells when exposed to various 
concentrations of galactose, which suggests that GLUT3 mRNA expression is 
specifically regulated by ambient glucose, yet not galactose. However, such an effect was 
absent in the same tissue in the study of Rajah et al (2001), in which GLUT1 and 
GLUT3 expression were stable across a range of glucose concentrations (Rajah et al.,
2001). Only brain-derived endothelial cells showed a decrease in GLUT1 expression in
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response to hyperglycemic. Again, this result conflicts with another study in rat, in which 
GLUT1 expression decreased in retinal microvessels, but not brain microvessels (Badr et 
al., 2000). These differences between studies could be due to species difference, different 
in vivo and in vitro experimental conditions, or disparate duration and/or level of glucose 
exposure. Clearly, dissimilar mechanisms are operating for gene regulation among the 
various species or tissues.
Even with the findings from the present study, it is difficult to deduce a mechanism for 
lowering glucose transport across the CBE under elevated glucose conditions. Previous 
studies have shown that GLUT1 mRNA expression increases under long-standing 
diabetic conditions in both mouse (Vannucci et al., 1997) and rat (Lutz and Pardridge,
1993) brain, while it decreases in human placental cultures (Hahn et al., 1998).
Similarly, overexpression of GLUT3 has been found in vivo in pregnant rat placental 
cells under hyperglycemic conditions (Boileau et a l , 1995) while underexpression or 
unchanged levels have been observed during hyperglycemia in retina (Knott et al., 1996) 
and human or rat testis. With these contradictory results, it would be difficult to conclude 
the role of GLUT1 and GLUT3 in CBE under diabetic conditions and thus further in vivo 
studies would be necessary.
The presence of GLUT4, an isoform which is insulin-regulated, in CBE suggests its 
glucose transport is insulin-sensitive. GLUT4 has mostly been found to decrease in 
expression (both mRNA and protein) in response to hyperglycaemia, as well as diminish 
in translocation to the cell surface (Garvey et a l , 1991). Furthermore, its reduction in 
expression has been found in skeletal muscle, a result that was suggested not to be related 
to either obesity or type 1 or 2 DM (Pedersen et al., 1990; Garvey et al., 1992; Kahn et 
al., 1992). However, in diabetic rat kidney, both GLUT1 and GLUT4 expression were
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significantly increased in acute diabetes, while GLUT2 and GLUT5 expression increased 
under chronic hyperglycemic condition in rat kidney (Chin et al., 1997). An increased 
level of GLUT2 and GLUT5 mRNA were also noted in another study, in the intestine of 
human diabetic subjects. It has been suggested that different GLUTs might respond to 
various durations or levels of glucose differently, and that even the same GLUT (e.g. 
GLUT4 mRNA in the brain) could respond differently to similar insults in different 
tissues (Kobayashi et al., 1996).
There are scarcely any studies on how SGLT2 responds to diabetic conditions. As a low 
affinity, high capacity, sodium-glucose co-transporter, its presence would seem to be 
reasonable as a backup or reserve to maintain acceptable glucose transport across CBE 
under adverse condition e.g. hypoglycemia.
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4.5 Conclusion
The published glucose transporter mRNA sequences were used to enable a RT-PCR 
investigation to determine which glucose transporter isoforms are expressed by CBE. 
GLUT1, GLUT3-5 and SGLT2 mRNA were present in this tissue. However, which 
among these transporters is the major candidate responsible for abnormal glucose 
transport under hyperglycemic condition is yet to be elucidated. Further in vivo studies, 
both electrophysiological and biochemical, in which the effects of hyperglycemia can be 
monitored, are required, to provide a better understanding of how different transporters 
respond to hyperglycemia. However, armed with this information, therapeutic 
intervention aimed at either the transcriptional level or translational level could be 
attempted.
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5.1 Introduction
5.1.1 Overview of the experiment
In this part of the study, western blotting was used to examine the expression of glucose 
transporter proteins in the bovine CBE. Any difference in protein expression between 
pars plicata and pars plana was also assessed.
Protein samples from the bovine CBE were extracted and separated by gel 
electrophoresis according to their molecular size. Proteins were then transferred onto a 
membrane support. Antibodies targeted against different glucose transporters were used 
to identify protein of interest, and visualised by the use of an enhanced 
chemiluminescense (ECL) detection system. Light emitted from the membrane was 
captured on photographic film, thereby providing information as to the molecular weight 
of the glucose transporter detected.
Western blotting was used in order to confirm the results in the previous chapter. 
Unfortunately, various difficulties were encountered in optimizing the immunoblotting 
system, therefore, few conclusive results could be made from these experiments.
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5.1.2 Western blotting
5.1.2.1 Basic principle
Western blotting, also named immunoblotting, is used for identifying a particular protein 
of interest in a complex mixture. It is one of the most powerful methods in detecting 
specific proteins (Towbin et al., 1979). In general, tissue samples are solubilised with 
detergent e.g. SDS, and the mixture of proteins is separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) according to molecular weight (Laemmli, 1970). The 
separated proteins are then transferred onto a supporting membrane e.g. polyvinylidene 
fluoride (PVDF) or nitrocellulose membrane. Antibodies specific for the protein of 
interest are used to react with the protein on the membrane and then the antibody-antigen 
complexes are revealed using anti-immunoglobulin “secondary” antibodies. Depending 
on which system is used, the anti-immunoglobulin might be labeled with a radioisotope, a 
fluorescent dye or an enzyme. Generally speaking, the sensitivity of western blotting 
depends on the specificity of the antibodies used and also the sensitivity of the detection 
system.
5.1.2.2 Antibody-antigen interactions
The vertebrate immune system produces antibodies as a defence response to a foreign 
substance, or “antigen”. The antigen can be a protein, polysaccharide or a nucleic acid. 
Different antibodies are unique in structure, with different binding sites that recognise 
their specific antigen. For large, protein antigens, the antibody targets a specific cluster of 
amino acids called the epitope. Due to their specificity, antibodies are widely used to 
reveal target protein molecules in cells or tissues in biological studies.
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The antibodies that are commonly used in immunological studies can generally be 
categorised into two types: monoclonal and polyclonal antibodies. The former type of 
antibody was firstly exploited by Kohler and Milstein (1975), who elegantly showed that 
monoclonal antibodies can possess exquisite specificity for a single epitope. Polyclonal 
antibodies are a heterogenous mixture of antibodies, that can recognise many epitopes of 
a single antigen. They therefore provide a higher chance of target protein detection, yet 
the reaction might not be as specific as that of monoclonal antibodies (Rosenberg, 1996).
5.1.2.3 Protein detection system
In the present study, a biotin-avidin or a biotin-streptavidin system was chosen because of 
their high sensitivity (Kurien and Scofield, 2003). In general, membrane-bound proteins 
were incubated with primary antibodies, and then with secondary antibodies conjugated 
with biotin. Biotin, also known as vitamin H, has an extraordinary high affinity for avidin, 
which has led to their application in immunological work. Four molecules of biotin can 
bind to one avidin molecule, and with more than one biotin molecule conjugated to each 
antibody molecule, this gives the ability of the target protein to bind more than one avidin 
molecule, thus providing signal amplification. Avidin, which can be conjugated with an 
enzyme, or fluorochrome, can then be used for signal detection. However, since avidin is 
a glycoprotein (Bruch and White, 1982), it tends to give rise to background staining by 
interacting with other glycoproteins (Bayer et a l , 1987). Streptavidin isolated from 
Streptomyces acidinii, therefore, was developed as a substitute for avidin, in order to 
reduce background by decreasing the non-specific binding, yet retaining the same high 
sensitivity (Green, 1990; Dunn, 1994).
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5.1.2.4 Signal detection schemes
Chemical methods are commonly used to enhance the signal detection from antibodies. 
Several methods can be adapted to produce the final visual image, the most common of 
which are described below:
Enzyme-linked antibodies. Enzyme-coupled secondary antibodies are one of the most 
commonly adapted methods in signal detection. Alkaline phosphate- or horseradish 
peroxidase (HRP)-coupled antibodies are well-known examples (Knecht and Dimond, 
1984). The antibody-enzyme conjugated antibodies, when reacted with substrate, give 
rise to a coloured reaction product, e.g. an HRP reaction with diaminobenzidine (DAB) 
yields a brown coloured product (Knecht and Dimond, 1984), while reaction with 
aminoethylcarbazole (AEC) results in a red product (Imam et al., 1986). However, this 
method of detection can not account for accurate quantitation, and has limited sensitivity 
(Rosenberg, 1996).
Chemiluminescent detection. This system makes use of the chemiluminescence of 
luminol, a substrate that can be oxidised to produce an excited state product that emits 
light (Leong et al., 1986; Vachereau, 1989). Signal detection is then achieved by the use 
of X-Ray film. During immunoblotting, enzyme-conjugated antibodies are used (as 
above). The enzyme then catalyzes the dephosphlorylation of the substrate, e.g. HRP 
catalyses the oxidation of luminol in the presence of hydrogen peroxide, to result in an 
excited stated luminol, which emits light as it returns to its ground state. This system is 
the most sensitive detection method available, and can detect as little as 1 pg of antigen in 
a sample (Vachereau, 1989). It has the advantages of allowing re-probing of the
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membrane with different antibodies. Furthermore, the exposure and reaction times are 
generally short and the film records can be stored permanently (Leong et al., 1986;
Kurien and Scofield, 2003).
Radioactive, In this system, radioactive labels such as iodinated (125I) staphylococcal 
protein A or streptococcal protein G can be conjugated to secondary antibodies (Dimond 
and Loomis, 1976; Harper et al., 1990). Subsequent autoradiography can then be 
performed to enable detection of antigen. These methods allow quantitation of target 
protein or antigen in the sample and provide good imaging quality (Kurien and Scofield,
2003).
5.1.3 Dot blotting
Dot blotting is a useful technique to screen for optimised concentration of samples, 
antibodies or other reagents e.g. blocking solutions. It is performed by dotting samples of 
interest or controls, directly onto a membrane support and then carrying out the 
immunological procedures. However, dot blotting can only act as a quick reference or 
starting point since its result might differ from that after proteins have gone through 
electrophoresis and electrotransfer, before being probed with the antibodies.
5.1.4 Regulation of glucose transporter proteins
Wound healing, GLUT1 protein was upregulated in the comeal wound healing process 
(Takahashi et al., 1996). This increase was related to an elevated transcriptional level and 
was believed to be essential for glucose supply during epithelial migration following 
wound closure. The increased level of GLUT1 was sustained well after two weeks of
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wound closure (Takahashi et al., 1996). However, an alternative hypothesis has been 
proposed to explain the increase of GLUT1 expression after wounding, based on the 
transporters’ role as a water channel (Fischbarg et al., 1990). This activity was thought to 
be crucial in regulating corneal homeostatic volume following wound healing 
(McCartney and Cantu-Crouch, 1992). Interestingly, a change in the localization of 
GLUT1 was also observed during wound healing, and was suggested to be a sign of 
redistribution of energy demand (Takahashi et al., 1996).
Hyperglycemia. GLUT1 protein expression was down-regulated in the cerebral 
microvessels of diabetic rats (Harik et al., 1988; Mooradian and Morin, 1991) and BBB 
of diabetic mice (Comford et a l, 1995). Yet in diabetic human cornea, its expression 
remained unchanged (Kumagai et al., 1994). In rat lens, an increased level of GLUT3 
was found in the major damaged zone induced by hyperglycemia, and this increase 
occurred before any change in mRNA level. This suggested that GLUT3 protein might 
insert into the membrane from the cytoplasmic pool, rather than due to the change in 
mRNA level (Merriman-Smith et al., 2003). However, GLUT3 expression did not show 
differential expression in rat testis when diabetic and normal groups were compared 
(Burant and Davidson, 1994).
Moreover, glucose transport function was found to be retarded, due to the downregulation 
of GLUT4 expression, in the adipose tissues and muscles of diabetic rats (Berger et al., 
1989; Garvey et al., 1989). Yet no significant change was observed in the protein 
expression level of GLUT1 and GLUT4 with various hyperglycemic levels in skeletal 
muscles (Pedersen et al., 1990). In contrast, GLUT1 protein expression was enhanced in 
murine fibroblast cells starved of glucose (Haspel et al., 1986).
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Growth and transcriptional factors, PDGF and serum induced an increase of GLUT1 
protein in the membrane preparation of human RPE cells. This elevation of protein level 
was not related to a change in mRNA, and therefore, the change might be post- 
translational (Takagi et al., 1994). Similar changes of GLUT3 protein expression have 
also been observed in the mouse brain (Choeiri et al., 2002). In rodents, GLUT3 provides 
a basal level of glucose transport, but GLUT1 is upregulated in response to mitogens or 
oncogens, which have an instant effect, to increase, mRNA levels (Wagstaff et al., 1995). 
Chickens, however, differed from rodents by upregulating GLUT3 in response to v-src 
(Wagstaff et al., 1995; Steane et al., 1998). These results highlight a species difference in 
the basal mechanism of glucose transporter protein expression, and in the response to 
different stimulants. Also, it is clear that mRNA and protein levels can be regulated 
independently, e.g. GLUT3 in rat lens (Merriman-Smith et al., 2003). This agrees with a 
previous study, which also showed an increase in protein level without an increase in 
mRNA expression (Khayat et al., 1998). This could be due to the regulation occurring at 
the translational or post-translational level, as demonstrated in the muscle cell study for 
GLUT3 (Khayat et al., 1998).
Others, Insulin is known to cause an increase in the translocation of GLUT4 from the 
intracellular cytoplasmic pool to the cellular membranes (Marcus et al., 1994; Kobayashi 
et al., 1996). However, the process was found to be retarded during both diabetic and 
fasting stages (Berger et al., 1989). On the other hand, glucose transporter expression also 
changes with developmental stage, and only the GLUT1, GLUT3, GLUT8 and SGLT1 
isoforms were found to be present constantly during bovine embryo growth (Augustin et 
al., 2001). Moreover, GLUT4 expression decreases with growth in ruminant species,
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such as bovine (Abe et al., 2001), but increases in non-raminant species, such as rodents 
(Castello et al., 1994).
5.1.5 Previous studies on glucose transporters
There have been many studies on glucose transporter protein expression or localization in 
different ocular tissues. GLUT1 has been the most commonly studied isoform in ocular 
tissues including retina and RPE (table 5.1). GLUT2 was found as a 60 kDa band in rat 
retina and was believed to be used in local glucose homeostatic functions as well as 
systemic glucose regulation (Watanabe et al., 1994). On the other hand, GLUT3 was 
noted in the fibers of the inner synaptic layer, which is rich in neuronal connections and 
plays an important role in meeting the metabolic requirement of synapses (Mantych et al., 
1993b). GLUT4, being one of the two isoforms in the GLUT family that are responsive to 
insulin (Wood and Trayhum, 2003), has only been found in bovine lens (Jacobs, 1993). 
There has not been any study to date on the SGLTs protein expression in ocular tissues.
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Transporter
protein Ocular Tissues Method
Protein 
size (kDa) Species Reference
GLUT1
Conjunctival
epithelium
FC
IHC —
Human
culture (Gherzi et al., 1991)
Comeal
endothelium IHC — Human (Kumagai et al., 1994)
Comeal
epithelium
FC — Humanculture (Gherzi et al., 1991)
IHC — Human (Kumagai et al., 1994)
WB
IHC
55 & 60, 
40 after 
glycosidase 
F digestion
Rat (Takahashi et al., 1996)
WB -5 0 Rat (Takahashi et al., 2000)
Canal of Schleme IHC — Human (Kumagai et al., 1994)
Ciliary body
WB — Rat (Takata et al., 1990)
CB-
binding
assay
. . .
Rabbit
Rat
Marmoset
Baboon
Human
(Kaulen et al., 1991)
IHC — Human (Mantych et al., 1993b)
CBE - Pars plana IHC — Human (Mantych et a l, 1993b)
CBE
IFEM — Mice (Tserentsoodol et al., 1998)
IHC . . . RatHuman (Harik et al., 1990)
IHC — Human (Kumagai et al., 1994)
IFEM
WB 44 Rat (Shin etal., 1996)
IHC — Rat (Takata et a l, 1991)
Ciliary muscle 
capillary
EM
IHC
. . . Rabbit
Human (Schlingemann et a l, 1998)
Iris-ciliary body WB 45-50 Rat (Tsukamoto et al., 1995)
Iris WB — Rat (Takata et a l, 1990)
Iris epithelium
Cyto-
chalasin
B-
binding
assay
—
Rabbit
Rat
Marmoset
Baboon
Human
(Kaulen etal., 1991)
m e — Rat (Takata et al., 1991)
IHC — Human (Mantych et a l, 1993b)
Iridial stroma IFEM — Mouse (Tserentsoodol e ta l,  1998)
Iridial capillaries IHC — Human (Kumagai et a l, 1994)
Iridial
microvessels IHC
. . . Rat
Human (Harik et a l, 1990)
Iridal vasculature IHC — Human (Mantych et a l, 1993b)
Trabecular
meshwork
Cyto-
chalasin
B-
binding
assay
—
Rabbit
Rat
Marmoset
Baboon
Human
(Kaulen et a l, 1991)
Lens fiber cells WB — Bovine (Jacobs, 1993)
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Transporter
protein Ocular Tissues Method
Protein 
size (kDa) Species Reference
Lens epithelial
IHC
WB 45 Rat
(Merriman-Smith et al., 
1999)
cells IHC . . . Rat (Merriman-Smith et al., 2003)
Lens cortex and 
nucleus
Cyto-
chalasin
B-
binding
assay
. . .
Rabbit
Rat
Marmoset
Baboon
Human
(Kaulen et al., 1991)
WB — Mouse (Gong et al., 2001)
Optic nerve IHC — RatHuman (Harik et al., 1990)
IHC — RatHuman (Harik et al., 1990)
IHC — Human (Mantych et al., 1993b)
' IHC — Human (Kumagai et al., 1994)
RPE WB 40-43 Humanculture (Takagi etal., 1994)
IFEM
IGEM
. . . Mouse (Tserentsoodol etal., 1998)
IF
IG — Rat (Bergersen et al., 1999)
RPE WB —
Chick
Culture (Ban and Rizzolo, 2000)
WB 45 Rat (Badr et al., 2000)
GLUT1
Vitreous hyaloid 
vessels IHC —
8 week 
gestation 
human eye
(Mantych et al., 1993b)
Choroidal plexus WB — Rat (Takata et al., 1990)
Retinal capillary 
pericytes WB 45-50
Bovine
culture (Mandarino et al., 1994)
WB 45-50 Bovineculture (Mandarino et al., 1994)
IHC — Humanculture (Knott et al., 1996)
WB — Rat culture (Antonetti etal., 1998)
Retinal capillary
IFEM
IGEM — Mouse (Tserentsoodol etal., 1998)
endothelial cells
WB 54 Bovineculture (Sone et al., 2000)
WB 55 and 60 Bovineculture (Rajah et al., 2001)
WB — BovineCulture (Zhang et al., 2003)
WB 55 Rat culture (Hosoyae/ al., 2001)
Retinal IHC — Human (Kumagai et al., 1994)
capillaries WB — Human (Tang et a l,  2003)
Retinal
microvessels WB 45 Rat (Badr et al., 2000)
IGEM — Human (Kumagai et a l, 1996)
Retinal IGEM — Rat (Femandes et al., 2003)
microvasculature IHC
WB 45-55 Rat (Badr et al., 1999)
Retina WB — Rat (Zhang et al., 2003)
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Transporter
protein’ - - ' i a f r '
Retina IHC — Rat (Takata et al., 1990)
Retina -  Rod 
outer receptors me 45
Bovine
(Hsu and Molday, 1991)
Retina -  Cone 
outer segments
WB Chick
Retina -  
Photoreceptor 
cells and Muller 
cells
WB
me 50 Human (Mantych et al,  1993b)
GLUT1 Retina -  
Photoreceptors 
Inner and outer 
plexiform layers 
Nucleus layers
Cyto-
chalasin
B-
binding
assay
. . .
Rabbit
Rat
Marmoset
Baboon
Human
(Kaulen et al., 1991)
Retina -  
Nerve fiber layer 
Ganglion cells 
Photoreceptor 
cells 
Muller cells
me . . . Human (Kumagai et a l,  1994)
GLUT2 Retina -  Muller cells
EM
me
WB
60 Rat (Watanabe et a l,  1994)
Iris-ciliary body WB 55 Rat (Tsukamoto et a l,  1995)
Lens epithelial
me
WB 45 Rat
(Merriman-Smith et al., 
1999)
cells me
WB 47 Rat
(Merriman-Smith et al., 
2003)
WB — Bovine (Jacobs, 1993)
Lens fiber cells
me
WB 45 Rat
(Merriman-Smith et al,  
1999)
me
WB 47 Rat
(Merriman-Smith et al,  
2003)
GLUT3
Lens cortex and 
nucleus WB
. . . Mouse (Gong et al,  2001)
Retinal me . . .
Human
culture (Knott et al,  1996)
endothelial cells WB 47 Bovineculture (Rajah et al., 2001)
Retinal
vasculature
me
WB 45 Rat (Badr et a l,  1999)
Retina -  inner 
synaptic layer
me
WB 50 Human (Mantych et a l,  1993b)
Retina -  
Inner and outer 
plexiform layers 
Inner nuclear 
layer
me
WB 44 Rat (Watanabe et al,  1996)
GLUT4 Lens fiber cells WB . . . Bovine (Jacobs, 1993)
Table 5.1 Summary of glucose transporter protein studies for the ocular tissues. FC: flow 
cytometry, IHC: Immunohistochemistry, WB: Western blotting, IFEM: 
Immunoflourescent electron microscopy, IGEM: Immunogold electron 
microscopy.
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5.2 Methodology: Western Blotting
5.2.1 Materials
All of the primary antibodies were purchased from Santa Cruz biotechnology, Inc. (UK). 
The biotin conjugated affinity purified secondary antibody was purchased from 
Chemicon international, Inc. (Hampshire, UK). The avidin-HRP and streptavidin-HRP 
conjugates were purchased from Bio-Rad Laboratories, Inc. (Hertfordshire, UK) and 
Amersham Biosciences (Bucks, UK) respectively. Kaleidoscope prestained standard and 
biotinylated SDS-PAGE standard (low range) were purchased from Bio-Rad Laboratories, 
Inc. (Hertfordshire, UK), while the SuperSignal® West Pico Chemilluminescent 
Substrate was purchased from Pierce Biotechnology, Inc. (Rockford, IL). Other reagents 
such as glacial acetic acid were purchased from Fisons Scientific Equipment 
(Loughborough, UK), acrylamide/Bis-acrylamide stock solution (30%) from Severn 
Biotech Ltd. (Worcestershire, UK), Ponceau S from Kodak (Eastman Fine Chemicals, 
New York, US), glycine, methanol and Tris-Base were from Fisher Scientific 
(Leicestershire, UK) and the rest including bromophenol blue, coomassie blue G-250, 
DAB, 1,3, Dithio-DL-threitol (DTT), gelatin, glycerol anhydrous, SDS, sodium chloride, 
temed, polyoxyethylenesorbitan monolaurate (Tween-20) were purchased from Sigma- 
Aldrich Co. Ltd. (Dorset, UK)
5.2.2 Sample preparation
Bovine kidney and CBE were isolated and stored as described in section 4.2.2, except 
that the tissues were not immersed in RNAlater, but directly in liquid nitrogen. For the 
isolation of retina, the bovine globe was cut open around the equator, and the anterior part
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of the eyes (including the vitreous) was carefully removed. The retina could then be 
peeled off directly from the RPE and choroid, and was immediately immersed in liquid 
nitrogen. Tissues frozen in liquid nitrogen were homogenised using a dismembrator 
(Mikro-Dismembrator U, B. Braun Biotech International) at 1600 rpm for 2 mins. They 
were solubilised in 1 ml of lx SDS sample buffer (50mM TrisCl (pH6.8), 5mM DTT, 1% 
SDS, 0.1% bromophenol blue and 7.5% glycerol). The mixture was centrifuged at 12,600 
x g for 10 mins and the supernatant transferred to a new Eppendorf tube. Protein 
concentrations were measured using a BCA protein assay kit (Pierce Biotechnology, Inc., 
Rockford, IL) according to manufacturer’s instructions.
5.2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Gel plates were cleaned and assembled in the Protean II cell cassette (Bio-Rad 
Laboratories, Inc., Hertfordshire, UK). Resolving gel mixtures were prepared in an 
universal container with a final acrylamide percentage of 10%. Gels were poured in 
between the glass plates and allowed to stand for 40 mins for polymerization. Butanol 
(Sigma-Aldrich Co. Ltd., Dorset) was used to overlay the gel surface during 
polymerization. With the presence of a sharp interface between the polymerised gel and 
the overlay, the butanol was poured off and gel surface was washed twice with Milli-Q 
water. A small volume of 5% stacking gel was poured on top of the resolving gel in 
which a comb was inserted to form the sample wells. The stacking gel was left to stand 
for another 40 mins for polymerization. After the stacking gel was set, the comb was 
carefully removed and the sample wells were rinsed with Milli-Q water. Every well was 
washed twice to ensure removal of the residual stacking gel fragments. For each sample,
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40 ug of total protein was loaded. The samples were separated in the SDS-PAGE by 
applying 100 V for 135 mins. Coomassie blue G-250 solution (2.5 mM, 50% methanol, 
10% glacial acetic acid and filtered with Whatman no.l filters) was used to stain the 
separated proteins on gels. Any degraded samples (which showed up as smears of 
proteins without sharp bands) were discarded.
5.2.4 Protein transfer
Preliminary experiments revealed better and more consistent transfer efficiency using a 
wet blotting rather a semi-dry blotting system. Therefore, protein samples run on gels 
were transferred to PVDF membrane (Bio-Rad Laboratories, Inc., Hertfordshire, UK) by 
using the wet blotting method using a Protean II cell blotting kit (Bio-Rad Laboratories, 
Inc., Hertfordshire, UK) under a voltage of 50 V for 3 hours. The PVDF membranes were 
stained with 1% Ponceau S solution to ensure good protein transfer efficiency. The 
membrane was then washed in Tris-buffered saline (TBS) for 15 mins to destain the 
membrane.
5.2.5 Blocking, antibodies incubation and detection
The PVDF membranes were blocked with a blocking solution of 3% non-fat dry milk 
(Marvel dried skimmed milk, Lincolnshire, UK) in 0.01% Tween-20 TBS (TTBS) for 
one hour. Then, they were incubated in primary antibody solution for an hour or more. 
After two changes of TTBS for 10 mins each, the PVDF membranes were incubated in 
biotinylated secondary antibodies for a further hour. They were washed again in TTBS 
for 30 mins with three consecutive changes of solution of 10 mins each. Lastly, they were
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incubated with avidin-HRP or strepavidin-HRP, which was diluted in 3 % blocking milk 
(0.01 % Tween-20) with 1 % gelatin for one hour, and then washed with TBS three times, 
for five mins each, before signal detection. Chemilumiescent signals were visualised 
using the SuperSignal® West Pico Chemilluminescent Substrate kit (Pierce 
Biotechnology, Inc., Rockford, IL) according to the manufacturer’s instructions.
5.2.6 Control experiments
Kidney or retina samples were used as the positive controls, and were loaded alongside 
the CBE samples in every experiment. Negative controls were done by omitting the 
primary antibody.
5.2.7 Dot blotting protocol
Different concentrations of positive control sample (kidney), negative control samples 
(bovine serum albumin) and standard (molecular weight marker proteins) were dotted 
onto PVDF membrane and allowed to dry. Membranes were incubated in different 
concentrations of primary antibodies and secondary antibodies. Initially, 1:100 or 1:1000 
primary antibody dilutions were tested, along with 1:20000 secondary antibody solutions. 
The optimal concentrations observed in dot blotting experiments were used as a starting 
point for later western blotting experiments.
5.2.8 ECL versus DAB
Serial dilutions ofbiotinylated standard protein (1:10, 1:50, 1:100,1:200,1:400 and 
1:800) were loaded and separated by SDS-PAGE. Proteins were transferred onto PVDF
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membrane, and blocked with 3% non-fat dry milk in 0.1% TTBS. Membranes were 
incubated with avadin-HRP for one hour, before being developed using DAB or ECL 
reagents.
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5.3 Results
5.3.1 SDS-PAGE results
Three sets o f kidney and of bovine CBE protein samples were analysed by SDS-PAGE, 
for any signs of degradation (Fig. 5.1). Samples which showed smears of proteins without 
sharp bands were not used for further experiments.
97 kDa 
66 kDa
45 kDa
Fig. 5.1 Representative result of bovine samples separated by SDS-PAGE.
K: kidney; CP: ciliary processes; PP: pars plana samples.
K CP PP
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5.3.2 ECL versus DAB
Serial dilutions of biotinylated standards were transferred onto PVDF membrane, and 
detected with either ECL or DAB. As shown in figure 5.2, ECL was clearly much more 
sensitive, and therefore was used for all subsequent experiments.
A B C D E F
A B C D E F
Fig. 5.2 Signal detection using DAB (top) or ECL (below) kit. A: 1:10; B: 1:50; 
C: 1:100; D: 1:200; E: 1:400; F: 1:800 dilutions of biotinylated- 
standards.
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5.3.3 Strategies to minimise background staining of Western blots
As shown in figure 5.3, preliminary experiments showed a high level of non-specific 
background staining. Such staining persisted when primary and secondary antibodies 
were omitted, which indicated that the non-specific binding might be due to particular 
protein bands (especially in kidney samples) binding to the avidin-HRP conjugates.
M RKCP PP
Fig. 5.3 Background staining in preliminary experiment. MR: Biotinylated 
standard marker; K: kidney; CP: ciliary processes; PP: pars plana 
samples.
Several strategies were tried to reduce the background problem:
Reduction o f the avidin-HRP concentration. This was partially successful, but also 
resulted in a loss o f sensitivity. At a concentration at which the avidin-HRP did not give 
any background staining, specific staining was also abolished e.g. the biotinylated- 
molecular weight standard markers were barely detectable. Therefore an increased 
concentration o f the biotinylated marker had to be loaded onto the gel to compensate for 
the loss in sensitivity.
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Alternative blocking agents. The use of teleost gelatin, and alterations in the Tween-20 
concentration (0.01-0.05%) provided little or no improvement.
The use ofStreptavidin-HRP to substitute for avidin-HRP conjugates. This caused 
lesser background staining, but at the expense of sensitivity. The concentration which 
gave no background staining, also abolished staining of the biotinylated-standard markers.
The use o f non-avidin biotin detection system. All the primary antibodies were raised 
from goat. Without commercial anti-goat HRP-conjugated secondary antibodies being 
available at the time the experiments were carried out, a direct detection system could not 
be utilised. Recently, a “CruzMarker” system (Santa Cruz Biotechnology Inc, UK) was 
launched, and this was tested in the present study. Unfortunately, the kit exhibited even 
lower sensitivity and specificity in comparison to the avidin-biotin system.
Due to the difficulties discussed above, no Western blotting protocol could be devised 
that was completely free from background staining when using primary antibodies raised 
in goat.
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5.3.4 Western blotting of GLUT and SGLT proteins
Only two glucose transporter proteins were detected using Western blotting, and even for 
these, the evidence was extremely weak.
Firstly, a band of molecular weight 41 kDa corresponding to GLUT1 was detected in a 
single experiment (fig. 5.4). An antibody against the human C-terminal (antibody sc-1605) 
was used. However, this result could not be repeated in three other experiments. Also, no 
41 kDa band was present in the kidney sample, which is known to express GLUT1.
In addition, due to the high background staining on kidney samples, retina samples were 
also adapted to use as positive controls in this experiment, but no positive results could be 
obtained after optimization o f the detection system.
97 kDa 
66 kDa
45 kDa
Figure 5.4 GLUT1 protein expressed on the first set of bovine CBE samples.
(a) control experiment without prim ary antibody incubation; (b) control 
experiment without prim ary and secondary antibodies incubation; (c) 
GLUT1 expressed on both the CP and PP samples. Note the non-specific 
binding background on higher molecular weighted range of kidney 
samples.
171
Glucose transporter: Protein expression in the CBE
Secondly, SGLT1 was detected as a 75 kDa protein band in kidney samples (n = 4) and 
also in pars plana in 2 out of these 4 replicate experiments, using tissues from different 
eyes in each case (Fig. 5.5). This was done by using a primary antibody against the 
mouse C-terminus of SGLT1 (antibody sc-20582).
MR K CP PP MR K CP PP
(a) (b)
Fig. 5.5 SGLT1 protein expression in different samples, (a) Positive staining was 
found in kidney (n = 4) and also in (b) pars plana (n = 2).
Table 5.2 shows the antibodies which did not provide signals above background when 
tested on positive control (bovine kidney) samples and on samples o f bovine CBE:
Target Product code Epitope Cross-reactivity
GLUT2 sc-7580 Human C-terminus Human, mouse, rat
GLUT3 sc-7582 Mouse C-terminus Mouse, rat
GLUT4 sc-1608 Human C-terminus Human, mouse, rat
GLUT5 sc-14844 Rat N-terminus Mouse, rat
Table 5.2 Antibodies providing no signals during Western blotting experiments. 
Goat anti-SGLT2 antibodies were not available, they were not 
tested in this study.
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5.4 Discussion
5.4.1 Specificity of antibodies
As there were no commercially available anti-bovine glucose transporter protein 
antibodies, all of the primary antibodies used in the present study were targeted against 
human, mouse or rat glucose transporter proteins. When the respective epitopes were 
checked with the manufacturer, only GLUT1, GLUT4, SGLT1 might have had a 
reasonable chance in detecting the corresponding bovine glucose transporters. Therefore, 
experiments were done concentrating on these 3 antibodies, yet no satisfactory results 
were obtained. The goat anti-GLUT4 primary antibody gave very high and non-specific 
binding on the membrane, and no conclusive results could be drawn.
5.4.2 Glucose transporter proteins in the bovine CBE
According to the results obtained in chapter four, one would expect the expression of 
several glucose transporter proteins in the bovine CBE. Unfortunately, due to the 
technical problems encountered in this study, no conclusive results could be drawn. 
However, it would not be a surprise to find the presence of GLUT1, since it is the most 
common form of GLUT transporter, and exists in all mammalian cells studied to date 
(Gherzi et al., 1991; Takata et al., 1991). However, the presence of SGLT1 in both 
kidney and pars plana in 50% of the experiments raised the concern whether this antibody 
was actually working non-specifically. (Unfortunately, the manufacturer could not give 
any related information to confirm the likelihood of cross-reactivity). No conclusion can 
be deduced at the present stage. In the RT-PCR experiment, no SGLT1 mRNA was found 
in the bovine CBE, therefore, the possibility of the anti-SGLTl antibody binding to 
SGLT2 or other SGLTl-like proteins in the bovine CBE could not be eliminated. Still, a
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more complete story would only be possible if there were more bovine-specific 
antibodies for glucose transporters available. At present, no concrete evidence can be 
given for the protein expression profile of different glucose transporters in the bovine 
CBE.
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6.1 Implications of glucose transporters in the CBE
Glucose transporters are important for mammalian cells, as they are crucial to ensure the 
flow of glucose in living tissues for normal metabolic functions (Kayano et al., 1990; 
Gould and Holman, 1993). In the CBE, glucose transporters might have other functions 
than just transporting glucose or other substrates and glucose transporters have been 
thought to transport water across cell membranes (Fischbarg et al., 1990; Loike et al., 
1993; Zampighi et a l , 1995; Loo et al., 1996). Since the CBE is known as the primary 
site for aqueous humour secretion, it is intriguing to suggest that glucose transporters may 
somehow facilitate aqueous humour formation. However, the exact mechanism by which 
these transporters might contribute to the aqueous humor formation remains to be 
elucidated.
In this study, SGLT2 mRNA was expressed in the bovine CBE. The presence of the 
SGLT isoform was interesting, since a facilitative transport mechanism might have been 
expected to ensure an adequate glucose flow from blood to aqueous, in order to meet the 
metabolic needs of the avascular ocular tissues. One possibility, as has been discussed 
earlier (section 4.4.4), is that the presence of the SGLT isoform is a supplementary 
mechanism for the glucose transport system, in case adverse conditions occur. Another 
possibility, derived from recently published study, is that the SGLT2 transporter might 
act as a “nutrient-sensing device”: it was noted that SGLT3, expressed in Xenopus laevis 
oocytes, could mediate glucose-induced depolarization of the membrane potential, and 
yet the transport itself did not show any glucose transport activity. SGLT3 has also been 
suggested as a glucose sensor in cholinergic neurons, thereby regulating muscle activity 
(Diez-Sampedro et al., 2003). In addition, GLUT1 has been thought to act as a glucose­
sensor, for glucose activation by mitogen-activated protein kinase (MAPK)
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(Bandyopadhyay et al., 2000), while GLUT2 has been suggested to play a similar role in 
hepatocytes (Guillemain et al., 2000). Furthermore, sugar entry via SGLT1 and SGLT3 
was proposed to act as a glucose sensor in the GLUTag cell, a model of intestinal L-cells 
(Gribble et al., 2003). Therefore, it is possible that the SGLT2 expressed in the bovine 
CBE is functioning as a glucose-sensing device. However, this idea remains speculative 
at this stage and awaits further experimentations.
6.2 Glucose transport across the CBE
According to the present study, the major glucose transport mechanism in the bovine 
CBE is carrier-mediated facilitative transport. The system demonstrates a 
stereospecificity for MDG over LG, and is likely to saturate when the plasma glucose 
concentration reaches approximately 10.6 mM. One might expect that, even under poor 
glycemic control, there would be a limit at which the glucose transport across the CBE 
would be stabilised, and that further increases in plasma glucose concentration would not 
potentially cause damage. However, it was found that glucose transporter mRNA level 
could alter shortly after an hour of hyperglycemic exposure (Knott et al., 1996), and 
remarkably, the Km value was increased two-fold after two months of exposure to 
diabetic conditions (Ennis et al., 1982). Thus, the present study will not be directly 
comparable to the in vivo condition in diabetic patients, since the true increase in plasma 
glucose concentration would be more subtle and much more sustained. One study has 
suggested that glucose is more detrimental than sucrose in causing barrier leakage 
(DiMattio and Streitman, 1986). In addition, the decrease in facilitated glucose transport 
is accompanied by an increase in passive glucose transport, due to the loss of barrier 
function under hyperglycemic condition in rats (DiMattio and Zadunaisky, 1983). This
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caused an overall change in glucose transporter regulation, damage to barrier function 
and an increase or decrease in the glucose flux. These alterations could cause anomalous 
fluctuations of glucose concentrations e.g. varied glucose level across the CBE, as occur 
in the eyes of diabetic patients. This has been suggested to increase the glucose influx 
across the CBE, which might accelerate cataract formation (Swamy-Mruthinti et al.,
1999). According to an earlier study, it was proposed that there existed a glycemic 
threshold, beyond which the rate of diabetic cataract formation would increase 
exponentially (Nagaraj et al., 1996). Beyond this threshold, formation of pentosidine, a 
product formed through glycoxidation, accelerated, as did the glycation rate. Therefore, 
one can postulate that if the glycemic threshold is lower than that of the saturation 
concentration, a cataract would inevitably form, despite the saturation kinetics. Therefore, 
it would be beneficial if one could downregulate the glucose influx across the CBE and 
prevent the aqueous humour from reaching abnormal glucose concentration which can 
precipitate the cataract formation process.
With the presence of GLUT1, GLUT3, GLUT4, GLUT5 and SGLT2 mRNA, one would 
also expect the presence of corresponding proteins in the tissues. Unfortunately, the 
protein study in this project could not be completed. Therefore, it is impossible to tell 
how the mRNA and protein levels are inter-related. Nevertheless, it is reasonable to 
postulate that the glucose transport across the CBE is insulin-responsive and mainly 
depends on concentration gradients across the CBE, since the presence of different GLUT 
isoforms confirmed our electrophysiological results that the transport mechanism was 
mainly facilitative and passive.
178
General discussion
6.3 Aqueous glycemic control and diabetic cataract
The different glucose transporters perform differently under hyperglycemic conditions. 
Even the same isoform can give varied responses when expressed in different tissues (or 
in different species). For example, expression of GLUT3, but not GLUT1, increased after 
hyperglycemic insult, in rats (Merriman-Smith et al., 2003). In addition, diabetes down- 
regulated GLUT1 expression in the rat retina and retinal microvessels, but not in the 
cerebral cortex (Badr et al., 2000).
With the present data, it is difficult to conclude which of the glucose transporters present 
in the CBE is the best candidate to target in order to lower the glucose influx in diabetic 
patients. However, a member of the GLUT family would probably make a better choice, 
since there are likely to be at least four of the family members expressed in the CBE. 
Also, it may be better to target a transporter involved in basal conditions (e.g. SGLT2 
may not be functional under normal conditions, or may not be responsible for the bulk of 
glucose transport). From the electrophysiological study, it was clear that the glucose flux 
was sensitive to certain drugs. Treatment with such glucose transporter inhibitors might 
be one possible way to lower the aqueous glucose level, yet how these drugs could be 
used to specifically target the CBE would require further investigation. Another approach 
would be gene therapy, in which the selected (targeted) isoform could be down-regulated. 
Firstly, however, it will be important to determine which glucose transporter isoform(s) 
are specifically upregulated under diabetic conditions. At this moment, the present study 
provides information of how glucose is transported across the CBE, and gives some ideas 
as to how the system could be regulated. It therefore represents a useful starting point 
from which further therapeutic approaches may be devised in order to lower the glucose 
concentration in the aqueous humour of diabetic patients.
Future perspectives
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7.1 Future perspectives
Two directions have been proposed to prevent cataract formation (Harding, 1999). The 
first one is to eliminate the risk factor while the other is to use anti-cataract drugs. The 
present study aimed to characterise the glucose transport into the eye which defines the 
glycemic level of the aqueous humour. By keeping the aqueous glycemic level normal, 
the crystalline lens will no longer be at risk of diabetic cataract and no cataractous and 
pathological pathways will be triggered. However, the ways by which glucose 
transporters are targeted so as to reduce the glucose flux across the CBE in vivo by drug 
or gene-therapy will require further investigation. Future experiments are needed to test 
the tissue specificity of potential pharmaceutical agents that are lower in toxicity, before 
clinical trials can be considered.
In addition, a more complete picture of the glucose transporter expression profile in the 
CBE is needed. With appropriate and specific antibodies against the glucose transporters, 
the protein expression profile will hopefully be characterised in the near future. The 
relationship between mRNA and protein expression can be deduced and a clearer picture 
regarding how different glucose transporters contribute to the glucose transport across the 
CBE will emerge. This basic information will help in extending important in vivo studies 
in which the expression profile of glucose transporters can be investigated under 
hyperglycemic conditions. With this knowledge, candidate genes or proteins which are 
differentially expressed in hyperglycemic conditions can be targeted and altered by drugs 
or even gene therapy. For gene therapy to be successful, a number of technical aspects 
will have to be addressed. These include a thorough knowledge about the target gene, the 
accessibility of the target cells or tissues and a suitable vector system with which to
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introduce the gene into the target organ. Viral and non-viral methods are used to transport 
foreign genetic material into cells. In diabetes, studies have suggested that gene therapy 
may be a highly effective therapeutic treatment. In general, gene therapy has been widely 
investigated in different diabetic complications such as diabetic nephropathy (Zem and 
Kresina, 1997; Kitamura, 1999) and diabetic retinopathy (Igarashi et al., 2003). At late- 
stage neuropathy, hepatocyte growth factor (HGF) gene-therapy has showed promising 
results in improving the functional abnormalities (Cruzado et a l , 2004). Lentivirus- 
mediated HIV-angiostatin expression reduced the severity in mouse diabetic retinopathy 
model (Igarashi et a l , 2003), while ciliary neurotrophic factor administered by eye drops 
inhibited retinal degeneration in diabetic rats (Aizu et al., 2003). A recent study has also 
demonstrated the possibility of using an ex vivo HGF gene in facilitating islet 
transplantation (Rao et al., 2004). Although these studies are at an experimental stage in 
animal models, the same scheme of treatment may possibly be applicable to the CBE. 
With careful gene therapy design, for example, a candidate gene responsible for the 
abnormal upregulation of glucose transport in the CBE could be modulated (i.e. 
downregulated) at the transcriptional level and consequently the aqueous glucose 
concentration might remain normal. To date, there have been few studies exploring the 
possibility of targeting glucose transporters directly, in order to lower their level of 
expression, to combat diabetic complications. Therefore, to tackle hyperglycemia via 
such an approach is a new direction for treating diabetic patients. In fact, it can even be 
used as a preventive measure to delay or prevent any consequent hyperglycemia-induced 
complications.
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7.2 Conclusion
The present study is important in demonstrating that the application of a number of drugs 
can regulate the glucose transport in the bovine CBE and thereby control the aqueous 
glycemic level. By characterising the transport kinetics and genetic expression of various 
glucose transporters, it is now possible to envisage new ways to lower the risk of diabetic 
cataract.
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CLUSTAL cladograms for GLUT1-5 and SGLT1-3 mammalian mRNA sequences
B C 0 6 1873RatGLU T1 
M M _011400M ou»G L U T l 
MM 006516H n m anG L P T l 
IHM 1746Q 2Bovim »Q LPn1  
B C 0 6 0 0 4 1 HuanmGLU T2
______________ i - --------------------------------------------------------- M M _012879RatGLUT2
------------------------------------------------------- M M _031197M oxu#GLDT2
—  ----------------- — — ----------------------------------------------------------  M M _012751RatGLUT4
---------------------------------- ---------------------------------------------------------  A B 008453M ouseG L U T 4
I---------------- ---------------------------------------------------------------------------  MM _Q01042HanianQLPT4
I-------------------------— ----- — ----------------------------------------------------ID 631SO B ovim G L P T 41
--------------------------- ----------------------------------------------------------------- B C 0 3 9 196HumanGLU T3
---------------------------------------------------------------------------------------------IMM 17 4 6 0 3 B o vim»QLP T3l
_________|------------------------------------------------------------------------------  M M _011401M ou»G L U T 3
'-------------- — — ------------------------------------------------------ M 75135M on*eG LUT3
------------------------------------------ -------------------------------------------------  U 17978R atG LU T 3
|--------   — --------------------------------------------  BC001820HunwmGLDT5
- I |   — -------  A J315928ShecpG LU  T5
----------------------------------— ------------------------------------------1 A F 308830B ovm e0L U  T5l
|---------------------------------------------------------------------------------- B C 023500M ouw G L O T 5
--------------------------- — — --------------------------------------  M M _031741RatGLUT5
--------------------------------------— ----------------------------------------------  D 26482R abbitG L U T5
HM _000343HnmanSGLTl 
M 24847HmnanSGLTl 
M 34044PigSG LTl 
Z 8 2 4 1 OSheepSGL T1 
MM 174606B ovineSG L  T1 
I AF5088Q7Bo viaeSQL T11 
M M _019810M oiueSG LTl 
BC 083845M onseSG L T1 
A F 208031M o use SG L T1 
MM_013033RatSGL T1 
D 16101R atSG LTl 
MM 003041  Hmn&nSOL 12
M M _133254M ou»SG LT2  
B C 022226M oa»SG L T 2  
A T 033886Mo v m SGLT2 
MM_022590RatSGL 12  
U29881RatSGLT2
F1331:
AF251268M om aSO L T2l 
A F 4119 6 0 Moqm SGL T 3  
XM _228086RatSGL 13
r t
The sequences in blue brackets are the bovine sequences used for prim er design in this study. 
Red bracketed sequences are sequences with likely mis-assigned labels.
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CLUSTAL analysis of mammalian SGLT2 mRNA and the bovine SGLT2-like
EST sequences
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U2 9881RatSGLT2
NM_0 0304lHumanSGLT2
AV6054 90BovineSGLT2-likeEST
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_02 2 5 90RatSGLT2
U29881RatSGLT2
NM_0 0304lHumanSGLT 2
AV6054 90BovineSGLT2-likeEST
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY 03388 6MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_00304lHumanSGLT2
AV6054 90BovineSGLT2-likeEST
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U2 9881RatSGLT2
NM_003041HumanSGLT2
AV 605490BovineSGLT2-likeEST
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_003041HumanSGLT2
AV6054 90BovineSGLT2-likeEST
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U2988lRatSGLT2
AGCATGGTGTGGTGGCCGGTTGGAGCCTCTCTGTTCGCCA-GCAACATCG 2 2 3  
AGCATGGTGTGGTGGCCGGTTGGAGCCTCTCTGTTCGCCA-GCAACATCG 2 2 3  
AGCATGGTGTGGTGGCCGGTTGGAGCCTCTCTGTTCGCCA-GCAACATCG 2 3 3  
AGCATGGTGTGGTGGCCGGTTGGAGCCTCTCTGTTCGCCA-GCAACATCG 2 2 8  
AGCATGGTGTGGTGGCCGGTTGGAGCCTCTCTGTTCGCCA-GCAACATCG 228 
AGCATGGTGTGGTGGCCGGTTGGGGCCTCTCTCTTCGCCA-GCAACATCG 24 9 
---------------------------------------------------------------------------------CCACGCGTCCGCC 13
GCAGCGGTCATTTTGTGGGCCTGGCAGGGACTGGCGCAGCAAGTGGCTTG 27 3 
GCAGCGGTCATTTTGTGGGCCTGGCAGGGACTGGCGCAGCAAGTGGCTTG 27 3 
GCAGCGGTCATTTTGTGGGCCTGGCAGGGACTGGCGCAGCAAGTGGCTTG 283 
GCAGCGGTCATTTTGTGGGCCTGGCGGGGACTGGTGCAGCAAGTGGCTTG 278 
GCAGCGGTCATTTTGTGGGCCTGGCGGGGACTGGTGCAGCAAGTGGCTTG 278 
GCAGTGGCCACTTTGTGGGCCTGGCAGGGACTGGCGCTGCAAGTGGCTTG 299 
CACGCGTCCGCCTTACAGGATCACCTCCTTCTGTTACA-CACACGAGAAA 62 * * ★ * * ★★★ *
GCGGTGGCTGGATTTGAGTGGAATGCGCTCTTCGTGGTGCTGCTCC-TCG 322 
GCGGTGGCTGGATTTGAGTGGAATGCGCTCTTCGTGGTGCTGCTCC-TCG 322 
GCGGTGGCTGGATTTGAGTGGAATGCGCTCTTCGTGGTGCTGCTCC-TCG 332 
GCCGTGGCTGGATTTGAGTGGAATGCGCTCTTTGTGGTGTTGCTCC-TCG 327 
GCCGTGGCTGGATTTGAGTGGAATGCGCTCTTTGTGGTGTTGCTCC-TCG 327 
GCTGTTGCTGGATTCGAGTGGAATGCGCTCTTCGTGGTGCTGCTAC-TGG 34 8 
AC CTGGACTT-AGAGGA— GGGCCTGTAGTGGAGGTCCTACACTG 104
★ ★ ★ ★ ★ ★ ★  ★ ★ ★  ' k ' k ' k ' k - k ' k - k ' k ' k ' k  ★
GATGGCTTTTTGTGCCAGTGTATCTGACCGCTGGTGTGATCACAATGCCT 372 
GATGGCTTTTTGTGCCAGTGTATCTGACCGCTGGTGTGATCACAATGCCT 372 
GATGGCTTTTTGTGCCAGTGTATCTGACCGCTGGTGTGATCACAATGCCT 382 
GCTGGCTCTTCGTGCCTGTGTATCTGACCGCCGGAGTGATTACCATGCCT 377 
GCTGGCTCTTCGTGCCTGTGTATCTGACCGCCGGAGTGATTACCATGCCT 377 
GCTGGCTGTTTGCACCCGTGTACCTGACAGCGGGGGTCATCACGATGCCA 398
GGGGGCACCTGGCATCCGTGAAGCCC-----------CAAACTCAGCCCCA 144★ * ★ * * ★ ★★★★★★ ★ *
CAGTACCTCCGCAAGCGCTTTGGTGGGCACCGTATTCGCCTCTACCTGTC 422 
CAGTACCTCCGCAAGCGCTTTGGTGGGCACCGTATTCGCCTCTACCTGTC 422 
CAGTACCTCCGCAAGCGCTTTGGTGGGCACCGTATTCGCCTCTACCTGTC 4 32 
CAGTACCTCCGCAAGCGCTTTGGTGGGCGCCGTATTCGCCTCTACCTGTC 427 
CAGTACCTCCGCAAGCGCTTTGGTGGGCGCCGTATTCGCCTCTACCTGTC 427 
CAGTACCTGCGCAAGCGCTTCGGCGGCCGCCGCATCCGCCTCTACCTGTC 4 4 8 
CTGTGCTCACCCAGACCTGCCTCCTGACGCCGGAGT-GCAGGAGCTCG-- 191 
★ ★ ★ ★  ★★★ ★ ★★★★★★ ★★ ★ ★
CGTGCTCTCGCTTTTTTTGTACATTTTCACCAAGATCTCGGTGGATATGT 472 
CGTGCTCTCGCTTTTTTTGTACATTTTCACCAAGATCTCGGTGGATATGT 472 
CGTGCTCTCGCTTTTTTTGTACATTTTCACCAAGATCTCGGTGGATATGT 4 82 
CGTGCTCTCGCTTTTTTTGTACATTTTCACCAAGATCTCGGTGGATATGT 477 
CGTGCTCTCGCTTTTTTTGTACATTTTCACCAAGATCTCGGTGGATATGT 477
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NM_0 0304lHumanSGLT2 
AV6054 90BovineSGLT2-likeEST
TGTGCTCTCCCTTTTCCTGTACATCTTCACCAAGATCTCAGTGGACATGT 4 98 
-GAGAATGGGCCATCATTTTGAAATCT------ GCCCTCCAGGAAAATTA 234
*  *  * *
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_00304lHumanSGLT2
AV6054 90BovineSGLT2-likeEST
TCTCTGGGGCAGTATTCATTCAACAGGCCCTGGGCTGGAACATTTACGCT 522 
TCTCTGGGGCAGTATTCATTCAACAGGCCCTGGGCTGGAACATTTACGCT 522 
TCTCTGGGGCAGTATTCATTCAACAGGCCCTGGGCTGGAACATTTACGCT 532 
TCTCCGGAGCAGTATTCATTCAACAGGCCCTGGGCTGGAACATTTACGCT 527 
TCTCCGGAGCAGTATTCATTCAACAGGCCCTGGGCTGGAACATTTACGCT 527 
TCTCCGGAGCTGTATTCATCCAGCAGGCTCTGGGCTGGAACATCTATGCC 548 
ATTGGAAAGGGGGAATCCTTTTCCAGTTCCCCGCAAAGACAGTCTATGTA 284 
*  * * * * * *  * * *  *  *  * *  *  * *  *
NM_133254MouseSGLT2
BC022226MouseSGLT2
AYO 3 38 8 6MouseSGLT2
NM_022590RatSGLT2
U2988lRatSGLT2
NM_003041HumanSGLT2
AV605490BovineSGLT2-likeEST
TCGGTCATCGCTCTCTTGGGCATCACCA— TGATTTATACTG-TGACAGG 569 
TCGGTCATCGCTCTCTTGGGCATCACCA— TGATTTATACTG-TGACAGG 569 
TCGGTCATCGCTCTCTTGGGCATCACCA— TGATTTATACTG-TGACAGG 57 9 
TCTGTCATCGCACTCTTGGGCATCACCA— TGATTTATACTG-TGACAGG 574 
TCTGTCATCGCACTCTTGGGCATCACCA— TGATTTATACTG-TGACAGG 57 4 
TCCGTCATCGCGCTTCTGGGCATCACCA— TGATTTACACGG-TGACAGG 595 
CTAGAGGCAGCCTGTCTGGGCTGTGCCCCCTGACCCAGGCCGGTTGCAGG 334 
★ ★★ ★★★★★ ★★ ★★★ ★ ★ ★ ★ ★★★★
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_00304lHumanSGLT2
AV605490BovineSGLT2-likeEST
AGGGCTGGCGGCACTGATGTACACAGACACTGTGCAGACCTTCGTCATTC 619 
AGGGCTGGCGGCACTGATGTACACAGACACTGTGCAGACCTTCGTCATTC 619 
AGGGCTGGCGGCACTGATGTACACAGACACTGTGCAGACCTTCGTCATTC 62 9 
AGGGCTGGCGGCACTGATGTACACAGACACTGTGCAGACCTTCGTCATTC 62 4 
AGGGCTGGCGGCACTGATGTACACAGACACTGTGCAGACCTTCGTCATTC 62 4 
AGGGCTGGCCGCGCTGATGTACACGGACACGGTACAGACCTTCGTCATTC 645 
A G G G C T G G C G ^H H H H ^^H G G T G C A G A C C T T C G T C A T T C  384 
* * * * * * * * *  * *  * * * * * * * * * * *  * * * * *  * *  * * * * * * * * * * * * * * * *
NM_133254MouseSGLT2
BC0 2 2 2 2 6Mous e SGLT2
AY033886MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_0 0304lHumanSGLT2
AV605490BovineSGLT2-likeEST
TTGCCGGGGCCTTCATCCTCACTGGTTATGCTTTCCATGAAGTGGGCGGG 669 
TTGCCGGGGCCTTCATCCTCACTGGTTATGCTTTCCATGAAGTGGGCGGG 669 
TTGCCGGGGCCTTCATCCTCACTGGTTATGCTTTCCATGAAGTGGGCGGG 67 9 
TTGCCGGGGCCTTCATCCTCACTGGTTATGCTTTCCATGAAGTGGGCGGG 67 4 
TTGCCGGGGCCTTCATCCTCACTGGTTATGCTTTCCATGAAGTGGGCGGG 674 
TGGGGGGCGCCTGCATCCTCATGGGTTACGCCTTCCACGAGGTGGGCGGG 695 
TCGCCGGGGCCTTCGTCCTCATGGGTTACGCCTTCCACGAGGTGGGCGGG 434 
*  *  * *  *  *  *  *  *  * * * * * *  * * * * *  *  *  * * * * *  * *  * * * * * * * * *
NM_133254MouseSGLT2
BC022226MouseSGLT2
AY03388 6Mous e SGLT 2
NM_0 225 9 ORatSGLT2
U29881RatSGLT2
NM_0 0304 lHumanSGLT2
AV605490BovineSGLT2-likeEST
TACTCGGGTCTCTTCGACAAATACCTGGGAGCAATGACTTCACTGACGGT 719 
TACTCGGGTCTCTTCGACAAATACCTGGGAGCAATGACTTCACTGACGGT 719 
TACTCGGGTCTCTTCGACAAATACCTGGGAGCAATGACTTCACTGACGGT 729 
TACTCAGGTCTCTTCGACAAATACCTGGGAGCAGTGACTTCACTGACGGT 724 
TACTCAGGTCTCTTCGACAAATACCTGGGAGCAGTGACTTCACTGACGGT 724 
TATTCGGGTCTCTTCGACAAATACCTGGGAGCAGCGACTTCGCTGACGGT 745 
TATTCGGGGCTTTTCGACAAATACTTGCGGGCAGTGACGTCCC^HHI 4 84 
* *  * *  * *  * *  * * * * * * * * * * * *  * *  *  * * *  * * *  * *  * * * * * * * *
NM_133254MouseSGLT2
BC022226MouseSGLT2
AYO 3388 6MouseSGLT2
NM_022590RatSGLT2
U29881RatSGLT2
NM_003041HumanSGLT2
AV6054 90BovineSGLT2-likeEST
GTCCAAGGATCCATCTGTTGGCAACATCTCCAGCACCTGCTAC-CAGCCG 7 68 
GTCCAAGGATCCATCTGTTGGCAACATCTCCAGCACCTGCTAC-CAGCCG 7 68 
GTCCAAGGATCCATCTGTTGGCAACATCTCCAGCACCTGCTAC-CAGCCG 778 
GTCCAAGGATCCAGCTGTTGGCAACATCTCCAGCACCTGCTAT-CAGCCG 773 
GTCCAAGGATCCAGCTGTTGGCAACATCTCCAGCACCTGCTAT-CAGCCG 773 
GTCCGAGGATCCAGCCGTGGGAAACATCTCCAGCTTCTGCTAT-CGACCC 794 
^^^^^^GGCCGTGGGCAACATCTCCAGCTCCTGCTATTCGACCC 534 
* * *  * * * * * * *  *  * *  * *  * * * * * * * * * * * *  * * * * * *  *  * *
NM_133254MouseSGLT2
BC022226MouseSGLT2
AGGCCTGACTCCTATCACCTGCTGCGTGACCCTGTGACAGGAGACCTGCC 818 
AGGCCTGACTCCTATCACCTGCTGCGTGACCCTGTGACAGGAGACCTGCC 818
188
AY033886MouseSGLT2 AGGCCTGACTCCTATCACCTGCTGCGTGACCCTGTGACAGGAGACCTGCC 828
NM_022590RatSGLT2 AGGCCCGACTCCTATCACCTGCTGCGTGACCCTGTGACAGGAGGGCTGCC 823
U2 9881RatSGLT2 AGGCCCGACTCCTATCACCTGCTGCGTGACCCTGTGACAGGAGGGCTGCC 823
NM_00304lHumanSGLT2 CGGCCCGACTCCTACCACCTGCTCCGGCACCCCGTGACCGGGGATCTGCC 84 4
AV6054 90BovineSGLT2-likeEST CGGCCGGACTCCTACCACT-------------------------------------553
★★★★ ★★★★★★★★ ★★★
Short sequences highlighted in red were the primers designed based on the bovine SGLT2-like EST.
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Sequencing results for GLUT1-5, SGLT1-2 and SGLT-2like EST
GLUT1
CTCCATCATGGGCAACCAGGAACTGTGGCCCCTGCTGCTGAGCGTCATCTTCATCCCAG
CCCTGTTGCAGTGCATCCTGCTGCCCTTCTGCCCCGAGAGCCCCCGCTTCCTGCTCATT
AACCGCAACGAGGAGAACCGGGCCAAGAGCGTGCTGAAGAAGCTGCGTGGGACCGCGGA
CGTGACCCGCGACCTGCAGGAGATGAAGGAGGAGAGCCGGCAGATGATGCGGGAGAAGA
AGGTCACCATCCTGGAGCTGTTCCGCTCAGCCGCCTACCGCCAGCCCATCCTCATTGCC
GTGGTGCTGCAGCTGTCCCAGCAGCTGTCCGGCATCAACGCTGTTTTCTATTACTCCAC
AAGCATCTTCGAGAAGGCGGGGGTGCAGCAGCCCGTGTATGCCACCATCGGCTCTGGCA
TCGTCAACACAGCCTTCACTGTCGTGTCGCTATTTGTGGTGGAACGAGCCGGCCGGCGG
ACCCTGCACCTCATAGGCCTGGCCGGCATGGCAGGCTGTGCA
GLUT2
ACAGCTGGAATCAGCCAACCTGTTTATGCAACCATTGGAGTTGGTGCTGTCAACACAGT
TTTCACTGCTGTCTCTGTGTTCCTTGTGGAGAAGGCAGGGCGACGCTCTCTGTTCCTAA
TTGGAATGAGTGGGATGTTTGTTTGTGCCATCTTCATGTCGGTGGGACTGGTNGCTCCT
GAGA
GLUT3
CCTTGTCTGTGGCCATCTTCTCCGTGGGTGGTATGATTGGCTCCTTCTCCGTCGGACTC
TTTGTCAACCGATTTGGCAGGCGCAATTCAATGCTTATTGTCAACCTGTTGGANATAGC
TGGCGGCTGCCTTATGGGATTCTGCAAAATAGCAGAGTCGGTTGAAATGCTGATCTTGG
GCCGACTGATTATCGGCCTCNTCTGCGGACTCTGCACAGGATTCGTGCCCATGTACATT
GGAGAGATCTCCCCTACTGCCCTGCGGGGCGCCTTTGGCACTCTCAACCAGCTGGGCAT
CGTTATCGGAATTCTGGTGGCCCAGATCTTTGGTCTAAAAGTCATCTTGGGGACTGAAG
ATCTCTGGCCTCTGCTCCTGGGCTTCACCATCTTACCAGCCATCATCCAGTGCAAA
GLUT4
GTGGCTGGGTACGTCCAACTGGACATGCAACTTCATCATCGGCATGGGTTTCCAGTATG
TGGCGGATGCTATGGGTCCCTACGTCTTTCTTCTATTCGCGGTCCTCCTGCTTGGCTTC
TTCATCTTCACCTTCTTAAAAGTGCCTGAAACCCGTGGCAGGACGTTTGACCAGATCTC
AGCCGTTTTCCACCGGACACCTTCTCTTCTGGAGCAGGAAGTGAAACCCAGCACAGAAC
TGGAGTACTTAGGGCCAGATGAGCATGACTGAGGGCCACAGAGGGGTGGGAGAGCCAGT
TCTCTCCACTTGCCCAGAGACCCCCCTCCTTTTCTCTGCAGCACTTTAACCCTCTCTTC
CCCATTACTTCCAGGGCAGAGAANACCCCTGCAGCCTGGTGGGATTGGGAAGCTGGAGG
GAACGGTGGTCTGAGCACCCCCTCATTCCCCTCGTGTGACCTCTTGGATTATTTGTGTT
GTGGGTTAGCAGTGG
GLUT5
CTCCATCATCGTCCTCATGGCGGGCCAGCAGCTCTCCGGAGTGAATGCGATCTACTACT
ACGCAGACCAGATTTACCTGAGTGCTGGAGTGAATGAGGACGATGTCCAATATGTGACG
SGLT1
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AAGGCAGAGTGCTACACCCCGAGGGCTGACTCCTTCCACATCTTCCGCGATCCTCTCAA
GGGAGACCTGCCCTGGCCTGGGCTCATCTTTGGGCTGACCATCATCTCCCTGTGGTACT
GGTGCACAGACCAGGTCATTGTGCAGCGCTGCCTCTCNGCCAAAAACATGTCCCACGTG
AAGGCCGGCTGCATCATGTGTGGGTACCTGAAGCTGCTGCCCATGTTCCTCATGGTGAT
GCCAGGGATGATCAGCCGCATCCTGTTCACAGAGAAAGTTGCCTGCACGGTCCCCTCAG
AGTGTGAGAAATACTGCGGCACCAAGGTTGGCTGTACCAACATCGCCTACCCGACCTTG
GTGGTGGAGCTCATGCCCAATGGACTGCGAGGCCTGATGCTGTCGGTCATGCTGGCCTC
GCTCATGAGCTCGCTGACCTCCATCTTCAACAGTGCCAGCACCCTCTTCACCATGGACA
TCTACACCAAGATCCGGAAGAAAGCCTCTGAGAAAGAGCTCATGATCGCAGGACGGTTG
TTCATGCTGGTGCTGATCGGTGTCAGCATCGCCTGGGTGCCCATCGTGCAGTCAGCACA
GAGTGGACAGCTCTTCGACTACATCCAGTCCATCA
SGLT2
CAACCGCCCATTCCGCGCAAGCACCTCTACCGCCTGGTTTTCAGTCTCCGGCACAGCAA
GGAAGAGAGGGAGGACCTGGATGCTGAGGAGCTAGAAGGTCCAACCGCAGCCCCCGTGC
AGAACGGGCGCCCTGAGCACGCAGTGGAGATGGAGGCGCCCCCGCCCCCAAGGCCAGGC
CTGTTGCGGCAGTGCCTGCTCTGGTTCTGTGGCGTGAGCAGGGGTGGGGTGGGCAGCCC
CCAACGCCCTACCCAGGAGGAGACGACTGCTGCAGCCAGGCGGCTGGAGGACATCAGTG
AGGACCCACGCTGGGCCCGCGTGGTCAACCTCAACGCCCTGCTCATGATGGCCGTGGCC
ACATTCCTCTGGGGCTTTTATGCCTGAGGCCCANTGCATTGGAACACCCTGAGCAA
SGLT2-like EST
GGGGCCTTCGTCCTCATGGGTTACGCCTTCCACGAGGTGGGCGGGTATTCGGGGCTTTT
CGACAAATACTTGCGGGCAGTGACGTCCCTGACGGTATCCGAGGATCACNTANGCGGGG
TGGTCCGAGGGAGGGCCTTGTCGCGGGTGCCGGGTCCCCTGACGGCCGTGCCCTCACAG
CCTTCCACGAGGTGGGCGGGTATTCGGGGCTTTTCGACAAATACTTGCGGGCAGTGACG
TCCCTGACGGTATCCGAGGATCA
The next two pages are examples of the sequencing output in ABI format.
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G G  G G
0 3 0  2 4 0
'  G G G 3 G G G  G G G  G G
G G G
400 410 420 430 440  4S0
> G G G  G G GG G G G G G ’ ‘ * G f C  : t « I C  T C  T C C
4 6 0  470
-  "G ’ G G  G '  7  7 G G T
4 6 0  4 9 0
r r c  T C  G G G G ‘ :
Sequencing output in ABI format of GLUT5 mRNA expressed in kidney sample.
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1 8 0
G G G S  S
2 5 0  2 6 0  2 ' 0  2 8 0
' G  S  G T G  ' G  G G G  S ' G G  G G G  G G
G G G
0
N t f N S S S M N S S S i l ' I ' I ' I M S f l N S l J H S H H S l H S i H J I N N t f S I S S i N U S H N N U . S N N S S S H M J I N S . M N H l l S f l S S I N ' t N S H S M t f S I K N S . ' J . N . S M t J N ' I N S N I r H - I N H S . ' J N J I S N N y S ' I M S
: T r » ? *o l t r * g t  : »t T t t t 6 C S 6 r s * t  g n n n Nl s t. n ■; a n n s v n n s * s n >« n N n v * N s 'i s s :i s n * x ■< m n n n n n ; :
Sequencing output in ABI format of GLUT5 mRNA expressed in the ciliary process.
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Appendix  IV
CLUSTAL analysis of bovine SGLT2-like EST and SGLT2 sequences
CLUSTAL W (1.82) Multiple Sequence Alignments 
Sequence format is Pearson
Sequence 1: AV208941BovineSGLT2 2275 bp
Sequence 2: AV6054 90BovineEST 553 bp
Sequences (1:2) Aligned. Score: 40
AV2 0894 lBovineSGLT2 AGATCGTGGGCAGAATGGAGGAGCACACAGAGGCAGGCTCAGCACCAGTGCTGGGGGAAC 60
AV605490BovineEST----- ------------------------------------------------------------------
AV208 94lBovineSGLT2 AGAAGGCTCTAATTGACAATCCTGCTGACATCCTAGTCATCGCTGCTTATTTCCTGCTGG 120 
AV6054 90BovineEST ------------------------------------------------------------------
AV20894lBovineSGLT2 TCATTGGTGTCGGCTTGTGGTCCATGTGCAGAACCAACAGAGGCACCGTCGGCGGCTACT 180
AV605490BovineEST ------------------------------------------------------------------
AV20894lBovineSGLT2 TCCTGGCGGGACGGAACATGGTGTGGTGGCCGGTCGGGGCCTCTCTCTTTGCCAGCAACA 240
AV6054 90BovineEST  C 1
AV20894lBovineSGLT2 TCGGCAGTGGCCACTTCGTGGGCCTGGCAGGGAC CGGTGCGGCGAGCGGCCTGGCGG 297
AV605490BovineEST CACGCGTCCGCCCACGCGTCCGCCTTACAGGATCACCTCCTTCTGTTACACACACGAGAA 61** ★ **** * * * * * * ★
AV20894lBovineSGLT2 TGGCTGGATTTGAGTGGAATGCACTGTTCGTGGTCCTGCTACTTGGGTGGCTCTTCGTGC 357
AV605490BovineEST AACCTGGACTTAGAGGAGGGCCTGTAGTGGAGGTCCTACA— CTGGGGGGCACCTGGCAT 119
* * * * *  * *  *  *  *  *  *  * * * * * *  *  * * * *  * * *  *  *  *
AV20894lBovineSGLT2 CAGTGTA-CCTGACTGCCGGCGTCATCACCATGCCGCAGTACCTGCGAAAGCGCTTCGGC 416
AV605490BovineEST CCGTGAAGCCCCAAACTCAGCCCCACTGTGCTCACCCAG-ACCTGC CTCCTGA 171
*  * * *  *  * *  *  *  * *  * *  *  *  * * *  * * * * * *  * *  *  *
AV20894lBovineSGLT2 GGCCATCGTATCCGCCTCTACTTGTCCGTGCTCTCGCTTTTTCTGTACATCTTCACCAAG 47 6
AV605490BovineEST CGCCGGAGTG-CAGGAGCTCGGAGAATGGGCCATCA-TTTTGAAATCTGCCCTCCAGGAA 229
* * *  * *  *  *  * *  *  *  * *  * *  * * * *  *  *  * *  *
AV20894lBovineSGLT2 ATTTCGGTGGACATGTTCTCCGGGGCAGTATTCATTCAACAGGCTCTGGGCTGGAACA-T 535
AV605490BovineEST AATTAATTGGAAA-------- GGGGGAATCCTTTTCCA--- GTTCCCCGCAAAGACAGT 277
*  *  *  * * * * *  * * * * * *  *  * * *  * * *  * *  * * * *
AV20894 lBovineSGLT2 CTATGCCTCCGTCATCGCGCTCCTGGGCATCACCA— TGATCTACACTG-TGACAGGAGG 592
AV605490BovineEST CTATGTACTAGAGGCAGCCTGTCTGGGCTGTGCCCCCTGACCCAGGCCGGTTGCAGGAGG 337
* * * * *  *  * *  * * * * * *  * *  * * *  *  *  *  *  *  * * * * * * *
AV208941BovineSGLT2 GCTGGCGGCACTGATGTACACGGACACGGTGCAGACCTTCGTCATTCTCGCCGGGGCCTT 652
AV605490BovineEST G C T G G C G | | ^ ^ ^ H H U ^ ^ ^ B CGGTGCAGACCTTCGTCATTCTCGCCGGGGCCTT 397
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AV20894lBovineSGLT2 CGTCCTCATGGGTTACGCCTTCCACGAGGTGGGCGGGTATTCGGGGCTTTTCGACAAATA 712
AV605490BovineEST CGTCCTCATGGGTTACGCCTTCCACGAGGTGGGCGGGTATTCGGGGCTTTTCGACAAATA 457
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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AV2 0894lBovineSGLT2 
AV6054 90BovineEST
AV2 0 8 9 4lBovineSGLT2 
AV6054 90BovineEST
AV208941BovineSGLT2
AV605490BovineEST
AV208941BovineSGLT2 
AV6054 90BovineEST
AV208 94lBovineSGLT2 
AV6054 90BovineEST
AV208941BovineSGLT2 
AV6054 90BovineEST
AV208941BovineSGLT2 
AV605490BovineEST
AV2 08941BovineSGLT2 
AV6054 90BovineEST
AV20894lBovineSGLT2 
AV605490BovineEST
AV208941BovineSGLT2 
AV6054 90BovineEST
AV208 94lBovineSGLT2 
AV605490BovineEST
AV2 0894lBovineSGLT2 
AV605490BovineEST
AV208941BovineSGLT2 
AV6054 90BovineEST
AV208 94lBovineSGLT2 
AV6054 90BovineEST
AV208 94lBovineSGLT2 
AV6054 90BovineEST
AV20894lBovineSGLT2
AV605490BovineEST
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CTTGCGGGCAGTGACGTCCCTGACGGTATCCGAGGATCCGGCCGTGGGCAACATCTCCAG 772
c t t g c g g g c a g t g a c g t c c c H ^ H H H B I ^ B H I c g g c c g t g g g c a a c : a t c t c c a g  5 1 7  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CTCCTGCTAT-CGACCCCGGCCGGACTCCTACCACCTGCTCCGGGACCCTGTGACGGGGG 831
CTCCTGCTATTCGACCCCGGCCGGACTCCTACCACT----------------------------553
* * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * *
ACCTGCCATGGCCCGCGCTGCTTCTGGGGCTTACTATCGTGTCCAGCTGGTACTGGTGCA 891 
GCGACCAGGTTATAGTGCAGCGCTGCCTGGCTGGGAAAAACCTCACCCACATCAAGGCGG 951 
GCTGCATCCTGTGCGGCTACTTGAAGCTGATGCCCATGTTCCTCATGGTCATGCCTGGAA 1011 
TGATCAGCCGCGTTCTTTACCCGGACGAAGTGGCGTGCGTGGTGCCCGAGGTGTGTAAGC 1071 
GCGTGTGCGGCACCGAGGTGGGCTGCTCCAATATCGCCTACCCGCGGCTCGTCGTGAAGC 1131 
TCATGCCCAATGGTCTGCGCGGACTCATGCTGGCGGTCATGCTGGCGGCGCTCATGTCCT 1191 
CGCTGGCCTCCATCTTCAACAGCAGCAGCACACTCTTCACCATGGACATCTACACGCGCC 1251 
TGCGGCCCCGCGCGGGCGACCGCGAGCTGCTGCTAGTAGGACGGCTCTGGGTGGTGTTCA 1311 
TCGTGGCCGTGTCGGTGGCCTGGCTGCCCGTGGTGCAGGCGGCGCAGGGCGGGCAGCTCT 1371 
TCGATTACATCCAGTCGGTCTCCAGCTACCTGGCGCCGCCGGTGTCGGCCGTCTTCGTGT 1431 
TGGCGCTCTTCGTGCCCCGCGTCAACGAGAAGGGCGCCTTCTGGGGACTGATCGGGGGCC 1491
TGCTGATGGGCCTGGCACGCCTGGTTCCCGAGTTCTCCTTCGGCTCCGGCAGCTGCGTGC 1551
GCCCCTCCGGGTGCCCGGCTCTCCTCTGCCGCGTCCACTACCTCTACTTCGCCATCCTGC 1611
TCTTCGTCTGCTCCGGCCTCCTCACCCTCGTGGTCTCACTGTGCACACCGCCCATTCCGC 1671
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AV2 0894 lBovineSGLT2 GCAAGCACCTCTACCGCCTGGTTTTCAGTCTCCGGCACAGCAAGGAAGAGAGGGAGGACC 1731
AV6054 90BovineEST ------------------------------------------------------------------
AV2 0894 lBovineSGLT2 TGGATGCTGAGGAGCTAGAAGGTCCAACCGCAGCCCCCGTGCAGAACGGGCGCCCTGAGC 1791
AV605490BovineEST ------------------------------------------------------------------
AV208 94 lBovineSGLT2 ACGCAGTGGAGATGGAGGCGCCCCCGCCCCCAAGGCCAGGCCTGTTGCGGCAGTGCCTGC 1851
AV605490BovineEST ------------------------------------------------------------------
AV2 0894 lBovirieSGLT2 TCTGGTTCTGTGGCGTGAGCAGGGGTGGGGTGGGCAGCCCCCAACGCCCTACCCAGGAGG 1911
AV605490BovineEST ------------------------------------------------------------------
AV2 0894 lBovineSGLT2 AGACGACTGCTGCAGCCAGGCGGCTGGAGGACATCAGTGAGGACCCACGCTGGGCCCGCG 1971 
AV605490BovineEST ------------------------------------------------------------------
AV2 0894 lBovineSGLT2 TGGTCAACCTCAACGCCCTGCTCATGATGGCCGTGGCCACATTCCTCTGGGGCTTTTATG 2031
AV6054 90BovineEST ------------------------------------------------------------------
AV20894lBovineSGLT2 CCTGAGGCCCACTGCATTGGACACCCTGAGCCACAGCCTTAGATGAGTGGGGGTGGGGAG 2091
AV605490BovineEST ------------------------------------------------------------------
AV20894lBovineSGLT2 CCAGCGGCGGTGAGAAGGGCCTGGGGCCAGAGAGTAGAGGGGAGGCCCCGGGACCCCTAC 2151 
AV6054 90BovineEST ------------------------------------------------------------------
AV2 0894 lBovineSGLT2 TCTCTGCCTTGTTTCTGCCTGGGACCCAGTCCATAGCCACACCCTGTGAGGCCTTGGCCA 2211
AV6054 90BovineEST ------------------------------------------------------------------
AV20894lBovineSGLT2 GCTGGCCACTGTAGTTCCCCTAAGAACAAATAAAGCTGCCTTGCCTAGTCAAAAAAAAAA 2271
AV6054 90BovineEST ------------------------------------------------------------------
AV208941BovineSGLT2 AAAA 2275 
AV605490BovineEST ----
The sequences highlighted in red were primers designed according to the bovine EST sequence, while 
those highlighted in yellow are primers for the real SGLT2 gene.
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